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CHAPTER 1 
ANTHRACYCLINES: 
CELLULAR PHARMACOKINETICS AND PHARMACODYNAMICS RELATED TO CELL KINETICS 
Introduction and outline of investigation 
INTRODUCTION and DEFINITIONS. 
Cytotoxic drugs are usually administered as bolus injection of a fixed dose 
2 
(mg/m ), preferably on one day. This fits best in the daily practice at an in-
or outpatient department. Moreover, uniformity in large cooperative clinical 
trials could be attained. This approach, however, does not take differences of 
drug handling in individual patients into account. 
The ultimate goal in cancer chemotherapy is to treat the individual patient with 
a minimum of side effects and a maximum of tumoricidal efficacy. Therefore drug 
delivery ideally has to be tailored to the individual patient's needs by optimal 
drug scheduling. Detailed knowledge of plasma pharmacokinetics, cellular 
pharmacokinetics and pharmacodynamics, related to cell kinetic parameters is 
indispensable for this purpose. 
Plasma pharmacokinetics deals with the study of the concentration-time 
relationships of the drug in different compartments of the body (21), related to 
the dose, the schedule and the route of administration. It provides parameters 
to describe mathematically the fate of the drug in the body (43, 69). 
Cellular pharmacokinetics describes the kinetics of the drug at the target-cell 
level (ЗА). Processes as influx, efflux and metabolism determine the final 
cellular drug concentration. 
Pharmacodynamics relates the drug concentration at the target (cellular) level, 
to the final pharmacological action: the therapeutic or toxic action, which in 
the case of cytostatics is cell kill (21, 59). 
Cell kinetics deals with the study of quantitative aspects of tumor growth, like 
growth fraction, cell cycle time and the resulting doubling time. It is 
important to determine whether, in which phase and to what extent cytostatic 
drugs influence the progression of the cells through the cell cycle (11, 34, 
66). 
Pharmacokinetic and pharmacodynamic studies may thus contribute to the 
individualization and the optimization of cancer chemotherapy by providing a 
rationale for an administration strategy. One has to realize, that translation 
of results from animal pharmacokinetic studies to clinical practice may be 
hazardous, as large interspecies differences exist in pharmacokinetic and 
pharmacodynamic behaviour of drugs (21, 30, 69, 71). 
This chapter gives an overview of the anthracycline drugs, their 
pharmacokinetics and pharmacodynamics related to cell kinetics and 
clonogenicity, and a summary of the aim of this study. 
For details is referred to some excellent reviews (7, 29, 31, 49, 50, 63, Θ1). 
ANTHRACYCLINES. 
History. In 1957 a team of soil biologists from the Farmitalia Laboratories 
10 
isolated from a soil sample from Puglia (Adriatic Sea, Italy) a red substance 
producing colony of Streptomyces peucetium var. caes jus (25). The pure red 
pigment isolated in the years 1961-1963 (25) was called daunomycin, the first 
known anthracycline compound. Anthracycline antibiotics are agents with potent 
antitumor activity (29, 31, 50) and negligible antibiotic activity (38). The 
chemical structures of the anthracyclines studied in this thesis are given in 
Fig. 1. 
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FIGURE 1. Chemical structure of anthracyclines. 
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Physico-chemically, the daunomycin molecule consists of a hydrophobic part, the 
tetracyclic chromophore (the red aglycone), which is linked to the aminosugar 
(daunosamine), the hydrophilic part of the drug. Structural changes in either 
the chromophore or the aminosugar influence the polarity and charge of the 
molecule (5, 25). As the polarity determines the affinity to cell structures 
like membranes and DNA, this property also affects cellular drug uptake and 
metabolism (5). The aminofunction on the daunosamine is essential for the 
cytotoxic activity in vitro and in vivo (52). 
Introduction of a hydroxyl-group at the C14 position (R , Fig. 1) results in the 
14-hydroxyl derivative of daunomycin: adriamcyin (16, 25). 4'-epi-adriamycin 
differs from adriamycin by epimerization of the hydroxyl-group in the position 
4' of the aminosugar (R ) (16, 25). In 4-demethoxydaunomycin the methoxy-group 
2 
at R (Fig. 1) has been replaced by a hydrogen-molecule (2, 16). 
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Since 1961 the anthracyclines have been studied extensively. 261 papers on 
anthracyclines were published from 1966-1971, increasing to 1230 papers in 
1971-1976 and to 2865 papers in 1976-1981. In the years 1981-1986 
anthracyclines were the subject of study in over 4000 papers. However, in only 
a few studies cellular pharmacokinetics of anthracyclines in man have been 
described (2A, 55, 75). 
Mechanism of action. The mechanisms by which anthracyclines exert cell kill and 
host-tissue toxicity have not yet been fully clarified (25). Most probably a 
combination of multiple biochemical effects (2, 7, 49) Is responsible: 
1. Intercalation of the В and С ring of the molecule (Fig. 1) between 
adjacent base pairs into the double helix of DNA (58, 25). Preference for G-C 
(18, 41, 57) as well as for A-T (16) has been described. These interStrand DNA 
cross-links inhibit DNA-replication (57), causing fragmentation, DNA breaks and 
chromosomal aberrations. As DNA- and RNA-polymerases are also inhibited, DNA-
as well as RNA-synthesis is decreased (15, 67). 
2. Inhibition of ribosomal RNA-synthesis, at concentrations even lower than 
those which affect DNA-synthesis. For different anthracycline compounds the 
ratio of RNA/DNA inhibition is different. Some have a stronger inhibiting 
effect on RNA-synthesis, others on DNA-synthesis (45, 48). 
3. Binding to cardiolipines in cell and organelle membranes, altering the 
membrane morphology and function (76, 84). Development of resistance to 
anthracyclines seems to be linked to membrane alterations (3). 
4. Formation of free radicals (5, 37), catalysed by the microsomal reductase 
P,r
n
· This damages cell membranes and DNA and may also play a role in cardiac 
muscle damage. 
5. Interference with mitochondrial oxydative pathways (35, 51). 
6. Processes as bioreductive activation to alkylating agents (47) and metal 
ion chelation (48). 
Metabolism. Plasma pharmacokinetic studies revealed that anthracyclines 
disappear from the plasma very fast as they are distributed into tissues and 
metabolized in the liver. Elimination takes place mainly through the bile 
(80%), only 6% has been found back in 5 days (red coloured) urine (44, 53). 
Liver diseases with a hyperbilirubinemia protract the elimination time (8), 
whereas drugs as phénobarbital increase the elimination. Intracellular 
metabolism (especially in liver and erythrocytes (8)) by NADPH-dependent 
aldo-ketoreductases mainly results in active, more hydrophilic 13-hydroxy 
metabolites (5), and to a minor degree by glycosidases in inactive aglycones. 
4'-epi-adriamycin is metabolized to several glucuronides (82). Whether these 
have significance for the antitumor effect is not yet understood. 
Clinical studies started in 1965 (9, 70). Daunomycin considerably improved the 
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results of the treatment of leukemia. For no clear reason the drug has hardly 
been used in the treatment of other malignancies (64). On the contrary, 
adriamycin has been administered as part of many (combination) chemotherapy 
schedules (31). Marked cytotoxic effects on a variety of experimental and human 
tumors have been described. In clinical practice activities in leukemia, 
malignant lymphoma (13), sarcoma (8), advanced breast cancer, small cell lung 
cancer, and ovarian cancer are most pronounced (31). 
Main side effects are nausea and vomiting usually 6 to 8 h after administration 
of a bolus injection, myelosuppression, tissue necrosis after extravasation, 
reversible alopecia, and (delayed) cardiotoxicity with increasing incidence 
above a total cumulative dose of 550-700 mg/m2 (36, 78), and related to the 
schedule of administration as well (83). 
CELLULAR PHARMACOKINETICS AND PHARMACODYNAMICS WITH REGARD TO ANTHRACYCLINES. 
Most studies on cellular anthracycline pharmacokinetics have been carried out in 
cell lines and animal tumor-models (7, 40, 69). After the introduction of 
reliable extraction procedures and high pressure liquid chromatographic 
detection methods (29), in 1975-1978 the first studies were published on in vivo 
tissue concentrations in man (post mortem and during surgery, 19). 
Intracellularly, anthracyclines are mainly localized in the nucleus, but they 
have also been found in mitochondria and other cell-organelles (42). High 
cellular to extracellular drug concentrations at ratios of over 50 to 500 
indicated that cells accumulate anthracyclines against a gradient (19, 69). 
From in vitro studies it was concluded that cellular anthracycline uptake takes 
place by diffusion and by active processes. The cell membrane appeared to be 
the rate-limiting barrier (5, 67, 68). The uptake furthermore is proportional 
to the extracellular drug concentration (5) but not proportional to the exposure 
time (28), Increases at higher temperature and at higher pH (46), is inversely 
related to the number of cells in suspension, is dependent on the lipophilicity 
of the compound under study (5), and is related to the cell cycle phase (73, 
74). Due to these factors a considerable heterogeneity of drug uptake into 
cells has been observed (4, 5). The uptake in the nucleus has been reported to 
become saturated first, while accumulation in the cytoplasme continued (33). 
Cell kill increased with higher cellular drug concentrations, according to 
exponential concentration-survival curves. The proportion of the anthracycline 
content which could be retained in the cell was a major determinant for the 
cytotoxic effect. Reduction of the efflux with drugs like calcium channel 
blockers, increased the cell kill of resistant cells (77, 79). 
In vivo studies confirmed the high tissue to plasma ratios observed earlier in 
animal-models. The ratios differed for different organs (69). Thus, plasma 
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anthracycline concentrations per se do not predict the actual concentrations at 
the sites of specific drug action (63). In a few studies an attempt has been 
made to correlate plasma anthracycline concentrations to the clinical response 
(61, 65). None of these have been convincing or of practical use. Therefore it 
was supposed that the drug concentration at the target tissue determines the 
drug effect (24). Especially flow cytometric techniques contributed to further 
research with regard to pharmacodynamic questions, as whether anthracycline 
concentrations in individual cells predict for the cytotoxic effects. 
In a few studies with observations on cellular pharmacokinetics during 24-48 h 
after drug administration (24, 55, 56, 75), considerable pharmacokinetic 
differences were observed for daunomycin and adriamycin (55, 56). Flow 
cytometric studies revealed a marked heterogeneity in daunomycin uptake in 
leukemic blast cells (32, 40, 69). Whether this heterogeneity is related to 
anthracycline-resistance remains to be investigated. 
THE EFFECT OF ANTHRACYCLINES RELATED TO CELL KINETICS. 
Most studies on the effects of anthracyclines on cell kinetics and cell survival 
have been performed on cell lines like the Chinese hamster ovary (CHO) cells, 
cultured in monolayers or suspension (7, 10, 20, 72, 74). Anthracycline uptake 
appeared to be cell cycle phase dependent (73, 74). Exponentially growing cells 
were more sensitive to anthracycline exposure than plateau-phase cells (7). The 
most lethal effects have been observed in cells exposed to anthracyclines in the 
S-phase. Some authors point to early (7) and mid S-phase (72), others to the 
exposure in late S-phase (26). Minor (10-20 times less) but dose dependent 
inhibiting effects have been observed after exposure in other phases of the cell 
cycle. At high dosages (which are lethal to normal tissues in vivo) adriamycin 
appeared lethal to cells in all phases of the cell cycle (10). The killing 
efficacy was not linearly related to increasing extracellular dosages (7). The 
induced changes in progression through the cell cycle differed for several cell 
lines investigated (7). 
Nondividlng cells were found to be least sensitive to anthracycline exposure 
(7). The consequences of this reduced cytotoxic effect on nondividing cells may 
be dramatic. On the one hand, due to this phenomenon normal tissues, such as 
hematopoietic cells, which presumably have a lower growth fraction than most 
tumor tissues (66) are protected, on the other hand, both the wide range in cell 
cycle times and the fairly low percentage of tumor cells in the so-called growth 
fraction (66), suggests that a considerable number of resting cells may escape 
from the cytotoxic effects of the exposure. 
Problems like these can in part be addressed using clonogenic assays. 
Experiments with human hematopoietic clonogenic cells are scarce (6, 14, 54). 
Although in clinical practice most cytostatics are administered as bolus 
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injections, in none of these studies the effect of such a short exposure to high 
dosages on clonogenicity has been investigated. 
AIM OF THIS STUDY. 
The aim of this study is to enrich our knowledge of cellular anthracycline 
pharmacokinetics and pharmacodynamics in man. This may lead to more effective, 
less toxic and more rational designed anthracycline containing chemotherapy 
schedules. 
Cellular concentration-time profiles in (subpopulations of) normal and leukemic 
hematopoietic cells were measured. Variations in administration schedules in 
vivo and in drug exposure in vitro were studied in order to find treatment 
regimens which have less side effects, without loss of cytotoxicity. Studies 
were performed with the two clinically most relevant anthracyclines: daunomycin 
and adriamycin, as well as with two recently introduced analogues with possibly 
reduced side effects: 4'-epi-adriamycin and 4-demethoxydaunomycin. The 
cellular anthracycline concentrations observed during therapy, were related to 
the inhibition of clonogenicity. 
In chapter 2 a high pressure liquid chromatographic method is described, used 
for the determination of anthracycline concentrations in cells and plasma. 
In chapter 3 a laser flow cytometric method is described to measure cellular 
anthracycline concentrations in individual and viable cells of subpopulations of 
human hematopoietic tissue. The data obtained are related to the results 
obtained with high pressure liquid chromatography. 
In chapter 4 adriamycin concentrations in leukemic blast cells are measured 
after different administration schedules, with special interest for the cellular 
adriamycin concentrations observed after bolus injection and after 72 and 96 h 
continuous infusion, as applied in the treatment of leukemia (chapter 4A) and 
multiple myeloma (chapter 4B). 
In chapter 5 leukemic cell daunomycin concentrations at different administration 
schedules are described. Bolus injections and 72 h continuous infusions are 
compared. Long-term infusions are applied in the treatment of acute 
nonlymphocytic leukemia in order to reduce side effects and to enlarge the 
cytotoxic effects. 
In chapter 6 4-demethoxydaunomycin concentrations in leukemic cells are measured 
in the frame of a Phase II study. Oral and intravenous administration are 
compared. 4-demethoxydaimomycin is the first anthracycline, which can be 
administered orally. This might have advantages for the treatment in the 
out-patient department. 
In chapter 7 nucleated blood cell 4'-epi-adriamycin concentrations are measured 
in patients with breast cancer, treated with weekly low dose bolus injections. 
This schedule had been reported to be less toxic, and rather effective in 
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patients with advanced disease. 
In chapter 8 cellular pharmacokinetics of four anthracyclines with minor 
differences in chemical structure, are studied in subpopulations of normal human 
hematopoietic cells. Differences between in vivo and in vitro cellular 
pharmacokinetics are evaluated. 
In chapter 9 cellular adriamycin concentrations in human normal hematopoietic 
cells, attained after different ways of administration are related to inhibition 
of clonogenicity. 
In chapter 10 adriamycin toxicity to normal and leukemic clonogenic cells is 
compared and related to cellular adriamycin concentrations attained in vivo. 
In chapter 11 the results of the studies described in this thesis are discussed 
leading to proposals for new treatment stategies, and for future investigations. 
REFERENCES. 
1. Andersson B, Beran M, Peterson C, et al. Significance of cellular 
pharmacokinetics for the cytostatic effects of daunorubicin. Cancer Res 42: 
178-183, 1982. 
2. Arcamone F. Doxorubicin and related compounds: physicochemical 
characterization of the DNA-complex; structure-activity considerations. In: 
Anthracycline antibiotics in therapy. Muggia FM, Young CW, Carter SK (eds.). 
Martinus Nijhoff, London, 1982, pp 74-86 and 179-190. 
3. Aubel-Sadron G, Londos-Gagliardi D. Daunorubicin and doxorubicin, 
anthracycline antibiotics, a physicochemical and biological review. Biochimie 
66: 333-352, 1984. 
4. Bachur NR. Adriamycin Pharmacology. Cancer Chemother Rep 6: 153-158, 1975. 
5. Bachur NR, Steele M, Meriwether ND, et al. Cellular pharmacodynamics of 
several anthracycline antibiotics. J of Med Chem 19: 651-654, 1976. 
6. Bailey-Wood R, Dal umore CM, Whittaker JA. Effect of adriamycin on CFUgra at 
plasma concentrations found following therapeutic infusions. Br J Cancer 50: 
351-355, 1984. 
7. Barranco SC. Cellular and molecular effects of adriamycin on dividing and 
nondividing cells. Pharmac Ther 24: 303-319, 1984. 
8. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin, chemotherapy, efficacy, 
safety and pharmacologic basis of an intermittent single high-dosage schedule. 
Cancer 33: 19-27, 1974. 
9. Bernard J, Boiron M, Jacquillat CL, et al. Traitement des leucémies aiguës 
lymfoblastiques de première atteinte par une association de 
prednisone-vincristine-rubidomycine. Pathol Biol 15: 919-922, 1967. 
10. Bhuyan BK, Blowers CL, Shugars KD. Lethality of nogalamycin, nogalamyсin 
analogs, and adriamycin to cells in different cell cycle phases. Cancer Res 40: 
3437-3442, 1980. 
11. Birkhead BG. Mathematical model of remission duration in acute myelogenous 
leukemia. Cancer Treat Rep 68: 595-601, 1985. 
12. Boiron M, Jacquillat C, Marty M, et al. Anthracyclines in the treatment of 
acute nonlymphoblastic leukemia. Cancer Treat Rep 65 (Suppl 4): 73-77, 1981. 
13. Bonnadonna G, Monfardini S, De Lena M, et al. Phase I and preliminary phase 
II evaluation of adriamycin (NSC 123127). Cancer Res 30: 2572-2582, 1970. 
14. Buick RN, Messner HA, Till JE, et al. Cytotoxicity of adriamycin and 
daunorubicin for normal and leukemia progenitor cells of man. J Natl Cancer 
Inst 62: 249-255, 1979. 
15. Calendi E, Di Marco A, Reggiani M, et al. On physico-chemical interactions 
between daunomycin and nucleic acids. Biochim et Biophys Acta 103: 25-49, 
1963. 
16. Casazza AM. Experimental evaluation of anthracycline analogs. Cancer 
Treatm Rep 63: 835-844, 1979. 
16 
17. Chabner BE. Clinical pharmacokinetics and drug monitoring. Pharmacological 
principles of cancer treatment. Chabner B, editor. Saunders, London, 1982, pp 
100-108. 
18. Chaires JB, Dattagupta N, Crothers DM. Studies on interaction of 
anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding 
studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry 
21: 3933-3940, 1982. 
19. Chan KK, Cohen JL, Gross JF, et al. Prediction of adriamycin disposition in 
cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep 
62: 1161-1171, 1978. 
20. Clarkson JM, Humphrey RM. The effect of adriamycin on cell cycle 
progression and DNA replication in Chinese hamster ovary cells. Cancer Res 37: 
200-205, 1977. 
21. Collins JM, Dedrick RL. Pharmacokinetics of anticancer drugs. 
Pharmacological principles of cancer treatment. Chabner B, editor. Saunders, 
London, 1982, pp 77-99. 
22. Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for 
preclinical pharmacology in phase I clincal trials. Cancer Treat Rep 70: 
73-80, 1986. 
23. Davies KJA, Doroshow JH, Hochstein P. Mitochondrial NADH 
dehydrogenase-catalyzed oxygen radical production by adriamycin, and the 
relative inactivity of 5-iminodaunorubicin. FEBS letters 153: 227-230, 1983. 
24. DeGregorio MW, Holleran WM, Macker BA, et al. Kinetics and sensitivity of 
daunomycin in patients with acute leukemia. Cancer Chemother Pharmacol 13: 
230-234, 1984. 
25. Di Marco A. Anthracyclines in cancer chemotherapy. Drugs Exptl Clin Res 9: 
751-765, 1983. 
26. Drewinko B, Patchen M, Young LY, et al. Differential killing efficay of 
twenty antitumor drugs on proliferating and nonproliferating human tumor cells. 
Cancer Res 41: 2328-2333, 1981. 
27. Dubost M, Gauter P, Maral R, et al. Un nouvel antibiotique a propriétés 
cytostatiques: la rubidomycine. Cane Res Acad Sci [D] Paris 257: 1813-1815, 
1964. 
28. Eichholtz-Wirth H. Dependence of the cytostatic effect of adriamycin on 
drug concentration and exposure time in vitro. Br J Cancer 41: 886-891, 1980. 
29. Eksborg S, Ehrsson H. Drug level monitoring: cytostatics. J Chrqmatogr 
340: 31-72, 1985. 
30. Fajardo LF, Eltringham JR, Stewart JR, et al. Adriamycin nephrotoxicity. 
Lab Invest 43: 242-253, 1980. 
31. Freireich EJ. The role of adriamycin in the treatment of adult acute 
leukemia. In: Adriamycin, its expanding role in cancer treatment. Ogawa M, 
Muggia FM, Rozencweig M (eds.). Excerpt Med Int Congr Ser 629, 1984, pp 3-9. 
32. Ganapathi R, Welter W, Krishan A. Intracellular adriamycin levels and 
cytotoxicity in adriamycin-sensitive and adriaraycin-resistant P388 mouse 
leukemia cells. J Natl Cancer Inst 68: 1027-1032, 1982. 
33. Garner A, Fox BW. Measurement of daunorubicin uptake of Yoshida Sarcoma 
cells in culture using flow cytofluorometry. Chem-Biol. Interactions 36: 
189-210, 1981. 
34. Goldman D. Pharmacokinetics of antineoplastic agents at the cellular level. 
In: Pharmacological principles of cancer treatment. Chabner B, editor. 
Saunders, London, 1982, pp 15-44. 
35. Goormachtigh E, Pollakis G, Ruysschaert JM. Mitochondrial membrane 
modifications induced by adriamycin mediated electron transport. Biochem Pharm 
32: 889-893, 1983. 
36. Gottlieb JA, Lefrak EA, O'Bryan RM, Burgess. Fatal adriamycin 
cardiomyopathy: prevention by dose limitation. Proc Am Assoc Cancer Res 14: 
88, 1973. 
37. Handa K, Sato S. Generation of free radicals of quinone group containing 
anticancer chemicals in NADPH-microsome system as evidenced by initiation of 
sulfate oxidation. Gann 66: 43-49, 1975. 
38. Jacobs JY, Michel J, Sachs T. Bactericidal effect of combinations of 
17 
antimicrobial drugs and antineoplastic antibiotic agents against staphylococcus 
aureus. Antimicrob Agents Chemother 15. 580-586, 1979. 
39. Inaba M, Kobayashi H, Sakurai Y, et al Active efflux of daunorubicin and 
adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 39-
2200-2203, 1979 
40. Krishan A, Ganapathi R. Laser flow cytometric studies on the intracellular 
fluorescence of anthracyclmes. Cancer Res 40: 3895-3900, 1980. 
41. Kumar Sinha B. Binding specificity of chemically and enzymatically 
activated anthracycline anticancer agents to nucleic acids. Chem Biol Interact 
30. 67-77, 1980. 
42. Londos-Gagliardi D, Aubel-Sadron G, Maral R, et al. Subcellular 
localization of daunorubicin in sensitive and resistant Ehrlich Ascites tumor 
cells. Eur J Cancer 16. 849-854, 1980. 
43. Luecke RH, Ryan MP, Woilsait WD A mathematical model and computer program 
for adriamycin distribution and elimination. Computer Methods and Programs in 
Biomed 20 25-31, 1985. 
44 Lum BL, Svec JM, Torti FM. Doxorubicin, alteration of dose scheduling as a 
means of reducing cardiotoxicity Drug Intell Clin Pharm 19: 259-264, 1985. 
45 Matsuzawa Y, Oki T, Takeuchi T, et al. Structure-activity relationships of 
anthracyclmes relative to cytotoxicity and effects on macromolecular synthesis 
m L1210 leukemia cells. J Antibiot 34· 1596-1607, 1981. 
46. McGown AT, Ward TH, Fox BW. Comparative studies of the uptake of 
daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and 
biochemical extraction procedures. Cancer Chemother Pharmacol 11: 113-116, 
1983. 
47. Moore HW. Bioactivation as a model for drug design bioreductive alkylation. 
Science 197: 527-532, 1977. 
48. Myers CE. Anthracyclmes. In: Pharmacological principles of cancer 
treatment. Chabner B, editor. Saunders, London, 1982, pp 416-434. 
49. Myers CE, Corden В, Gianni L Antitumor antibiotics I· anthracyclmes. 
In. Cancer chemotherapy 1983. Pinedo HM and Chabner BA, eds., Elsevier, 
Amsterdam, 1983, pp 66-79. 
50 Muggia FM, Young CW, Carter SK (eds ). Anthracycline antibiotics m cancer 
therapy Martmus Nijhoff Publishers, The Hague, 1982. 
51. Muhammed H, Ramasarma T, Ramakrisna CK. Inhibition of mitochondrial 
oxidative phosphonlation by adriamycin. Biochim et Biophys Acta 722- 43-50, 
1982. 
52 Oki T. Microbial transformation of anthracycline antibiotics and 
development of new anthracyclmes Anthracycline antibiotics. El Khadem, 
editor. Academic Press, New York, 1982, pp 75-91. 
53. Oosterbaan MJM, Dirks RJM, Vree TB, et al. Clinical pharmacokinetics of 
adriamycin. J Drug Res 7: 1372-1378, 1982. 
54. Park CH, Amare M, Savin MA, et al. Prediction of chemotherapy response in 
human leukemia using an in vitro chemotherapy sensitivity test on the leukemic 
colony-forming cells. Blood 55 595-601, 1980. 
55. Paul C, Baurain R, Gahrton G, Peterson C. Determination of daunorubicin and 
its main metabolites in plasma, urine and leukemic cells in patients with acute 
myeloid leukemia. Cancer Letters 9· 263-269, 1980. 
56. Paul C. Anthracycline cytostatics in acute leukemia. Thesis, Stockholm, 
1981. 
57. Pearlman LF, Simpkins H. The different effects produced by daunomycin and 
adriamycin on RNA, polynucleotides, single stranded, supercoiled DNA and 
nucleosomes. Biochem and Biophys Res Comm 131: 1033-1040, 1985. 
58. Philips DR, Roberts GCK. Proton nuclear magnetic resonance study of the 
self-complementary hexanucleotide d(pTpA)3 and its interaction with daunomycin. 
Biochemistry 19: 4795-4801, 1980. 
59. Powis G. Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14: 
177-183, 1985. 
60. Preisler HD, Gessner Τ, Azarnia Ν, et al. Relationship between adriamycin 
plasma level and the outcome of remission induction therapy for acute 
nonlymphocytic leukemia. Cancer Chemother Pharmacol 12: 125-130, 1984. 
18 
61. Preisler HD, Raza Α. In vitro assessment of drug sensitivity in acute 
nonlymphocytic leukemia. Ree Res in Cane Res 94: 102-115, 1984. 
62. Price LA, Hill BT. Safer cancer chemotherapy using a kinetically based 
experimental approach. The Mt Sinai J of Med 52: 452-459, 1985. 
63. Riggs CE, Bachur MR. Clinical pharmacokinetics of anthracycline 
antibiotics. In: Pharmacokinetics of anticancer agents in humans. Ames MM, 
Powis G, Kovack JS (eds). Elsevier, Amsterdam, 1983, pp 229-278. 
64. Riggs JR. Daunomycin review. Seminars in Oncology 11: Suplement 3, 1984. 
65. Robert J, Hoerni B, Vrignaud P, et al. Early phase pharmacokinetics of 
doxorubicin in non-Hodgkin lymphoma patients. Cancer Chemother Pharmacol 10: 
115-119, 1983. 
66. Shackney SE, Ritch RS. Cell kinetics. Pharmacological Principles of cancer 
treatment. Chabner B, editor. Saunders, London, 1982, pp 45-76. 
67. Skovsgaard T. Carrier mediated transport of daunomycin, adriamycin and 
rubidazon in Ehrlich ascites tumor cells. Biochem Pharm 27: 1221-1227, 1978. 
68. Skovsgaard T, Nissen NI. Membrane transport of anthracyclines. Pharmac 
Ther 18: 293-311, 1982. 
69. Sonneveld P. Pharmacokinetics of adriamycin in the rat. Thesis, Leiden, 
1980. 
70. Tan C, Kon-Ping Y, Morphy ML, Karnovsky DA. Daunomycin as antitumor 
antibiotic in the treatment of neoplastic disease. Clinical evaluation with 
special reference to childhood leukemia. Cancer 20: 333-336, 1967. 
71. Terasaki T, Iga T, Sugiyama et al. Quantitative evidence for interspecies 
difference in tissue distribution mechanism of adriamycin. J Pharm Dyn 5: 
S-67, 1982. 
72. Tobey RA. Effects of cytosine arabinoside, daunomycin, mithramycin, 
azacytidine, adriamycin and camptothecin on mammalian cell cycle traverse. 
Cancer Res 32: 2720-2725, 1972. 
73. Tokita N, Jett JH, Raju MR, et al. Correlation between cell cycle 
perturbations and survival levels after exposure to adriamycin for two Chinese 
hamster cell lines. Eur J Cane Clin Oncol 19: 547-551, 1983. 
74. Tokita N, Raju MR. Cell cycle dependent adriamcyin uptake in Chinese 
hamster cells. Eur J Cancer 21: 243-247, 1985. 
75. Trillet V, Lakhal M, Lang J, et al. Cellular pharmacokinetics of 
daunorubicin: uptake by leukemic cells in vivo and fate. Eur J Clin Pharmacol 
29: 127-129, 1985. 
76. Tritton TR and Yee G. The anticancer agent can be actively cytotoxic 
without entering the cells. Science (Wash. DC) 217: 248-250, 1982. 
77. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and 
anthracycline antibiotics. Cancer Treat Rep 67: 889-894, 1983. 
78. Von Hoff DD, Layard MW, Basa Ρ, et al. Risk factors for doxorubicin-induced 
congestive heart failure. Ann Int Med 91: 710-717, 1979. 
79. Yanovich S, Preston L. Effects of verapamil on daunomycin cellular 
retention and cytotoxicity in P388 leukemic cells. Cancer Res 44: 1743-1747, 
1984. 
80. Yesair DW, Thayer PS, McNitt S, et al. Comparative uptake, metabolism and 
retention of anthracyclines by tumors growing in vitro and in vivo. Eur J 
Cancer 6: 901-907, 1980. 
81. Young RC, Ozols RF, Myers CE. The anthracycline neoplastic drugs. New Engl 
J Med 305: 139-153, 1981. 
82. Weenen H, Lankelma J, Penders PGM, et al. Pharmacokinetics of 
4'-epi-doxorubicin in man. Invest New Drugs 1: 59-64, 1983. 
83. Weiss AJ, Manthei RW. A hypothesis concerning the effect of changes in 
scheduling upon the cardiotoxicity of adriamycin. Oncology 40: 223-226, 1983. 
84. Wingrad LB, Tritton JR, Egler KA. Cell surface effects of adriamycin and 
carminomycin immobilized on cross-linked polyvinyl alcohol. Cancer Res 45: 
3529-3536, 1985. 
19 

CHAPTER 2 
RAPID QUANTITATIVE DETERMINATION OF FOUR ANTHRACYCLINES AND THEIR MAIN 
METABOLITES IN HUMAN NUCLEATED HEMATOPOIETIC CELLS 
P.A.J. Speth, P.CM. Llnssen, J.B.M. Boezeman, 
J.M.C. Wessels and C. Haanen 
Journal of Chromatography 377: 415-422, 1986 
INTRODUCTION. 
Anthracyclines belong to the most potent cytostatic drugs in the treatment of 
cancer (1). Their concentrations in body fluids have been determined with a 
number of methods among which high performance liquid chromatography (HPLC) has 
proved to be the most valuable (2, 3, 4, 5). 
This paper describes factors that determine the extraction recovery of 
anthracyclines from human hematopoietic cells. A modification of the method of 
Baurain et al. (3) permits rapid determination of cellular concentration of 
four anthracycline compounds and their cytostatic active 13-hydroxy metabolites 
in the target cell. The method has been applied in studies of the in vivo 
cellular pharmacokinetics in leukemic cells, of which examples are given. 
EXPERIMENTAL 
Drugs and chemicals. Adriamycin (ADM), daunomycin (DNM), 4'-epi-adriamycin 
(E-ADM) and 4-demethoxydaunomycin (D-DNM) were kindly supplied by Farmitalia 
Carlo Erba (Milan, Italy). The 13-hydroxy metabolites adriamycinol (ADMol), 
4'-epi-adriamycinol (E-ADMol), daunomycinol (DNMol) and 4-demethoxydaunomycinol 
(D-DNMol) were kindly supplied by prof. F. Arcamene (Farmitalia Carlo Erba, 
Milan, Italy). Desipramine was a gift from Ciba Geigy (Basel, Switzerland). 
All other chemicals were purchased from Merck (Darmstadt, G.F.R.) and were of 
analytical grade. 
Preparation of cell suspension. Blood samples from patients were obtained in 
heparinized polypropylene tubes on ice. After immediate centrifugation plasma 
was removed for analysis of the anthracycline concentration. To obtain a pure 
white blood cell suspension, erythrocytes in the pellet were lysed with at least 
4 volumes of ammonium chloride (8.29 g NH.Cl, 1 g KHCO and 37 mg К EDTA per 
liter, pH 7.3) on ice (6). After centrifugation at О С the white cells were 
resuspended in 500 vl of cold phosphate buffered saline, pH 7.4. Cell numbers 
were counted. The recovery of white cells after the lysis step amounted to 
80-90%. Plasma and cell suspensions were stored at -20 С until analysis by 
HPLC. 
Extraction. A 250-yl volume of the thawed cell suspension containing less than 
10 cells was sonicated at 75 W for 15 s (MSE Soniprep 150 Ultrasonic 
Disintegrator, MSE Scientific Instruments, Crowley, U.K.) and extracted twice 
with 3 ml of chloroform/methanol (9:1 v/v) supplemented with 100 μΐ 1 M Tris 
buffer (pH 8.8) containing the internal standard (DNM for ADM, and ADMol for 
E-ADM, DNM and D-DNM). The two chloroform phases were collected and evaporated 
in one step at 35 С under air. The dry residue was dissolved in 750 yl of 
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chloroform/methanol (9 1 v/v). After addition of 50 μΐ of Tris buffer, mixing 
and 5 min centrifugation at 1000 g, 500 μΐ of the organic phase was injected 
into the chromatographic system. Samples of 500 μΐ plasma were extracted in a 
similar way 
High performance liquid chromatography The chromatographic system consisted of 
a double head pump (LC3-XP, Pye Unicam, Cambridge, U K . ) , a sampling valve 
(Valco, Houston, TX, U S.A ) and a sampling loop of 500 μΐ The analytical 
column (10 cm χ 3 0 mm I.D ) was packed with spherical silica-gel SI-60, 
particle size 7 μη (Chrompack, Middelburg, The Netherlands). A fluorescence 
detector (FS 970 L.S Fluorometer, Schoeffel Instr, Ramsey, NJ, U S A ) was used 
with an excitation wavelength of 488 nm Emission was detected above 550 nm. 
The column was eluted with chloroform-methanol-glacial acetic acid-water 
(720 210:40.30) supplemented with 0 3 mM MgCl , and 10 pg/ml desipramine. The 
flow-rate was set at 0.8 ml/min Quantification of the cellular drug 
concentrations was achieved by measuring the peak-height ratio of the drug and 
the internal standard, and it was calculated from a calibration curve of 
peak-height versus concentration The detection limit of the drugs investigated 
was 1 ng at a signal-to-noise ratio of 3.1 Results are expressed in ng/ml for 
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plasma and cells, assuming that 10 cells equalize 1 ml. 
Calibration curve Samples of 250 yl cell suspension were spiked with the 
appropriate drugs A calibration curve in the anticipated range from 1 to 500 
ng/ml was made each time before analysis. The correlation coefficients of the 
calibration curves were always better than 0 96 
Day-to-day variation and recovery. At the start of this study for each of the 
investigated drugs, a suspension of nucleated blood cells was prepared, divided 
into numerous samples and stored at -20 C. These samples were used as so-called 
"reference samples" each time cells were analysed for their anthracycline 
concentration Thus, the day-to-day variation over the whole procedure of 
extraction and analysis could be calculated over a long period of time. This 
variation was expressed as the standard deviation, divided by the mean and 
multiplied by 100%. The recoveries of the parent drug and the 13-hydroxy 
metabolites after extraction were measured over a concentration range from 5 to 
200 ng/ml and were compared with the direct assay of the standard in 
chloroform/methanol (9:1 v/v) 
Cellular pharmacokinetics With the method described, cellular and plasma 
pharmacokinetics of ADM, E-ADM, DNM and D-DNM were studied in patients treated 
for acute myelogenous leukemia and solid tumors. The plasma and cell 
concentration data were fitted according to a two-compartment open model, and 
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the pharmacokinetic parameters were calculated according to the conventional 
procedures (7). 
RESULTS AND DISCUSSION. 
Extraction efficiency. A number of factors determine the recovery of the 
extraction of anthracyclmes from cell suspensions. Best results were obtained 
with the procedure which consisted of somcation of 250 μΐ cell suspensions 
containing less than 40.10 cells/ml, followed by 2 extraction steps with 3 ml 
chloroform/methanol (9:1 v/v) under addition of 100 μΐ 1 M Tris buffer, pH 8.8, 
and evaporation of the collected organic phases in one step at 35 С under air. 
Data thus obtained were set at 100% Variables in this method are discussed 
below and related to these data. 
-mm peak height 
χ 10 cells / 250 ul 
FIGURE 1. Influence of absolute cell number on the recovery of the ADM 
extraction. Concentration ADM per 10 cells after one (θ), tuo (x), 
and three extractions (O) with 3 ml chloroform/methanol (9:1 v/v) of 
250 μ7 cell suspension, (data of one out of three experiments). 
Sonication of the cell suspension at 75 W for 15 s improved the extraction of 
anthracyclines. Recovery after extraction of the non-sonicated cell suspension 
was 64 ± 18%, which increased to 100 ± 8% in the case of sonication (n = 9). 
The effects of the cell concentration, as well as the number of extraction 
steps, on the recovery of ADM from cells is illustrated in Fig. 1. After 3 
extractions with 3 ml chloroform/methanol (9:1 v/v), the curve is linear up to 
25x10 cells per 250 μΐ (r = 0.99). After 2 extractions linearity is observed 
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to 15x10 cells per 250 μΐ (r = 0.99). Two extractions of 25x10 cells per 250 
μΐ, or 1 extraction of more than 5x10 cells per 250 μΐ, revealed data which 
were outside the 95% confidence interval compared with 3 extractions. 
Extraction with chloroform/methanol (4:1 v/v) as applied by Baurain et al. (3) 
resulted in recovery of 77% (ADM), 68% (DNM), 74% (E-ADM) and 68% (D-DNM), 
compared to the extraction with chloroform/methanol (9:1 v/v) (n = 5). 
With an increase of the volume of the cell suspension from 100 to 500 μΐ, a 
gradual decrease in recovery from 100 to 76% was observed after one extraction. 
A second extraction improved the recovery. 
With the method described for ADM, E-ADM, DNM and D-DNM, linearity of extraction 
efficiency was observed up to 60.10 cells/ml (n = 16) with r-values of 0.98 
(ADM), 0.96 (E-ADM), 0.97 (DNM) and 0.96 (D-DNM) (Fig. 2). 
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FIGURE 2. Extraction efficiency of ADM, E-ADM, DNM and D-DNM from 
suspensions with increasing cell concentrations per ml. Linearity was 
observed to above 40.10 cells per ml. 
Stability, day-to-day variation and recovery. Each time cellular anthracycline 
concentrations were measured, two reference samples were extracted as well. The 
storage period of the reference samples varied from 6 to 9 months. The 
concentration of the different anthracyclines did not change during this storage 
period (Table 1). The day-to-day variation over the whole procedure of 
extraction and chromatographic determination of the reference samples was 6.9% 
for ADM (n =20), 9.1% for DNM (n = 18), 9.0% for E-ADM (n = 21) and 10.1% for 
D-DNM. (n = 23). The recoveries after the extraction procedure of the four 
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anthracyclines were 92.4 ± 12.8% (ADM), 91.9 + 8.8% (DNM), 83.9 ± 13.8% (E-ADM) 
and 94.3 ± 8.1% (D-DNM). 
TABLE 1. Cellular anthracycline concentrât ions (ng/10 cells) over a 
storage period up to 9 months at -20 C. 
Number 
STORAGE PERIOD 
1 month 9 months 
4 4 
decrease 
adriamcyin 2100 ± 200 2100 ± 200 N.S.* 
4'-epi-adriamycin 2500 ± 100 2400 ± 200 N.S. 
daunomycin 4600 ± 200 4500 ±200 N.S. 
4-demethoxydaunomycin 3800 ± 300 3700 ± 300 N.S. 
* N.S.: not significantly different 
Chromatography. Chromatograras of cell samples spiked with 25 ng/ml cell 
suspension of ADM, E-ADM, DNM or D-DNM and their 13-hydroxy metabolites are 
shown in Fig. 3. Blank cells showed only the injection peak and the internal 
standard. Retention times were at most 2 min 31 s. 
ADMol г ' Э Г 
ADM 2 ' 0 1 " 
DNM 1 ' 3 7 " ( i n t . S t . ) 
ADMol 1·ί\" ( i n t . s t ) 
E-ADMol Î ' H 
E-ADM Γ 5 1 " 
ADMol г-П" ( i n t . s t . ) 
DNMol Г 53 
DNM Г 3 7 " 
ADMol г'ЭГ' ( i n t . s t . ) 
D-DNMol Г 5 2 
D-DNM Г 36" 
I о -*— ·" » 
ï ^ ( _ y - ADMol г ' З Г ( i n t . s t . 
Ι < Г BLANC 
0
 — * I n j e c t i o n 
FIGURE 3. Chromatograms of blank and spiked cell samples. Samples 
were spiked with 25 ng/ml D-DNH, DNM, E-ADM, ADM and their 13-hydroxy 
metabolites. Inst, st.: internal standard. 
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Cellular pharmacokinetics Fig 4 and Table 2 illustrate the importance of 
cellular pharmacokinetics, which differ considerably from plasma 
pharmacokinetics ADM (75 mg) was administered either as a bolus injection or 
as a 4-h continuous infusion D-DNM (18 mg) was administered as a bolus 
injection only 
b Mo ÖÜ bo NJti^T ON 
FIGURE 4 The cellular and plasma concentration-time profiles of ADM 
and ADHol measured over a period of six days after 75 mg of ADH 
administered as a bolus injection (left) or as a 4-h infusion 
(middle), and after IS mg of D-DNM bolus injection (right) (x) 
cellular anthracyclme concentration, (+) plasma concentration, (o) 
plasma 13-hydroxy metabolite 
TABLE 2 Cellular and plasma pharmacokinetics of 75 mg Adriamycm 
administered as bolus injection or as 4-h infusion and of 18 mg 
4-demethoxydaunomycin administered as bolus injection 
DRUG l/2a 
00 
1/20 
(h) 
в 
AUC 
(ng/ml) (ng/ml) (vg h/L) 
Adriamycm bolus 0 3 
Adriamycm infusion 0 1 
4-demethoxydaunomycin 0 4 
PLASMA 
34 3 
42 8 
47 2 
818 
900 
37 6 
25 5 
14 
2 4 
1601 
1552 
188 
CELLS 
Adriamycm bolus 
Adriamycm infusion 
4-demet hoxydaunomyсin 
0 1 
0 1 
0 6 
103 
117 
15 
11900 
9500 
6635 
4237 
4511 
1035 
637700 
765880 
28457 
T, ., first half-life time, T, ... 
l/Za L/¿p terminal half-life time 
A and В are calculated concentration constants 
AUC area under the curve 
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The most remarkable facts are the rapid cellular uptake during, and the 
considerable loss a few minutes after the end of the bolus injection, the 
continuous cellular uptake in the case of prolonged infusion (up to a 
cellular/plasma ratio of more than 600) and the long cellular terminal 
half-life. While no cellular ADMol was observed, cellular D-DNMol very soon 
exceeded cellular D-DNM concentrations. 
Although the maximum plasma level was reduced one decade compared to a bolus 
injection in the case of prolonged ADM infusion, the cellular concentrations at 
the end of the infusion and thereafter were of the same order of magnitude as 
observed in the case of the bolus injection. 
CONCLUSION 
In pharmacokinetic studies of anthracycline antibiotics great effort is 
generally given to evaluating the disappearance rate of plasma concentrations 
(2, 8, 9, 10). However, cellular concentration-time profiles are much more 
relevant in vivo, since cells are the target of the drug. In studies on 
cellular pharmacokinetics so far (11, 12, 13, 14), no attention has been paid to 
the specific factors that affect the extraction recovery of anthracyclines from 
human hematopoietic cells. Extraction of suspensions containing more than 
40x10 cells/ml is very likely to underestimate the actual cellular drug 
concentration, unless attention is paid to: the absolute cell number and the 
volume which is extracted, to prior sonication, and to the number of extraction 
steps. 
Eksborg et al. (15) described a decrease in ADM plasma concentrations after a 
prolonged storage time. This was not confirmed by Oosterbaan et al. (9). In 
our study, no decline in concentrations was observed over a storage period of 9 
months at -20 С in cell suspensions containing ADM, DNM, E-ADM and D-DNM. 
Preliminary data from our laboratory suggest good correlations between cellular 
drug concentrations and cytotoxicity (chapter 9 and 10). Studies on drug 
concentrations in the target cells in vivo should be extended to improve our 
knowledge of the working mechanism of cytostatic drugs. Since only mean 
cellular drug concentrations are obtained with this method, these observations 
also have to be extended to flow cytometric studies of anthracycline 
concentrations in individual cells (16). However, chromatography will remain 
necessary and will be complementary to this technique. 
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CHAPTER 3 
QUANTIFICATION OF ANTHRACYCLINES IN HUMAN HEMATOPOIETIC CELL SUBPOPULATIONS 
BY FLOW CYTOMETRY CORRELATED WITH HIGH PRESSURE LIQUID CHROMATOGRAPHY 
Paul A.J. Speth, Peter CM. Linssen, Jan B.M. Boezeman, 
Hans M.C. Wessels and Clemens Haanen 
Cytometry 6: 143-150, 1985 
SUMMARY. 
The major white cell subpopulations present in bone marrow and peripheral blood 
can be discriminated by forward and perpendicular light scatter two parameter 
flow cytometry (FCM). Fluorescent properties of anthracycline antibiotics allow 
measurement of the concentration of these cytotoxic drugs in hematopoietic cells 
by FCM as a third parameter. 
Analysis of scatter-gated fluorescence histograms provides quantitative 
information about the cellular concentrations of at least four cell categories 
in human blood and bone marrow cells. Mean cellular anthracycline-fluorescence 
measured by FCM correlated well with the overall cellular concentration of 
adriamycin, daunomycin, and their main metabolites determined with high pressure 
liquid chromatography (HPLC). 
In incubation experiments with human hematopoietic tissues, the final 
concentration of various anthracyclines in subpopulations of white cells 
appeared to be dependent on cell density, incubation time, temperature, and type 
of compound and its concentration. 
FCM analysis is a rapid, sensitive and quantitative method for measurement of 
cellular anthracycline concentrations in subpopulations of cells and therefore 
provides an useful new tool in monitoring chemotherapy. 
INTRODUCTION. 
Anthracycline antibiotics are endowed with powerful cytotoxic properties against 
malignant cells. These drugs have a prominent role in chemotherapeutic regimens 
in current cancer treatment (5, 19, 28). They are supposed to act mainly by 
intercalation in DNA, -inhibiting both DNA replication and RNA transcription 
(1)-, by membrane binding, and by free-radical formation (19). 
The conventional kinetics of these drugs in plasma of patients have been studied 
extensively with thin layer chromatography (4, 17) and high pressure liquid 
chromatography (HPLC) (13, 21). The calculated distribution volume of 
anthracyclines is in the order of 25 1/kg (13, 21), illustrating that these 
drugs have been accumulated almost completely in the tissues outside the plasma 
compartment. Nevertheless, data on concentrations in human tissues are scarce, 
although knowledge of cellular concentrations should offer more relevant 
information on the influence of anthracyclines on cellular kinetics. Several 
studies with cell lines have shown that most anthracyclines accumulate almost 
exclusively in the nucleus (9) and that the fluorescent property of 
anthracyclines allows measurement of cellular drug concentrations with use of 
flow cytometry (FCM) (8, 12, 16, 24, 25). 
This paper describes the correlation between the rapid and quantitative 
technique that employs FCM multiparameter analysis for the determination of the 
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cellular anthracycline concentrations in subpopulations of human bone marrow and 
blood, and the cellular anthracycline concentrations as measured with HPLC. The 
FCM method enables rapid monitoring of cellular anthracycline concentration on a 
cell-per-cell basis and requires relatively small numbers of cells (2x10 ) with 
a detection level that equals that of HPLC. Therefore FCM facilitates the study 
of cellular anthracycline kinetics in different cell types and subpopulations 
and may provide a new approach to monitoring and individualization of cytostatic 
therapy. 
MATERIALS AND METHODS. 
Anthracyclines. The anthracyclines adriamycin and daunomycin were obtained from 
Laboratoire Roger Bellen S.A. (Neuilly sur Seine, France) and Specie, (Paris, 
France) respectively. Carminomycin was obtained from Bristol Meyers (Syracuse, 
NY, U.S.A.). For experimental use adriamycin and daunomycin, and their 
metabolites adriamycinol and daunomycinol were generously supplied by prof. F. 
Arcamene, Farmitalia Carlo Erba (Milan, Italy). 
Bone marrow. Normal bone marrow for in vitro studies was obtained from cardiac 
surgery patients (Dept. Cardiac Surgery, Head Prof. L.K. Lacquet). The 
samples were collected in buffered acid citrate dextrose solution (ACD formula 
A, pH 7.4). The admixture of peripheral nucleated cells in the bone marrow 
sample was calculated according to Holdrinet et al. (14). Only bone marrow 
samples with less than 20% admixture of peripheral nucleated blood cells were 
used for further study. Prior to incubation, the cells were washed and 
resuspended in phosphate buffered saline, pH 7.4 (PBS) to a final cell 
concentration of 3x10 nucleated cells per ml. 
Incubation. Bone marrow cells (3x10 nucleated cells/ml PBS) were incubated in a 
shaking water bath at 37 С in stoppered polypropylene tubes (Greiner, Nürtingen, 
G.F.R.). The anthracycline compounds were added to final concentrations as 
indicated, ranging from 0.05 up to 3.0 ug/ml. The lower part of this range was 
deliberately chosen since the final cellular concentrations measured after 
incubation for 120 min with these drug concentrations are comparable with the 
anthracycline concentrations observed in hematopoietic cells in patients during 
chemotherapy with these cytostatics. Incubations at 0 С were performed in order 
to investigate the process of cellular anthracycline uptake and efflux. 
The incubation was terminated by addition of 4 ml cold lysis buffer (8.29 g 
NH.Cl, 37 mg К EDTA and 1 g KHCO per liter, pH 7.3) to 1 ml incubation medium, 
to lyse erythrocytes and normoblasts (27). The tubes were kept on ice for 5 min 
with regular tilting, centrifuged (900 g, 5 min at 0 C) and the supernatant was 
discarded. This procedure was repeated a second time. The cells were 
resuspended in cold PBS at a concentration of 3x10 nucleated cells/ml and kept 
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on ice until FCM analysis, usually within 3 h. Cytospin preparations were made 
for morphological control. For HPLC analysis cells were stored at -20 C. 
Light scatter and cellular fluorescence measurement by FCM. FCM analysis was 
performed on a System-50H Cytofluorograf (Ortho Diagnostic Systems, Westwood, 
MA, U.S.A.) equipped with a 5-W argon laser (164-05, Spectraphysics, 
Mountainview, CA, U.S.A.) running at 488 nm, 0.5 W. Fluorescence was measured 
with a barrier filter 0G550 (Melles Griot Optical Industries, Costa Mesa, CA, 
U.S.A.). The Cytofluorograf was aligned with l.S-ym fluorescent microspheres 
(Fluoresbrite, Polysciences, Warrington, PA, U.S.A.). The coefficient of 
variation (cv) of the fluorescence was 1.7%. Thereafter the flow cytometer was 
calibrated daily with an extra neutral density filter, OD 2.0 (Melles Griot, 
Optical Industries, Costa Mesa, CA, U.S.A.) in front of the 0G550 filter 
projecting the mean fluorescence signal in histogram channel 100. The position 
of this peak was checked regularly. The combination of forward light scatter 
(FLS) and perpendicular light scatter (PLS) was used to discriminate the major 
3 
white cell subpopulations (23, 24, 26). For each sample, at least 12x10 cells 
were analysed at a flow-rate of 1000 cells/s. 
Data of FLS, PLS and fluorescence per cell were measured in area mode, stored in 
list mode and analysed on a PDP 11/34 computer (Digital Electronic Company, 
Maynard, MA, U.S.A.). Mean fluorescence is expressed in arbitrary fluorescence 
units/cell (FU/cell) representing the mean fluorescence of the cells 
investigated, with the blank samples used to correct the anthracycline 
fluorescence for endogenous fluorescence. All fluorescence data thus given are 
corrected for the blanks by subtracting the blank value. Statistical analysis 
provides standard deviation and coefficient of variation of the mean 
fluorescence together with the number of cells in each selected subpopulation. 
Extraction procedure and chromatographic analysis. The method used was according 
to the straight-phase method described by Baurain et al. (3) with minor 
modifications. Briefly, 10 cells were sonicated for 15 s at 75 W with a MSE 
Soniprep 150 Ultrasonic Disintegrator (MSE Scientific Instruments, Crowley, 
U.K.). 250 yl of the sonicated cell suspension was added to 3 ml 
chloroform/methanol 9:1 (v/v), followed by 100 μΐ Tris buffer (1 M, pH 8.8) 
containing the internal standard. After two extractions with 
chloroform/methanol 9:1 (v/v), the chloroform phase was collected and 
evaporated. The residue was dissolved in 750 yl chloroform/methanol, with 
addition of 50 yl Tris-buffer (1 M, pH 8.8). A 500-yl sample was injected into 
the column (Lichrosorb 5SÌ60 column 100 mm χ 4.6 mm I.D.). The column was 
eluted with chloroform, methanol, glacial acid, and a 0.3 mM MgCl. water 
solution (720:210:40:30 v/v) under addition of deslpramine 5 mg/L (kindly 
supplied by Ciba Geigy, Basel, Switzerland) to decrease adsorption effects of 
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anthracyclines to the tubings. Detection was carried out with a fluorometer (FS 
970 L.S. Fluorometer, Schoeffel Instr , Ramsey, NJ, U.S.A.), λ-excitation at 
488 іш, λ-emission above 550 nm Quantification of the drug concentration was 
achieved by measurement of the peak-height ratio of drug and internal standard 
and calculated from a calibration curve of peak-height versus concentration. 
The detection limit of adnamycin, daunomycin and their metabolites was 1 ng. 
The withm-day precision of the method was 6.4% (n = 37). 
RESULTS. 
Scatter and fluorescence parameters. Since treatment of a bone marrow or blood 
sample with lysis buffer removes the erythrocytes and normoblasts almost 
completely the lymphoid, monocytoid and myeloid subpopulations can be clearly 
distinguished by two parameter light scatter FCM (FLS and PLS) as indicated in 
Fig. 1. 
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FIGURE 1. Dot display of forward light scatter (FLS) versus 
perpendicular light scatter (PLS) of nucleated human bone marrow cells 
after lysis of erythrocytes and normoblasts. The combination of FLS 
and PLS reveals distinct cell subpopulations m bone marrow or 
peripheral blood. 
With small light scatter gating, the small signals caused by erythrocyte ghosts 
and aggregates of thrombocytes can be ignored. The identity of the different 
subpopulations was determined by sorting each of these cell clusters followed by 
staining and microscopical examination. The lymphoid population consists of 98% 
lymphocytes, the myeloid population of 95% myeloid cells and granulocytes, and 
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what is referred to as monocytoid cells consists in blood: of monocytes, and in 
normal bone marrow: of monocytes, myeloblasts and proerythroblasts. 
Lysis with cold NH.Cl did not decrease the cellular fluorescence intensity as 
was shown by control experiments with saline instead of NH.Cl. The procedure 
did not interfere with cell viability as was demonstrated with propidium iodide 
exclusion and fluorescein diacetate cell staining and by uncompromised 
clonogenicity in bone marrow culturing. The recovery of nucleated white cells 
after NH.Cl lysis varied around 80%. 
Cells that do not contain anthracyclines exhibit weak green autofluorescence 
within the cytoplasm. The autofluorescence of the monocytoid population is 
slightly higher than that of the myeloid and lymphoid cells, which may be due to 
different amounts of cytoplasm. 
Anthracycline concentrations in subpopulations. Normal human bone marrow cells 
were incubated during 120 min at 37 С with 0.5 vg/ml of several anthracyclines. 
Of these the data of adriamycin (ADM), daunomycin (DNM) and carrainomycin (CMM) 
are given in Fig. 2 in a three dimensional plot illustrating the extremes of 
differential cellular concentrations. 
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FIGURE 2. Cellular fluorescence of subpopulations after incubation 
with adriamycin, daunomycin and carminomycin 0.5 \ig/ml for 120 min at 
37 C. On the x-axis PLS, on the y-axis FLS, on the z-axis arbitrary 
fluorescence units/cell. 
The final cellular concentration of DNM was higher than that of ADM. CMM is 
concentrated preferentially by the myeloid cells, and less by the lymphoid 
36 
cells. 
By placing windows in the scattergram the mean fluorescence intensity of 
separate cells out of each subpopulation can be measured, plotted and expressed 
in mean FU/cell. Fluorescence histograms from the total amount of cells and 
from each selected subpopulation can be obtained very easily, enabling the 
analysis of the fluorescence characteristics of each subpopulation (Fig. 3). 
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FIGURE 3. Fluorescence frequency histogram of the main subpopulations 
of human bone marrow cells, incubated with saline (blank, left) and 
0.5 vg daunomycin/ml (right) for 120 min at зУс. 
Bone marrow cells (3x10 cells/ml) were incubated for 120 min at 370C with 
adriamycin (ADM), adriamycinol (ADMol), daunomycin (DNM) and daunomycinol 
(DNMoL) in final concentrations of 0.05 up to 1.0 pg/ml. After incubation the 
cellular fluorescence of 12x10 cells was measured by FCM. For each of the 
drugs a close linear correlation was observed between the anthracycline 
concentrations in the medium and the mean FU/cell (n = 6, r = 0.99)(Fig. 4). 
The slope of the curves is different for the four drugs used. As the molar 
absorptivity (7.89 χ 10 at 500 nm) and the emission spectrum curve of the four 
drugs are identical (10, 11) it can be concluded that DNM has been accumulated 2 
to 6 times more than ADM. The metabolites ADMol and DNMol are accumulated in 
amounts less than half that of their parent drug. In two experiments it was 
shown that the linearity of the curve was maintained when the concentration 
range was extended from 0.05 to 3.0 yg/ml. A similar linear relationship was 
observed when the cellular fluorescence in each of the separate subpopulations 
was plotted against the anthracycline concentrations in the incubation medium. 
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The monocytoid and blast cells appeared to take up slightly more than myeloid 
cells and lymphoid cells. 
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FIGURE 4. Correlation of cellular fluorescence with drug concentration 
in the medium. Bone marrow cells were incubated at 3x10 eel Is/ml 
with 0, 0.05, 0.1, 0.3, 0.5, 0.7 and 1.0 vg/ml of adriamycin (Ο), 
adriamycinol(0), daunomycin (Ü) and daunomycinol (Ж) for 120 min at 
37 C. After NHjCl-lysis the mean cellular fluorescence of all the 
cells was determined by FCH, (FU/cell, y-axis) and plotted versus the 
anthracycline concentration in the medium fpg/nJ, x-axls). 
Correlation of FCM with HPLC. In a second series of experiments 3x10 cells were 
incubated during 120 min with 0.1, 0.5 and 1.0 yg ADM, ADMol, DNM and DNMol/ml. 
Most of the cells were used for determination of the cellular anthracycline 
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content by HPLC. In the remainder of 12x10 cells the mean cellular 
fluorescence was determined by FCM as described above. The FCM and HPLC values 
closely correlated for each of the drugs as is shown in Fig. 5 (n = 36, 
r = 0.99). 
From these data it can be calculated that an increase of 100 FU/cell equals an 
increase of circa 3 to 4 fg anthracycline/cell. From Fig. 4 it can be read that 
the fluorescence intensity/cell detectable after incubation with 0.05 ug ADM and 
ADMol/ml for 120 min approaches the detection limit. When the cellular 
concentration of these two drugs was subsequently determined by HPLC, only small 
peaks were observed in the chromatogrem. Incubation of peripheral blood cells 
with the mentioned anthracycline concentrations resulted in a similar good 
q 
correlation between FCM and HPLC values (n = 36, r = 0.93). Assuming that 10 
cells represent a volume of circa 1 ml, the measured cellular concentration was 
observed to be a factor 26 (ADM), 5 (ADMol), 85 (DNM) and 30 (DNMol) times the 
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FIGURE 5. Correlation of HPLC and FCM values. Bone marrow cells were 
incubated with 0.1, 0.5 and 1.0 vg/ml of the drugs indicated. Part of 
the sample was extracted and analysed by HPLC (ng parent+metabolite 
per 10 cells, x-axis). Part was analysed by FCM (FU/cell, y-axis). 
concentration in the incubation medium. 
The effect of cell density. In a third series of experiments the concentration 
of cells was varied from 10 to 10 cells/ml. Cells were incubated with 0.1 and 
0.5 vg/ml ADM and DNM under the conditions as described above. For both drugs a 
markedly decreased FU/cell was observed, which was not linearly correlated with 
an increasing cell concentration. The relation was even different for the two 
drug concentrations and was observed in all subpopulations (Fig. 6). The 
greatest differences were noted in incubations with less than 3.10 cells/ml. 
Differential cellular anthracycline concentrations. To illustrate the potential 
of FCM in the investigation of human cellular pharmacokinetics of 
anthracyclines, cells were incubated at 0oC and 370C for 15, 120 and 240 min at 
0.5 vg/ml with ADM, DNM and carminomycin (CMM). For each time point, the 
cellular fluorescence was determined by FCM. Data were analysed to obtain the 
cellular concentrations per subpopulation, i.e., lymphoid (Ly), monocytoid (Mo) 
and myeloid (My) cells. All three drugs showed a rapid initial increase in 
cellular concentrations, but the final maximum concentrations differed per drug 
and per subpopulation and was reached at different time periods (Fig. 7). DNM 
was taken up to the highest, ADM was taken up to the lowest concentrations. 
39 
'^DRIAMYCIN 
θ 1 иС/И. ILTWHOID CELL.5) 
β I UC/HL CUVELOID CELLS) 
0 I UG/«. [UONOCTTOIO CELLS) 
β S UC/H. CLTWWIO CELLS] 
β 3 UG/kl· CUTELOID CELLS! 
• 3 ÜC/UL СУОШСГТОІО CELLS) 
-OAUNOMYCIN 
-105CELLS / ML MEDIUM 
CELL-CONCENTRA Τ ION CU»« 
-la-CELLS / ML MEDIUM 
CELL-CCMCENÌNATICN CUAVE 
FIGURE 6. Influence of cell density during incubation 
up 
on final 
cellular fluorescence. 0.1  to 8x10 bone marrow cells were 
incubated with 0.1 and 0.5 vg adriamycin and daunomycin/ml for 120 min 
at 37 C. Cellular fluorescence is expressed in FV/cell (y-axis) and 
plotted for the main subpopulations versus cell density (x-axis). 
(data from a représentâtive experiment outof a series). 
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FIGURE 7. Concentration time curve for human bone marrow cells 
incubated with 0.5 \xg/ml of adriamycin, daunomycin and carminomycin 
for 15, 120 and 240 min at 370C. On the x-axis the time in minutes. 
On the y-axis mean FU/cell for the subpopulations. (ІЗ) lymphoid, (<Q) 
aonocytoid and (O) myeloid cells. The data given are corrected for 
the blank. SD is given (n = 6). 
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TABLE 1. Ratio of differential uptake in the main cell subpopulations 
of human bone marrow. See also Fig. 7. Statistical analysis was 
perforaed with the two sided paired student t test. 
lymphoid/myeloid lymphoid/monocytoid myeloid/monocytoid 
Time (min) 15 120 240 15 120 240 15 120 240 
Adriamycin 0.4* 0.6* 0.8 0.5* 0.6+ 0.6* 1.3+ 1.0 0.8 
Daunomycin 1.1+ 1.1 1.1 0.6* 0.8+ 0.8* 0.5* 0.7+ 0.7* 
Carminomycin 0.7+ 0.5* 0.5* 0.4* 0.6* 0.6* 0.6+ 1.2 1.3+ 
*:p<0.01, +:p<0.05. 
In general the cellular fluorescence at 240 min was somewhat higher compared to 
that at 120 min, but except for ADM (Ly and Mo) this difference was not 
significant. The cellular concentrations in the different subsets were 
expressed as Ly/Mo, Ly/My or My/Mo ratio (Table 1). For DNM the Ly/My ratio was 
1.1, for CMM it came close to 0.50 (p<0.01) indicating that CMM uptake by 
lymphoid cells was only 50% compared to myeloid cells. The Ly/Mo ratio at 240 
rain equals or is lower than 0.80 (p<0.01). In ADM and DNM the My/Mo ratio was 
less than 1.0, indicating that monocytoid cells concentrate more of these 
compounds compared to other cell types. 
Almost no cellular drug concentrations were observed if the incubation was 
performed at 0 C. No fluorescence was lost as long as the cells were kept on 
ice after the termination of the incubation. When the cells were not kept on 
ice or were reincubated in drug-free medium, rapid loss of fluorescence was 
noted to a different extent for each of the drugs. 
DISCUSSION. 
Pharmacological studies of anthracyclines in humans have been directed mostly to 
the kinetics of these drugs and their metabolites in body fluids. Data on 
cellular anthracycline concentrations in human normal or leukemic cells are 
scarce (22, 24). With HPLC such data can be acquired provided that many 
millions of cells are available. The HPLC method is laborious and does not 
provide information about concentrations present in different cell 
subpopulations of hematopoietic or tumor tissue. 
Three-parameter FCM techniques only need small numbers of cells (2x10 cells) 
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and allow discrimination of subpopulations (23, 24, 26) for which the respective 
fluorescence intensity as a measure for cellular anthracycline content can be 
determined simultaneously. 
FCM does detect but not discriminate fluorescence of different anthracyclines or 
their metabolites. The 13-hydroxy metabolites of ADM and DNM have the same 
fluorescent properties as their parent drugs (10, 11). The lower cellular 
concentrations (Fig. 4) after incubation under similar conditions reflects an 
impaired uptake. This in part could be explained by the different polarity of 
the drugs, as was described for uptake by L1210 cells earlier (2). 
Recently attempts have been made to correlate FCM data to fluorometric 
techniques to quantitate cellular ADM (6) or DNM (18) concentrations or to 
with other quantitative techniques like HPLC, and offered a rapid, sensitive and 
reproducible technique for determination of cellular anthracycline 
concentration. This method required only a few thousand cells per measurement. 
The detection level is comparable to that reached with HPLC, but it may be 
called even better taken into account that only a few thousand cells per 
measurement are required. Pharmacokinetics in hematopoietic cells can thus 
easily be monitored. Attention must be given to the numerous factors that 
appear to influence cellular concentrations. 
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CHAPTER 4A 
CELLULAR AND PLASMA ADRIAMYCIN CONCENTRATIONS AFTER CONTINUOUS INFUSION 
CHEMOTHERAPY IN PATIENTS WITH LEUKEMIA 
Paul A.J. Speth, Peter CM. Linssen, Hans M.C. Wessels and Clemens Haanen 
Submitted to European Journal of Clinical Pharmacology 
SUMMARY 
To determine whether constant-rate adnamycin (ADM) infusions resulted in 
cellular ADM concentrations at least comparable to those observed after bolus 
injections, ADM cellular and plasma concentrations were measured in IB patients 
with acute and chronic nonlymphocytic leukemia ADM was administered at 
2 
30mg/m /day, either as bolus injections or as 4, 8 and 24 h infusions at day 1, 
2 
2 and 3. The treatment protocol furthermore consisted of 1 mg/m vincristine at 
2 
day 2 and 200 mg/m cytosine arabinoside at day 1 to 7 Negligible accumulation 
of plasma ADM was observed Peak plasma ADM concentrations after the third 
bolus injection amounted to 1640 ± 70 ng/ml (n = 7). Maximal concentrations 
during 4h infusion then amounted to 176 ± 34 ng/ml (n = 5), during 8 h infusion 
to 85 ± 50 ng/ml (n = 4) and to 47 ± 5 ng/ml after 3x24 h infusion (n = 2). 
Nucleated blood and bone marrow cell ADM concentrations correlated well 
(r = 0.82). ADM was accumulated in leukemic cells after consecutive 
administrations The shorter the administration time-span, the higher the 
initial leukemic cell concentration (bolus injection- 11070+1470 versus 3x24 
hinfusion. 8040±β20)) and the more of the cellular ADM was lost immediately 
after the end of the administration. Thereafter, cellular ADM concentrations 
only slowly decreased with a long half-life time of circa 85-110 h, independent 
of the mode of administration After continuous infusion and bolus injection of 
the same dose similar leukemic blast cell ADM concentrations were attained 
9 
(7710 ± 1190 ng/10 cells), while the peak plasma concentrations differed almost 
2 log During continuous infusion, the ratio cell to plasma ADM concentrations 
increased, because the cells accumulated ADM to 30-100 times the plasma 
concentration After the administration the ratio further increased, due to the 
divergence of the plasma and cell ADM disappearance curve. 
As a comparable therapeutic efficacy was observed in all regimens, the 
antileukemic effect appeared not to be related to the peak plasma 
concentrations, while acute toxicity phenomena decreased with increasing 
duration of the infusion Continuous ADM infusion deserves more attention in 
the treatment of patients with anthracyclines. 
INTRODUCTION. 
In the treatment of acute leukemia ADM plays an important role as potent 
cytotoxic anthracycline antibiotic (1). ADM is usually administered as bolus 
injection over 1-5 min. Part of the toxic effects (nausea, vomiting and 
cardiotoxicity) has been related to this rapid administration (2). Especially 
the risk of cardiotoxicity is a therapy-limiting side effect (3), which seems to 
be related with peak plasma concentrations (2) Administration of ADM as 
continuous infusion reduces the maximal plasma concentration, which has allowed 
46 
treatment up to higher cumulative dosages (2). 
To investigate whether continuous infusion and bolus injection resulted in 
similar leukemic cell ADM concentrations, cellular and plasma ADM concentrations 
were studied as a function of the duration of the continuous infusion on three 
subsequent days in patients with acute nonlymphocytic leukemia. 
PATIENTS, MATERIALS AND METHODS. 
Patients. Eighteen patients entered this pharmacokinetic study. fifteen with 
acute nonlymphocytic leukemia, two with blastic transformation of chronic 
nonlymphocytic leukemia and one with end-stage Hodgkin's disease. The age was 
44 ± 17 years (range 17-67 years), 8 females and 10 males. All had normal liver 
and renal functions. 
The patients were treated with a remission induction regimen consisting of ADM 
2 2 
(30 mg/m ) at day 1,2 and 3, vincristine bolus injection 1 mg/m at day 2, and 
2 2 
cytosine arabinoside 100 rag/m in continuous infusion for 24 hr plus 50 mg/m 
twice daily as bolus injection at day 1 to 7. ADM was administered as bolus 
injection in 7 patients, as 4 h infusion in 5 patients, as 8 h infusion in 4 
patients, and as 3x24 h infusion in 2 patients. In case of 24 h infusion a 
central venous catheter was used to avoid the risk of extravasation. A Syringe 
Driver MS 26 (Graseby Medical, Watford, U.K.) was used for infusion. 
Blood and bone marrow sampling. From 5 min up to 240 h after the start of the 
administration venous blood was drawn in heparinized polypropylene tubes 
(Greiner, Nürtingen, F.R.G.) on ice. Of two patients in each regimen blood was 
sampled frequently; of the other patients samples were only drawn at expected 
peak and nadir concentrations. In many occasions also a bone marrow sample was 
obtained at one of these times. After 10 min centrifugation (900 g, 0 C) 
plasma was removed and stored at -20 C. Erythrocytes in the pellet were lysed 
with cold ammonium chloride (4). The recovery of the leucocytes after the lysis 
step was 80-95%. The leucocytes were resuspended in phosphate buffered saline 
and counted. Part of the suspension was stored at -20 С until analysis with 
high pressure liquid chromatography, part was kept on ice until determination of 
the cellular ADM concentration with flow cytometry within a few hours. 
Bone marrow samples were collected in Acid Citrate Dextrose solution (ACD 
formula A, pH 7.4). At the same a blood sample was taken as well to compare 
bone marrow and blood cell ADM concentrations. The admixture of peripheral 
nucleated blood cells in the bone marrow samples was calculated (5) to exclude 
samples with more than 20% blood admixture from the study. After lysis of 
erythrocytes and normoblasts as described above, cells were resuspended, counted 
and stored until analysis. 
Chemicals. ADM was obtained from Laboratoire Roger Bellon S.A. (Neuilly sur 
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Seine, France). Pure ADM, the metabolite adriamycinol (ADMol) and daunomycin 
(internal standard) for chromatographic purposes were generously supplied by 
prof. F. Arcamone, Farmitalia Carlo Erba (Milan, Italy). All other chemicals 
used for extraction and chromatographic analysis were of analytical grade and 
were obtained from Merck (Darmstadt, F.R.G.). 
High pressure liquid chromatography (HPLC)• The method has been described in 
chapter 2 (6). Briefly: 100 vi Tris buffer (pH 8.8, 1 M) containing daunomycin 
as internal standard was added to 500 μΐ plasma or 250 \il sonicated cell 
suspension. Following two extractions with chloroform/methanol 9:1 (ν/ν), the 
organic phase was evaporated under air at 35 C. The dry residue was dissolved 
in 750 μΐ chloroform/methanol under addition of 50 μΐ Tris buffer. 500 μΐ 
aliquots were injected into a straight-phase HPLC system with a 100 mm χ 3.0 mm 
column packed with LiChrosorb Si60 (particle size 7 y). Drug recovery from 
plasma and cells was circa 92%. The day-to-day variation in the determination 
of a reference sample during 20 consecutive days amounted to 6.9%. The 
detection J.imit of ADM and ADMol was 1 ng. Cellular ADM concentrations were 
9 9 
expressed in ng/10 cells, assuming 10 cells to be equal to 1 ml. 
Flow cytometry (FCM). Cellular ADM uptake in different subpopulations of 
hematopoietic cells has been determined with FCM, as described in chapter 3 (4). 
In brief: cells from the cell suspension passed the 486 nm laser beam of a 
Cytofluorograf 50H flow cytometer (Ortho Diagnostic Systems Inc. Westwood, MA, 
U.S.A.), running at 500 raW. Forward and perpendicular light scatter signals 
enabled discrimination of lymphocytes, blast cells, monocytes and granulocytes. 
Simultaneously, ADM concentrations in individual cells could be determined due 
to its fluorescent property. 
Pharmacokinetics. The ADM and ADMol cellular and plasma concentration-time 
curves were fitted according to a two-compartment open model, and 
pharmacokinetic data were calculated according to the conventional procedures 
(8). 
RESULTS. 
Plasma and cellular concentration-time curves of ADM and the main active 
2 
metabolite ADMol are given in Figures 1-3. 30 mg ADM/m was administered as 
bolus injection (<5 min, Fig. 1), or as continuous infusion of 4 h (figure not 
depicted), 8 h (Fig. 2) and 24 h (Fig. 3). 
Ρ1asma concent rat ions. Maximum plasma concentrations measured at 5 min after the 
bolus injections (Fig. 1) were short-lasting and amounted to 1640 ± 470 ng/ml. 
A short first half-life time of circa 5 min was followed by a considerably 
longer second plasma half-life time of 22 ± 19 h with plasma concentrations of 
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FIGURE 1. (left) Cellular (m) and plasma (9) adriamycin concentrations 
in 7 patients treated for acute nonlymphocytic leukemia with 3 sub­
sequent bolus injections. (O) plasma adriamycinol. Arrows indicate 
moment of administration. Hean values are given. SD amounted 5 to 
35%, with large inter individual differences. 
FIGURE 2. (right) Cellular and plasma adriamycin concentrations in 4 
patients treated for acute nonlymphocytic leukemia with 8-h infusions 
on 3 subsequent. Legends as under Fig. 1. 
less than 50 ng/ml at a few hours after administration. Peak and nadir plasma 
ADM concentrations did not increase significantly on subsequent days of 
administration. The metabolite ADMol was soon detectable in plasma, was always 
less than 40 ng/ml, and seldom exceeded the concentration of ADM. 
Pharmacokinetic characteristics of the concentration-time curves after three 
injections are given in Table 1. 
In case of long-term infusions (4, 8, 24 h respectively), the mean maximum 
plasma concentrations were reduced to circa 12% (172 ± 34 ng/ml), 5% (85 ± 50 
ng/ml) and 3% (47 ± 5 ng/ml) respectively of the mean peak plasma values after 
bolus injection (calculated from all observations on subsequent days). 
Cellular ADM concentrations. At 5 min after the first bolus injection high, but 
9 
only a few minutes lasting cellular peak concentrations of 5740 ± 2100 ng/10 
cells were observed. During the 15 (to 60) min thereafter a rapid efflux was 
9 
observed until a plateau was reached of 3080 ± 830 ng/10 cells. Subsequently 
the mean cellular ADM concentrations hardly decreased, with a long half-life 
time of circa 120 h. Peak cell ADM concentrations after the second and the 
9 
third injection were 67801190 and 9060±2270 ng/10 cells respectively. Similar 
patterns of accumulation were observed at 4 h, 8 h and 24 h administration 
times, be it that the peak cellular ADM concentrations was less high, paralell 
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to the longer time-span. With increase of the infusion periods, the amount of 
ADM rapidly lost from the cell after the end of the infusion, decreased. 
Calculated from all observations on subsequent days, the initial loss after 
bolus injection was 37 ± 19%, after long-term infusions 18 ± 14% (4 h), 12 ± 22% 
(8 h), while hardly immediate loss was observed after the 3x24 h infusion. At 
72 h after the start of the treatment, when the rapid first had ended, cellular 
9 
ADM of 7710 ± 1190 ng/10 cells were measured with considerable interindividual 
differences. Only during infusions longer than 8 h, cellular ADMol was 
occasionally observed at concentrations just above the detection limit (50 
9 
ng/10 c e l l s ) . 
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FIGURE 3. (left) Cellular and plasma adriamycin concentrations in 2 
patients treated for acute nonlyinphoctyic leukemia with 3x24-h 
infusions. Legends as under Fig. 1. 
FIGURE 4. (right) FCH-determined cellular adriamycin concentrations in 
subpopulations of blood cells of a patient treated for acute non-
lymphocytic leukemia, (x) blast cells, (o) mature granulocytes, (o) 
lymphocytes. Concentrations in blood and bone marrow cells (not 
depicted) at 24 h and 48 h were similar. 
The ratios of cellular to plasma concentrations for the different infusion 
schedules increased from 3.7 at the peak after the bolus injection up to over 
1000 times 72 to 96 h later. During the administration the cells accumulated 
ADM. Even during the 3x24 h infusion the cellular ADM concentrations increased 
to over 150 times the plasma concentration. Thereafter ADM was retained to a 
considerable extent, while the plasma concentrations rapidly dropped. 
Determination of cellular ADM concentrations in subpopulations of blood and bone 
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marrow cells, for example in the circulating leukemic blast cells, revealed the 
highest concentrations in granulocytes, monocytes and blast cells, whereas 
lymphocytes contained less ADM per cell (Fig. 4). From the limited number of 
data available thus far, no relation could be detected between succesful 
remission induction and blast cell ADM concentrations at the end of the 
infusion, or at the nadir 24 h thereafter (as a parameter for efflux). 
Comparing the area under the curve (AUC) values after bolus injections and 
continuous infusions for the patients from whom blood was sampled frequently, 
large interindividual differences in plasma AUC's or cellular AUC's were 
observed. However, no important differences between the different ways of 
administration were noted. 
As in animal studies an increase of life span of tumor-bearing animals had been 
observed, attained by ADM administration on wider intervals (7), instead of the 
conventional schedule (day 1, 2 and 3), the cellular ADM concentration-time 
curve was determined in patients to whom ADM was administered with wider 
intervals. In one patient with acute leukemia in relapse ADM was administered 
at day 1, 5 and 9, as bolus injections, in another as 8 h infusions. Cellular 
and plasma concentrations of the first patient are given in Fig. 5. ADM was 
retained intracellularly, and accumulated at this 4 days Interval as well. 
Cng/ml) 
Figure 5. Cellular and plasma adrlamycin concentrations in a patient 
treated with adriamycin bolus injections at day 1, 5 and 9. Legends 
as under Fig.l-
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Cellular ADM concentrations in bone marrow cells. Cellular ADM concentrations 
were measured by HPLC in bone marrow and peripheral blood cells of 
simultaneously obtained samples, taken at different times after administration. 
The ADM concentrations for bone marrow and peripheral blood nucleated cells 
correlated well (r = 0.82, η = 47, Fig. 6). Bone marrow cells contained circa 
10% more ADM than nucleated blood cells. No differences in ADM concentrations 
were observed between bone marrow from patients with overt leukemia or from 
patients in complete remission. In case bone marrow and blood cells were 
obtained simultaneously at 5 min, 1 and at 2 h after ADM injection, cellular ADM 
concentrations were comparable in these samples as well, indicating a rapid 
penetration of ADM in the bone marrow cells as well. 
Blood cells ( пд/Ю") 1 
IS-
10-
0-
0 5 10 IS 
bone morrow cells 1 ng/IO') 
FIGURE 6. Correlation between cellular adriamycin concentrations in 
nucleated blood and bone marrow cells. Bone marrow and blood samples 
were collected simultaneously from 5 min to 240 h after administration 
(n=45, [X0.001). 
Clinical outcome. In this small group of patients complete remissions were 
obtained in 4 outof 5 patients treated with bolus injections and in 7 outof 9 
évaluable patients with acute leukemia treated with constant-rate infusion. 
These results were independent of the duration of the infusion. Although 
difficult to judge in a polychemotherapy regimen, we observed less nausea and 
vomiting in the case of continuous infusion. Mucositis was observed in 1 
patient treated with 3x24 h infusion. 
52 
TABLE 1. Cellular and plasma pharmacokinetic parameters after the 
third of three administrations of adriamycin. 
Mode of No A В 
admini- of measured calculated 
stration pat ng/ml ng/ml 
Τ Τ 
l/2o l/2ß 
min 
AUG 
Pg.h/L 
Vf 
Bolus 
4 h 
β h 
24 h 
7 
5 
4 
2 
1640170 
176134 
85150 
471 5 
ng/109cells 
27114 
131 3 
31110 
381 9 
ng/109ce Ils 
PLASMA 
412 221 9 
211 451 3 
211 31111 
512 581 8 
CELLS 
22901 480 
32301 720 
203011320 
24901 670 
1450184 
Plateau-conc. 
ng/109cells 
Bolus 7 1107011490 752011490 1018 
4 h 5 935014260 80401 120 1413 
8 h 4 882011580 77201 270 1513 
24 h 2 88401 820 84571 720 612 
111132 7176401 51000 86051 675 
721 3 7548001127900 743012820 
90120 7709001128220 589011581 
55112 7520301 90700 892011340 
771011190 
A: concentrations measured at 5 min after administration. The very 
rapid fall in cellular peak concentration does not allow a reliable 
calculation of the A value. B: calculated concentration constant. 
T, ., and T, . • half-lifetimes. l/Za 1/¿P 
AUG: cumulative area under the curve up to 120 h. Vf: distribution 
volume. 
"Plateau concentration" refers to the final cellular ADM 
concentration, measured at circa 1 h after the end of the third 
administration, when the rapid first half-life has ended. 
Except for the peak plasma-values no statistical significant 
differences between different ways of administration were observed 
(two-sided student-t). 
DISCUSSION. 
Plasma pharmacokinetics of antineoplastic drugs have improved our understanding 
of their mechanism of action, but have not essentially contributed to the design 
and improvement of drug scheduling, which still remains empirically based. The 
concentrations in the leukemic cells were considerably different from the plasma 
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concentrations (9, 10) and certainly more relevant for the cytotoxic effect. 
Determination of ADM concentrations in the target cells should have been 
performed in the evaluation of therapy schedules, in which continuous infusions 
were applied to reduce toxicity or enhance the efficacy (11, 12). In the design 
of better tolerated therapy schedules our data are in favour of continuous ADM 
infusion instead of bolus injection. The usage of bolus injections mainly 
originates from logistic arguments and was not based on (cellular) 
pharmacokinetic data. The plasma ADM concentrations reported here are in good 
agreement with the low plasma ADM concentrations Eksborg predicted in the case 
of long-term infusions (13). Although during 24 h infusion the maximum plasma 
value is only 3% of the peak concentration after bolus injection, the final 
cellular concentrations attained were in the same range irrespective of the mode 
of administration. This may explain, why the antitumor efficacy was independent 
of the mode of administration as was observed in the case continuous infusion 
chemotherapy of leukemia (14) and slowly proliferating tumors (3, 11, IS). 
An intriguing phenomenon is the short-lasting high cellular ADM concentration 
immediately after bolus injections followed by a considerable loss up to over 
40% thereafter. This is a great contrast to the almost absence of loss of 
cellular ADM in the case of long-term infusions. As the nuclear membrane is not 
expected to be a barrier in nuclear ADM uptake, -rapid and even higher uptake in 
isolated nuclei has been observed (16)- apparently intercalation in DNA is a 
time consuming process, thus preventing rapid and tight ADM binding of the 
-shortly present- cytoplasmatic ADM. When plasma concentrations dropped below 
the cytoplasmatic concentration at about 1 h after injection, the not tightly 
bound cellular ADM fraction also leaked outof the cell. The longer the duration 
of the exposure to ADM, the more tight the binding to DNA and the less the loss 
of ADM from the cell after the end of the exposure. Similar efflux processes 
were observed in in vitro experiments (chapters 8 and 9). Peak plasma ADM 
concentrations appeared to be not essential for the cytotoxic effect as opposed 
to what has been concluded from in vitro experiments (17, 18, chapter 9 and 10). 
The correlation between ADM concentrations in nucleated bone marrow and 
peripheral blood cells justifies monitoring of cellular ADM concentrations in 
peripheral blood cells, as a measure for bone marrow cell ADM concentration. 
In subsequent investigations the biological significance of the observed 
cellular anthracycline concentrations will be determined by measuring the 
inhibition of clonogenicity. 
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CHAPTER 4B 
PLASMA AND CELLULAR ADRIAMYCIN CONCENTRATIONS IN MYELOMA PATIENTS 
TREATED WITH 96 HOURS CONTINUOUS ADRIAMYCIN INFUSION 
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SUMMARY. 
Adriamycin (ADM) concentrations in blood cells, bone marrow cells and in plasma 
were measured in 7 patients with advanced multiple myeloma. ADM was 
2 
administered as 96 h infusions of 9 mg/m /24 h every three weeks. Plasma ADM 
concentrations reached maximum levels of 15.8 ± 4.4 ng/ml (mean ± SD). Plasma 
adriamycinol (ADMol) was measurable from 20 h after start, gradually increasing 
during the whole infusion period up to 5.9 ± 3.5 ng/ml. Cellular ADM 
concentrations in nucleated blood cells 3 h after the start of the infusion 
9 
amounted to 250 ng/10 cells, increasing throughout the 96 h infusion up to 
9 
2927 ± 748 ng/10 cells. At that time bone marrow cells contained 2962 ± 847 
9 
ng/10 cells. Flow cytometric determination of ADM concentrations present in 
plasma cells in the bone marrow revealed a mean concentration of 107 arbitrary 
9 
fluorescence units /cell, corresponding with circa 4000 ng/10 cells. The area 
under the cellular concentration-time curve of 96 h infusions revealed similar 
or slightly higher values than observed after bolus injections of a similar 
dose. Cellular drug concentrations attained after 96 h ADM infusions were of 
the same magnitude as observed after administration of the same dose as a bolus 
injection. This pharmacokinetic study showed that continuous infusion is the 
equivalent of bolus injection in delivering ADM to the target cells, although 
plasma ADM concentrations remained very low. It provides support for 
administering ADM as continuous infusion with lesser toxicity and better patient 
tolerance. 
INTRODUCTION. 
Multiple myeloma (MM) is a chronic, slowly progressive disease of neoplastic 
plasma cells (1, 2). In general, treatment consists of intermittent melfalan 
and prednison. Cytostatic treatment with high dose bolus injections of S-phase 
specific drugs does not seem appropriate, because of the low number of S-phase 
cells. Recently introduced polychemotherapeutic regimens are toxic but not of 
proven benefit, as the overall survival remained essentially unchanged (3). 
Recently Barlogie et al. (4) reported a rapid and marked tumor-mass reduction 
in 14 of 20 patients with advanced MM, treated with 96 h continuous adriamycin 
(ADM) and vincristine (VCR) infusion and dexamethason orally. Part of the 
response is supposed to be due to the long-lasting continuous exposure of plasma 
cells to ADM and VCR. 
In 7 patients with advanced MM, treated in accordance to this schedule (ADM: 9 
2 
mg/m /day, 4 days) cellular and plasma ADM concentrations were measured. We 
compared these values with the cellular and plasma concentrations attained when 
2 
ADM (30 mg/m /day 1) was given as bolus injection (9 other patients). 
58 
PATIENTS, MATERIALS AND METHODS. 
Patients. 7 patients with end-stage MM, refractory to prior therapy with 
alkylating agents, were selected for this study. All had advanced disease with 
bone lesions and high paraprotein levels. Cellular and plasma pharmacokinetics 
after 1 bolus injection was previously studied in 9 other patients, under 
maintenance treatment for acute leukemia in remission. 
Drugs and drug administration. ADM was obtained from Roger Bellon (Neuilly sur 
2 
Seine, France). ADM 9 mg/m /day and VCR 0.4 mg/day were administered over 96 h 
via an indwelling central venous catheter, either Port-a-cath (Pharmacia, 
Piscataway, NJ, U.S.A.) or Hickman catheter (Evermed, Kirkland, Wa, U.S.A.). 
Except for the first course, treatment was given on an outpatient base, using 
the Travenol infusor (Travenol, Deerfield, II, U.S.A.) or Act-a-Pump (Pharmacia, 
Piscataway, NJ, U.S.A.). Additional therapy consisted of 40 mg dexamethason 
orally on day 1 to 4. One cycle was given every three weeks (4). Bolus 
2 
injections of ADM (30 mg/m /day 1) were administered once a month. Additional 
treatment consisted of cytosine arabinoside subcutaneously. 
Blood and bone marrow sampling. Blood for analysis of plasma and cellular ADM 
concentrations was obtained at time intervals indicated in Fig. 2. Just prior 
to the end of the infusion bone marrow was aspirated. The blood and bone marrow 
samples were handled as described in chapter 2 (5). In brief: samples were 
placed on ice immediately to stop further ADM metabolism. In the case of bone 
marrow, peripheral blood admixture was determined to exclude samples with less 
than 80% nucleated bone marrow cells (6). After centrifugation of the blood 
samples, plasma was removed and stored at -20 С for ADM analysis. Erythroid 
cells were lysed with ammonium chloride at ОС. The white cells were 
resuspended in cold phosphate buffered saline. One part was stored at -20 С 
until analysis with high pressure liquid chromatography. Another part was kept 
on ice for flow cytometric determination of the cellular ADM concentration. 
Chromatographic determination of plasma and cellular ADM concentrations. Plasma 
concentrations were determined by high pressure liquid chromatography (HPLC) as 
described in chapter 2 (5). In short: after extraction of 500 vl plasma in 
chloroform/methanol 9:1 (v/v) under addition of daunomycin as internal standard, 
the chloroform phase was evaporated under air. The dry residue was dissolved in 
chloroform/methanol 9:1 (v/v) and injected on a Lichrosorb 7SI60 column (100 mm 
χ 3.0 mm I.D.) of a straight-phase chromatographic system. The detection limit 
was 1 ng. Cellular ADM concentrations were determined using the same procedure 
as described above for plasma. After sonication for 15 s at 75 W, 250 μΐ cell 
suspension containing less than 40x10 cells/ml was used for extraction. 
9 9 
Cellular ADM concentrations were expressed in ng/10 cells, assuming that 10 
cells are equal to 1 ml. 
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perpendicular light scatter 
FIGURE 1. Scatter plot of a bone marrow sample of a patient with 
multiple myeloma. The combination of forward and perpendicular light 
scatter signals was used to discriminate plasma cells from other 
subpopulations. The window indicated 3 contained circa 80% plasma 
cells. (1) mainly dead cells, (2) lymphocytes, (4) myeloid cells. 
Flow cytometric (FCM) determination of ADM concentration m plasma cells. 
Cellular ADM concentrations in plasma cells were determined with three parameter 
laser flow cytometry as has been described in chapter 3 (5) using a 50H 
Cytofluorograf (Ortho Diagnostic Systems, Westwood, MA, U.S.A.), equipped with a 
5 W Argon laser, exciting at 488 nm with an output of 500 mW. The combination 
of forward and perpendicular light scatter enabled identification and sorting of 
viable plasma cells (Fig. 1). Cells from the cluster indicated in this figure 
were sorted for microscopical examination. A considerable enrichment of plasma 
cells was obtained with a purity of circa 80% plasma cells, while the bone 
marrow smear only contained circa 10% plasma cells. 
ADM fluorescence of cells of this distinct subpopulation was measured 
simultaneously and expressed in arbitrary fluorescence units/cell (FU/cell), 
corrected for autofluorescence by subtraction of the blank value. In chapter 3 
g 
we showed that 100 FU/cell corresponded with circa U fg/cell or 4000 ng/10 
cells (5). 
Pharmacokinetics• The ADM and ADMol cellular and plasma concentration-time 
curves were fitted according to a two-compartment open model, and 
pharmacokinetic data were calculated according to the conventional procedures 
(7). 
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FIGURE 2. (left) Plasma (·) and cellular (о) adriamycin (ADtt) con-
2 
centration-time curve during and after 96 h infusion of 9 mg ADM/m /24 
h. Hean±SO (n=7). (a) adriamycinol in plasma. 
FIGURE 3. (right) Plasma and cellular adriamycin concentrations curve 
2 
after 30 mg/m bolus injection on day 1. tfeaniSD (n=9). Legends as 
under Fig. 1. 
RESULTS. 
2 
Plasma pharmacokinetics. During 96 h continuous infusion of ADM (9 mg/m /day) 
plasma ADM concentrations were detectable from 3 h after the start of the 
infusion (Fig. 2). After 48 h infusion steady state concentrations were reached 
(two-sided paired student-t) with maximum plasma concentrations of (mean ± SD) 
15.6 ± 4.4 ng/ml (range 7.3 to 20.5 ng/ml). After the infusion a rapid biphasic 
decrease in plasma ADM concentrations was noted with a first half-life of 5 min 
and a second half-life of 27 ± 7 h. The main metabolite adriamycinol (ADMol) 
appeared in most patients after 20 h at a concentration of 1.5 ng/ml, slowly 
rising during the infusion to levels of 5.9 ± 3.5 ng/ml (range 3.5 to 9.6 
ng/ml). In one patient no plasma ADMol was found. 
2 
After bolus injections of 30 mg/m , peak plasma concentrations measured at five 
min (Fig. 3, η = 9 patients) amounted to 1447 ± 68 ng/ml (range 777 to 2475 
ng/ml). The half-lives were similar, the first half-life was circa 5 min and 
the terminal half-life 31 ± 8 h (Table 1). ADMol was formed rapidly with 
maximum plasma levels of at most 15 ng/ml. 
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TABLE 1. Cellular and plasma pharmacokinetic parameters (mean ± SD). 
A 
ng/ml 
В 
ng/ml 
l/2a 
h 
l/2ß 
h 
AUC 
yg.h/L 
plasma 15.8+ 4.4 
cellular 2927+748 
96 h INFUSION (n = 7) 
N.D. 0.1±0.05 27± 7 1478± 280 
N.D. 0.1±0.05 87+56 698866±162251 
BOLUS INJECTION (n = 9) 
plasma 2405+1723 20± 8 0 1±0.05 31± 8 
cellular 573812097 2965±183 0 2±0.1 116±41 
1064± 257 
5488541 71586 
A measured peak (bolus) or maximum (96 h infusion) concentration 
B: calculated concentration constant. 
T... and Τ,,,.- half-life times. AUC. area under the curve until 
l/Zot l/^P 
infinity. Between 96 h infusion and bolus injection, peak plasma and 
peak cell ADM concentrations differed significantly (p<0.001). Other 
values were not different. (TWo-sided student-t). N.D · not done. 
Cellular pharmacokinetics. Cellular ADM concentrations in nucleated blood cells 
during continuous infusions revealed a pattern different from the plasma 
concentration-time curve (Fig. 2) The cellular ADM concentrations continuously 
increased and maximum cellular drug concentrations at the end of the infusion 
were 2927 1 748 ng/10 cells (range 1990 to 4530 ng/10 cells). No cellular 
ADMol was observed. The half-life times of cellular ADM (mean of 87 h) was 
considerably longer than the plasma ADM half-life time (Table 1). 
Cellular ADM concentrations after bolus injection (Fig. 3) showed peak 
9 
concentrations of 5738 1 2097 ng/10 cells at 5 m m after injection, followed by 
α 
a release of cellular ADM to levels of 3208 1 793 ng/10 cells half an hour 
thereafter, with terminal half-lives of 116 1 41.1 h. No cellular adriamycinol 
was detectable. 
Cellular ADM concentrations were also measured in bone marrow samples taken at 
the end of the infusion. Mean cellular ADM concentrations of bone marrow cells 
9 
were 2962 1 847 ng/10 cells (table 2). Bone marrow and blood cell ADM 
concentrations correlated well (r = 0.96, ρ < 0.01, η = 5). No correlation with 
plasma concentrations was observed. Since only a minor part of these cells are 
plasma cells, no conclusions about ADM uptake by these plasma cells can be drawn 
from the overall data. 
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TABLE 1. Maximum plasma (ng/ml) and cellular (ng/lO cells) adriamycin 
(ADM) and adriamycmol (ADMol) concentrations, observed at the end of 
the infusion period of 96 h. 
patient plasma 
ADM ADMol 
blood 
cells 
bone marrow 
cells 
plasma 
cells 
(ng/ml) (ng/ml) (ng/109cells) (ng/io'cells) (FU/cell) 
1 
2 
3 
4 
5 
6 
7 
Mean+SD: 
20.1 
12.8 
14.9 
18.9 
20.5 
16 3 
9.5 
15.8+4.4 
3.8 
3.2 
8 8 
9.6 
8.4 
8.1 
0 
6.0+3 
2570 
4530 
3300 
2840 
2730 
2530 
1990 
29271748 
not done 
4570 
3040 
2550 
2410 
not done 
2240 
2962±847 
not done 
56 
79 
112 
180 
58 
157 
107±48 
ADM concentrations in plasma cells measured with FCM. The bone marrow samples 
were also analysed with three parameter FCM An example of a scatter plot is 
given in Fig. 1. In this example only 8% of all white cells were plasma cells 
From sorting, 78-86% of the cells in the window indicated appeared to be plasma 
cells, the remainder being some blast cells and lymphocytes. ADM concentrations 
in these plasma cells amounted to 107 ± 48 FU/cell (range 56 to 180 FU/cell). 
These concentrations were in the same order of magnitude as the ADM 
concentrations observed in blast cells of leukemic bone marrow (96 ± 29 FU/cell) 
shortly after bolus injection. However no correlation was observed between bone 
marrow cell concentrations and the plasma cell concentrations. In a patient 
with circulating plasmacytoid cells, increase in plasma cell ADM concentration 
was paralell to the increase observed in blood cells in other patients 
DISCUSSION 
Recently an impressive 70% response rate has been reported in 20 patients with 
multiple myeloma refractory to alkylating agents, treated according to a 
2 
schedule containing 9 mg ADM/m /24 h, given over 96 h (VAD-schedule) (4). This 
course was designed assuming that slowly proliferating plasma cells might be 
better eradicated by longer lasting exposure to ADM and VCR as compared to bolus 
injection. Both drugs showed pronounced cytotoxicity when cells of a cell line 
were exposed in their proliferation phase (8) compared with exposure in the 
resting phase. After longer lasting exposure the surviving fraction decreased, 
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although not as a simple exponential function of the dose (9). Toxicity has 
been reported to be reduced in the case of prolonged infusion of adriamycin 
(10), thus improving the therapeutic index (11). However, prolonged infusion of 
VCR alone appeared to have limited activity in patients with refractory MM (12). 
This paper demonstrates that blood and bone marrow cells, including plasma 
cells, accumulated ADM during the infusion of ADM in the same order of magnitude 
as observed shortly after ADM bolus injection. Two main pharmacokinetic 
differences between the bolus injection and the 96 h infusion were: 1) the 
reduced peak plasma concentration from over 1500-2000 ng/ml (bolus injection) to 
less than 20 ng/ml, and 2) the slow increase in cellular drug concentration with 
negligible loss after the infusion, compared with the rapidly achieved peak 
cellular ADM concentration within 5 min after a bolus injection, followed by a 
rapid and considerable cellular efflux thereafter. The rates of ADM loss from 
nucleated cells during the terminal half-life time were comparable. 
None of the patients experienced nausea or vomiting, whereas almost all treated 
with the bolus injection had. No mucositis was observed. All could handle the 
pump device at home without difficulties. The limited number of patients 
studied, and the fact that all had end-stage disease, does not permit to draw 
conclusions from the pharmacokinetic data for the final clinical outcome. 
We may conclude that 96 h continuous ADM infusions resulted in cellular ADM 
concentrations comparable with those observed after bolus injections without 
concomittant high plasma concentrations. Long-term infusions in the treatment 
of breast cancer (10) have demonstrated to have similar clinical results, while 
these prolonged infusions, were less toxic, were better sustained by the 
patient, and allowed longer lasting treatment, in comparison to the conventional 
bolus injections. ADM infusions may therefore be the preferred means for giving 
the drug. 
REFERENCES• 
1. Durie BGM and Salmon SE. A clinical staging system for multiple myeloma. 
Cancer 36:842-854, 1975. 
2. Catovsky D. Leukemias and myeloma. In: Cancer Chemotherapy 1983, the E0RTC 
cancer chemotherapy annual 5. Pinedo HM and Chabner BA (eds.). Elsevier 
Science Publishers, Amsterdam, 1983, pp 217-229. 
3. Kyle RA, Pajak TF, Henderson ES, et al. Multiple myeloma resistant to 
melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU) and 
prednisone. Cancer Treat Rep 66: 451-456, 1982. 
4. Barlogie В, Smith L and Alexenian R. Effective treatment of advanced 
multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353-1356, 
1985. 
5. Speth PAJ, Linssen PCM, Boezeman JBM, et al. Quantification of cellular ADM 
concentrations in subpopulations of human hematopoietic cells correlated with 
high performance liquid chromatography. Cytometry 6: 143-150, 1985. 
6. Holdrinet RSG, Van Egmond J, Wessels JMC, et al. A method for quantification 
of peripheral blood admixture in bone marrow aspirates. Exp Hematol 8: 
103-107, 1980. 
7. Wagner JG. Fundamentals of clinical pharmacokinetics. Drug Intelligence 
64 
Publishers, Hamilton, 1975. 
8. Drewinko B, Patchen M, Yang LY, et al. Differential killing efficacy of 
twenty antitumor drugs on proliferating and nonproliferating human tumor cells. 
Cancer Res 41: 2328-2333, 1981. 
9. Eichholtz-Wirth H. Dependance of the cytostatic effect of adriamycin on drug 
concentration and exposure time in vitro. Br J Cancer 41: 886-891, 1980. 
10. Leghe SS, Benjamin RS, Mackay В, et al. Reduction of doxorubicin 
cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 96: 
133-139, 1982. 
11. Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin 
Oncol 2: 1289-1304, 1984. 
12. Jackson D, Spurr C, Richards F, et al. Vincristine infusion in refractory 
multiple myeloma. Proceedings Am Assoc Cancer Res and ASCO (abstract) C-839, 
1985. 
65 

CHAPTER 5 
LEUKEMIC CELL AND PLASMA DAUNOMYCIN CONCENTRATIONS AFTER BOLUS INJECTION 
AND 72 HOURS INFUSION IN THE TREATMENT OF LEUKEMIA 
Paul A.J. Speth, Peter CM. Linssen, Hans M.C. Wessels and Clemens Нлапеп 
Part of this chapter will appear in British Journal of Haematology 
Submitted to Clinical Pharmacology and Therapeutics 
SUMMAKY. 
To evaluate the effect of the duration of DNM infusion on leukemic cellular drug 
concentrations, cellular and plasma daunomycin (DNM) concentrations were 
2 
measured in 20 patients with acute non-lymphocytic leukemia. DNM 45 mg/m was 
administered either as a bolus injection or as a U, 8 and 24 h constant-rate 
infusion during Э subsequent days, in combination with administration of 
vincristine on day 2, and cytosine arabinoside on days 1 to 7. In the case of 
bolus injections peak plasma DNM levels amounted to 227 ± 116 ng/ml. Maximum 
plasma levels were only 16 ± 6 ng/ml after 3x24 h DNM infusions. Daunomycinol 
(DNMol) maximal plasma concentrations were 171 ± 53 and 98 ± 34 ng/ml 
respectively. Terminal plasma DNM half-life times were 14 ± 4 h. Despite 
different maximum plasma concentrations for different ways of administration, 
leukemic cell DNM concentrations at the third day of administration were 
9 
comparable: 16810 ± 2580 ng/10 cells in the case of bolus injections and 
q 
10310 ± 5510 ng/10 cells after 72-h infusions. Leukemic cell DNMol 
9 9 
concentrations were respectively 3500 ± 1600 ng/10 cells and 2850 ± 1720 ng/10 
cells. Cellular DNM concentrations decreased rapidly with a terminal half-life 
of 13 ± 4 h. The ratio of the cellular versus plasma concentrations at the end 
of the bolus injection was circa 50 (DNM) and 15 (DNMol) increasing in time up 
to 1000 at 24 h after the administration. The area under the cellular curve was 
in the same order of magnitude in the case of bolus injection or 72 h infusion. 
DNM concentrations in nucleated blood correlated well with those in bone marrow 
cells (r = 0.93, η = 26). 
The reduced plasma DNM concentrations during continuous infusion resulted in 
less side effects, while leukemic cell DNM concentrations at the end of the 
infusion were similar to those observed after bolus injection. Comparable 
therapeutic efficacy was attained. 
INTRODUCTION. 
Daunomycin (DNM) and cytosine arabinoside (Ara-C) have been till now the main 
drugs in use in the treatment of acute leukemia (1,2). DNM usually is 
administered as bolus injection (2), whereas Ara-C mainly is given as prolonged 
infusion. Plasma pharmacokinetic studies have had a limited impact on the way 
anticancer drugs are administered (3). In pharmacokinetic studies plasma DNM 
and daunomycinol (DNMol) concentrations have not been found useful in estimating 
the target tissue concentrations (4,5,6). Recent clinical reports suggested 
improvement of the DNM administration schedule, as side effects had been 
diminished (7, 8). In this pharmacokinetic study, the effect of bolus 
injections compared to constant-rate infusions on leukemic cell DNM 
concentrations was evaluated. 
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PATIENTS, MATERIALS AND METHODS. 
Patients. Pharmacokinetic studies were done in 20 patients with acute 
nonlymphocytic leukemia at first presentation, at relapse or during remission. 
The mean age was 43 ± 8 years (17-67), 7 were females, 13 males. All had normal 
liver and renal functions. 
The patients were treated with a remission induction regimen consisting of DNM 
2 2 
(45 mg/m ) on day 1,2 and 3; cytosine arabinoside 100 mg/m in continuous 
2 
infusion for 24 hr plus 50 mg/m twice daily as bolus injection on day 1 to 7 
2 
and vincristine bolus injection 1 mg/m on day 2. DNM was administered as bolus 
injection in 4 patients, as 4 h infusion in 2 patients, as β h infusion in 3 
patients and as 3x24 h infusion in 11 patients. Long-term infusion was done via 
a Hickman catheter (Evermed, Kirkland, Wa, U.S.A.), using a Syringe Driver MS 26 
(Graseby Medical, Watford, U.K.). 
Blood and bone marrow sampling. Venous blood was drawn at regular intervals from 
5 min up to 216 h after the first administration in heparinized polypropylene 
tubes on ice. After 10 min centrifugation (900 g, 0 C) plasma was removed and 
stored at -20 C. After lysis of the erythrocytes with cold ammonium chloride 
(10) the remaining leucocytes were resuspended in phosphate buffered saline and 
counted. Part was stored at -20 С until analysis with high pressure liquid 
chromatography, part was kept on ice, until flow cytometric determination of 
cellular DNM concentrations in the blast cells. 
Bone marrow samples were collected in Acid Citrate Dextrose solution (ACD 
formula A, pH 7.4)on ice. At the same time always a peripheral blood sample was 
taken as well, to compare bone marrow and blood cell DNM concentration. Bone 
marrow samples containing more than 20% admixture of peripheral nucleated blood 
cells were excluded from the study (11). After lysis of erythrocytes and 
normoblasts as described above, cells were resuspended, counted and stored until 
analysis. 
Chemicals. DNM was obtained from Specia (Paris, France). Pure DNM, the 
metabolite daunomycinol (DNMol) and adriamycin (internal standard) for 
chromatographic purposes were generously supplied by prof. F. Arcamone, 
Farmitalia Carlo Erba (Milan, Italy). All other chemicals used for extraction 
and chromatographic analysis were of analytical grade and were obtained from 
Merck (Darmstadt, F.R.G.). 
High pressure liquid chromatography (HPLC). The method has been described in 
chapter 2 (12). Briefly: 500 yl plasma or 250 ul sonicated cell suspension 
were extracted twice with chloroform/methanol 9:1 (v/v). After evaporation of 
the organic phase, the dry residue was dissolved in 750 yl chloroform/methanol. 
500 yl aliquots were injected into a straight-phase HPLC system with a 100 χ 3.0 
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mm column packed with LiChrosorb Si60 (particle size 7 μ). Drug recovery from 
plasma and cells was circa 92%. The day-to-day-variation in the determination 
of a reference sample during ten consecutive days was 9.1% (n = 18). Detection 
9 
limit was 1 ng. Cellular DNM concentrations were expressed in ng/10 cells, 
9 
assuming 10 cells are equal to 1 ml. 
Flow cytometry (FCM). As described in chapter 3 (10) the population of the 
leukemic blasts can be discriminated by FCM on basis of their scatter 
characteristics. Simultaneously, cellular DNM concentrations can be quantified 
from the cellular fluorescence, using a Cytofluorograf 50H (Ortho Diagnostic 
Systems, Westwood, MA, U.S.A.) equipped with a 5 W argon laser, using the 488 nm 
line, running at 0.5 W. 
Pharmacokinetics. The DNM and DNMol cellular and plasma concentration-time 
curves were fitted according to a two-compartment open model, and 
pharmacokinetic data were calculated according to the conventional procedures 
(12). 
RESULTS. 
Plasma and cellular disappearance curves of DNM and the main metabolite DNMol 
2 
are given in Figures 1-3. DNM 45 mg/m was infused as bolus injection (<5 min), 
or as 4, 8 and 24 h constant-rate infusion on day 1, 2 and 3 of the treatment. 
10', 
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FIGURE 1. (left) Cellular Cm) and plasma (9) daunomycin (closed 
symbols) and daunomycinol (open symbols) concentrations in 4 patients 
treated for acute nonlymphocytic leukemia with 3 subsequent bolus 
injections. Arrows indicate moment of administration. Mean values 
are given. 
FIGURE 2. (right) Cellular and plasma daunomycin and daunomycinol 
concentrations in 3 patients treated for acute nonlymphocytic leukemia 
with 3 subsequent 8-h infusions. Legends as under Fig. 1. 
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Plasma concentrations. Pharmacokinetic characteristics of the concentration-time 
curves are given in Table 1. The mean peak plasma concentration after all bolus 
injections (Fig. 1) was 227 ± 116 ng/ml. A short distribution phase with a 
plasma half-life time of 20 ± 13 min, was followed by disappearance phase with a 
terminal half-life time of 18 ± 7 h. The metabolite DNMol almost immediately 
was observed in plasma, and at 30 min exceeded the DNM concentrations. DNM and 
DNMol hardly accumulated at subsequent injections. 
In the case of 3x24 h infusion steady state DNM concentrations were reached at 
24 h, whereas a continuous increase of plasma DNMol was observed during the 
infusion-time. The final disappearance rate of DNMol was similar to that of 
DNM. Mean maximum plasma concentrations during continuous infusion (4, 8, 24 h 
respectively) were reduced to 48% (120 ± 30 ng/ml), 33% (96 ± 15 ng/ml) and 9% 
(16 ± 6 ng/ml) respectively of the peak plasma value after bolus injection. 
( nç/ml ) 
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FIGURE 3. (left) Cellular and plasma daunomycin and daunomycinol 
concentrations in 11 patients treated for acute nonlymphocytic 
leukemia with 3 subsequent 24-h infusions. Legends as under Fig. 1. 
FIGURE 4. (right) Cellular and plasma daunomycin concentrations. 
Daunomycin was administered as 8 h infusion on day 1 and 4. Legends 
as under Fig. 1. 
Cellular concentrations. Maximum cellular DNM concentrations of 17200 ± 1310 
9 
ng/10 cells were observed at 5 min after the first bolus injection. These peak 
cellular DNM concentrations were not significantly higher after the second and 
third injection. In the first 2 h after the injection, cellular DNM is only 
slowly released from the cells. In the next few hours the efflux of DNM 
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TABLE 1. Pharmacokinetic characteristics of plasma and cellular 
daunomycin concentrât ions 
Mode 
of 
admin. 
No 
of 
pat 
A 
measured 
ng/ml 
В 
calculated 
ng/ml 
Γ1/2α Tl/2ß A U C 
min h ug.h/L 
Vf 
PLASMA 
bolus 
4 h 
8 h 
24 h 
4 
2 
3 
11 
2271116 
120± 30 
96± 15 
16± 6 
18± 7 
28113 
26119 
131 9 
20113 
161 9 
18110 
121 6 
1817 8581134 2690116980 
913 20041470 
1516 21331890 
1614 15001330 
bolus 4 
4 h 2 
8 h 3 
24 h 11 
CELLS 
9 9 
ng/10 cells ng/10 cells 
1681012580 
1524012070 
1374013040 
1031015510 
1082013020 35120 
1468111800 61 4 
1218011770 161 3 
949012100 15112 
1014 5682601 12080 
913 6304601 18970 
1212 6565301120600 
1616 6164101 22460 
A: measured peak (5 min after bolus) or maximal (infusion) DNM 
concentration. В: calculated concentration constant. 
T, .„ and T, .«„: half-life times. l/2a 1/Zp 
AUC: area under the curve up to 120 h. Vf: distribution volume. 
Except for the peak plasma-value no statistically significant 
differences were observed between the different ways of DNM 
administration (two-sided student-t). 
increased, at a similar rate as the DNM plasma disappearance rate. 
DNMol appeared intracellularly at a lower speed (compared to its appearance in 
plasma), and reached less high cellular concentrations than the cellular DNM 
9 
concentrations. Maximum concentrations were 3500 1 1600 ng/10 cells at 6 to 8 
h after bolus injection. The pattern of DNM efflux from the cells was similar 
after bolus injection and after continuous infusion. DNMol in both cases was 
retained in the cells to a higher extent. 
The ratio of the cellular to plasma concentration was circa 40 at the end of the 
bolus injection due to rapid cellular DNM accumulation. Thereafter this ratio 
increased up to over 500 times 24 h later due to the rapid initial plasma DNM 
clearance and the slower DNM release from the cells. 
The plasma and cellular area under the curve (AUC) values of bolus injections 
and prolonged infusions, showed no significant differences in relation to the 
duration of the infusion. 
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FIGURE 5. Correlation between cellular DNH concentrations in nucleated 
blood and bone marrow cells. Bone marrow and blood samples were 
collected from the end of the administration to 144 h. (n=26, 
p<0.001). 
In 2 patients cellular DNM concentrations were determined, in the case DNM was 
administered at longer intervals. Cellular and plasma DNM concentrations of DNM 
administered as β h infusion at day 1 and 4, are given in Fig. 4. Although 
plasma DNM concentrations fell below the detection limit at 24-48 h, cellular 
DNM concentrations could be demonstrated at up to 72 h after infusion. DNMol 
persisted both in plasma and cells. 
DNM concentration in bone marrow cells. Cellular DNM concentrations in bone 
marrow cells and peripheral blood cells were determined by HPLC in pairs of 
blood and bone marrow samples. The observed cellular DNM concentrations in 
nucleated bone marrow cells correlated well with those observed in peripheral 
blood cells (r = 0.93 η = 26, Fig. 5). No differences were observed between 
cellular DNM concentration in leukemic bone marrow cells and normal bone marrow 
cells of patients in remission. 
Leukemic cells DNM concentration. Flow cytometry (FCM) allowed rapid and 
quantitative determination of DNM and DNMol concentrations in individual cells. 
From the fluorescence signal DNM cannot be discriminated from DNMol. Fig. 6 
gives an example of the course of cellular DNM + DNMol concentrations in a 
patient with circulating blast cells treated with 3 bolus injections. In 
myeloid cells DNM + DNMol concentrations were higher and were retained longer 
than in blast cells and in lymphocytes. 
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FIGURE 6. FCn-determined cellular daunomycin+daunomycinol concen­
trations in subpopulations of blood cells of a patient with acute 
leukemia, treated with daunomycin bolus injections, (x) blast cells, 
Ca) mature granulocytes, Co) lymphocytes. Blood and bone marrow cell 
concentrations at 24 h and 48 ft were similar Cnot depicted). 
Clinical course. Complete remissions were obtained in 7 of 11 patients treated 
with 72 h infusions. These data were comparable with the complete remission 
rate observed in a far larger number of patients treated in our centre with 
9 
bolus injections. The time to granulocytopenia (<0.5xl0 ) and the time to 
α 
recovery (>0.5xl0 /L) were 3 ± 2 and 21 ± 6 days respectively. These data are 
similar to those after bolus injections as well. In the case of continuous 
infusion nausea and vomiting were considerably less frequent and intense. No 
mucositis was observed. 
DISCUSSION. 
In this and other studies (4, 5, 13) differences between cellular and plasma 
disappearance rates of anthracyclines were observed illustrating the limited 
value of plasma pharmacokinetic studies. 
After a 3x24 h infusion the maximum plasma value was 8% of the bolus peak 
concentration, nevertheless the final cellular concentrations attained, were in 
the same order of magnitude (table 1). This supports the observed similar 
antitumor effect after continuous infusion and bolus injection chemotherapy (β). 
These results are in contradiction with the conclusions from in vitro 
experiments, that peak plasma concentrations are essential for the cytotoxic 
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effect (14). In vivo the total cytotoxic effect of DNM is independent of the 
schedule of administration (15). In mice, an improved anti-leukemic activity 
was found, dependent on the schedule of treatment. Administration on day 1, 3 
and 6 resulted in an increase of life span, compared with DNM monotherapy 
administered on day 1, 2 and 3 (16). We found persisting cellular DNM 
concentrations, in the case of administration with larger intervals, on day 1 
and 4. This might support the suggestion that also in man improvement of 
therapy-results can be obtained by better spacing of the drug administration. 
Whether long-term infusion selects for increasingly resistent cell types, as has 
been suggested from literature (17), remains to be determined from the duration 
of the remission in man . 
As in other studies (6, 18), patients treated with prolonged infusions felt 
better (less or no vomiting). Whether, in comparison with adriamycin, also 
chronic (cardiac) side effects (18) are reduced, remains to be investigated. 
2 2 
Although DNM is administered at 150% of the ADM dose (45 mg/m and 30 mg/m 
respectively) (19), plasma DNM concentrations were at least 50% lower than peak 
plasma adriamycin concentrations (chapter 4), due to a more rapid DNM 
distribution into the tissues with a 2 times higher distribution volume. 
Despite this lower peak plasma concentrations, the maximum cellular DNM 
concentrations observed, were almost 2 times higher compared to cellular ADM 
concentrations (chapter 4). This was also observed in vitro. Cellular DNM 
concentrations exceeded those of ADM, even at lower medium drug concentrations. 
Cellular DNM uptake is faster, as DNM has a higher lipophilicity compared to ADM 
(20). 
Another remarkable difference between ADM and DNM was, that cellular DNM 
concentrations were retained at their maximum level for 1 to 2 h, whereas 
meanwhile the plasma concentrations steeply decreased. From 3 h after the end 
of the infusion, cellular DNM concentrations started to decrease markedly as 
well. Peterson et al. (5) concluded that DNM, compared to ADM has a lower 
affinity for DNA, and therefore was retained in the cell for a shorter period 
than was observed for ADM. Drug polarity also influenced the cellular kinetics 
of DNMol, when compared to DNM. Due to the lower partition coefficient of DNMol 
(20), cellular DNMol concentrations were lower than cellular DNM concentrations, 
whereas in the plasma this relation was inverse. 
In contrast to other authors, who reported on a limited number of observations 
(6), we found a good correlation between DNM concentrations in nucleated bone 
marrow and peripheral blood cells. This might justify sampling of peripheral 
blood cells to monitor concentration-time curves in bone marrow cells, as the 
bone marrow cell DNM concentrations were reflected in the concentrations in 
circulating blood cells. 
It has to be investigated, whether "on line" determination of DNM concentrations 
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in nucleated blood cells during continuous infusion of DNM, can be used to adapt 
the DNM dose to the patient's individual needs. Proven efficacy and reduced 
toxicity in the case of long-term DNM infusion, justifies further exploration of 
this mode of administration. 
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CHAPTER 6 
PLASMA AND HUMAN LEUKEMIC CELL PHARMACOKINETICS OF 
ORAL AND INTRAVENOUS 4-DEMETH0XYDAUN0MYCIN 
Paul A.J. Speth, Fons A.J. van de Loo, Peter CM. Linssen, 
Hans M.C. Vessels and Clemens Haanen 
Clinical Pharmacology and Therapeutics, accepted for publication 
SUMMARY. 
2 
4-demethoxydaunomycin (D-DNM) was administered orally (30 mg/m ), and as bolus 
2 
injection or 4 h and 24 h infusion (10 mg/m ) to 7 patients with acute leukemia 
on 3 consecutive days, replacing daunomycin in a conventional polychemotherapy 
regimen. Cellular (nucleated blood and bone marrow cells) and plasma drug 
concentrations were studied. Peak plasma D-DNM concentrations at 5 min after 
bolus injection were circa 50 ng/ml. The steady state levels in case of 4 and 
24 h infusion were circa 25 and 6 ng/ml respectively. Rapid and extensive 
formation of 4-demethoxydaunomycinol (D-DNMol) was observed. The shape of the 
D-DNM concentration-time curve after oral ingestion resembled the one observed 
during a 4 h infusion. 
D-DNM concentrations in nucleated blood and bone marrow cells were in the same 
order and amounted to 292 to 485 times the plasma concentration. Cellular 
D-DNMol concentrations were 115-218 times the plasma concentration. Maximal 
cellular D-DNM concentrations were attained at the end of D-DNM administration, 
whereas cellular D-DNMol concentrations increased more slowly. After oral D-DNM 
ingestion, plasma and cellular D-DNMol concentrations exceeded D-DNM 
concentrations. Plasma and cellular D-DNMol accumulated on subsequent days. 
D-DNM disappearance rates in plasma and cells were almost comparable, with a 
first and a terminal half-life of circa 0.4 h and 15 h. Terminal half-life of 
D-DNMol in cells was 72 h, compared with 47 h in plasma. 
Complete remissions were obtained in 4 out of 6 évaluable patients, of whom 2 
had an unmaintained relapse after former anthracycline containing regimens. 
INTRODUCTION. 
Daunomycin (DNM) has been one of the major drugs in the treatment of acute 
leukemia (1). Major side effects are nausea, vomiting, and cardiotoxicity which 
are in part related to high plasma concentrations (2). Recently 
4-demethoxydaunomycin (D-DNM) has been introduced, an analogue of DNM in which 
the methoxy-group at position 4 of the aglycone has been replaced by a hydrogen 
molecule (3). When compared with DNM, D-DNM has been reported to have a higher 
anti-tumor (3) and anti-leukemic activity (4) with reduced cardiotoxicity (5). 
2 2 
D-DNM is equimyelotoxic at 10 mg/m compared with DNM at 45 mg/m (5). It is 
the first anthracycline available for both oral and intravenous administration. 
This paper decribes cellular and plasma pharmacokinetics of D-DNM and D-DNMol, 
studied in patients with acute leukemia, who received D-DNM on three consecutive 
days intravenously (short and long-lasting infusion) or orally. 
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PATIENTS, MATERIALS AND METHODS. 
Patients. Pharmacokinetics were studied during β courses in 7 patients with 
acute leukemia. Five patients had acute nonlymphocytic leukemia in relapse, one 
patient had an untreated acute nonlymphocytic leukemia and 1 patient had an 
acute lymphocytic leukemia with an extramedullary relapse. In 2 patients D-DNM 
was administered as bolus injections, lasting 1 min. In 2 patients D-DNM was 
administered as 4 h infusions and in 2 other patients as 24 h infusions. In 2 
patients D-DNM was administered orally; one of them (patient 8) had received 
D-DNM in a previous course as 4 h infusion (patient 3). 
The leukemias were classified according to the criteria of the French American 
British working party (6). The patients were treated according to the modified 
AML-6 protocol of the Leukemia and Lymphoma Cooperative Group of the European 
Organisation on Research and Treatment of Cancer including D-DNM intravenously 
2 2 2 
10 mg/m or orally 30 mg/m , instead of daunomycin intravenously 45 mg/m on 
2 
days 1,2 and 3. The schedule further consisted of cytosine arabinoside 50 mg/m 
2 
as bolus injection b.d. and 100 mg/m as 24 h continuous infusion for days 1 to 
2 
7, and vincristine 1 mg/m bolus injection on day 2. 
Chemicals. D-DNM was obtained from Farmitalia Carlo Erba (Milan, Italy). Pure 
D-DNM and 4-demethoxydaunomycinol (D-DNMol) for chromatographic purposes were 
kindly provided by prof. F. Arcamene (Farmitalia, Carlo Erba, Milan, Italy). 
All further chemicals used were purchased from Merck (Darmstadt, F.R.G.) and 
were of analytical grade. 
Blood and bone marrow sampling. Blood was collected in heparinized polypropylene 
tubes (Greiner, Nürtingen, F.R.G.) and kept on ice to stop further D-DNM 
metabolism. Samples were handled as described in chapter 2 (7). In brief: 
after centrifugation at 0 C plasma was removed and stored at -20 С until 
chromatographic analysis. Erythrocytes in the pellet were lysed with 
ammoniumchloride. The remaining white cells were resuspended in cold phosphate 
buffered saline. The suspension was stored at -20 С until analysis with high 
pressure liquid chromatography (HPLC). 
To evaluate whether D-DNM concentrations in bone marrow cells can be assessed by 
measuring D-DNM concentrations in blood cells, in each patient simultaneously 
with a blood sample, at least on one occasion a bone marrow sample was obtained 
as well. Bone marrow was collected in Acid Citrate Dextrose (ACD buffer, 
formula A, pH 7.4) on ice. Peripheral blood admixture was calculated (8) to 
exclude samples containing less than 80% bone marrow cells from analysis. In 
total 15 adequate pairs of blood and bone marrow samples were obtained at 
maximal, intermediate and nadir plasma D-DNM concentrations. Erythrocytes and 
normoblasts in the samples were lysed and the samples were processed as 
described above. 
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Determination of cellular and plasma D-DNM concentrations. Cellular D-DNM 
concentrations were determined with the HPLC method described in chapter 2 (7). 
In short: 250 yl sonicated cell suspension or 500 μΐ plasma was extracted twice 
with 3 ml chloroform/methanol 9:1 (ν/ν), using adriamycinol as internal 
standard. The chloroform phase was evaporated under air. The dry residue was 
dissolved in 750 vl chloroform/methanol 9:1 (v/v). 500 μΐ was injected on a 
Lichrosorb 7SÌ60 column of a straight-phase system, eluted with 
chloroform-methanol-glacial acetic acid-water (720:210:40:30) supplemented with 
0.3 mM magnesium chloride and 10 yg/ml desipramine (7). Quantification of the 
drug concentration was achieved by measurement of the ratio of peak-height of 
drug and internal standard and calculating the drug concentration from a 
calibration plot of concentration versus peak-height. Detection limit was 1 ng. 
9 9 
Cellular drug concentrations were expressed in ng/10 cells, assuming that 10 
cells have a volume of 1 ml. 
Pharmacokinetics. The D-DNM and D-DNMol cellular and plasma concentration-time 
curves were fitted according to a two-compartment open model, and 
pharmacokinetic data were calculated according to the conventional procedures 
(9). Especially after infusions the calculated Α-value overestimates the real 
maximal drug concentration, while in case of short first half-life times after 
bolus injections, the Α-value cannot be estimated very accurately. Therefore, 
the measured maximal plasma and cell concentrations at the end of the bolus 
injection or the long-term infusion were given, instead of the calculated 
constant A, as is usually done. 
RESULTS. 
Plasma pharmacokinetics. Peak plasma D-DNM concentrations at 5 min after bolus 
injection were 49 ± 15 ng/ml, without accumulation during three subsequent days 
of administration. The biphasic disappearance curve showed half-lives of 20 ± 3 
min and 15.4 ± 3.1 h. D-DNMol immediately appeared in the plasma and surmounted 
plasma D-DNM concentrations from 3 h on. D-DNMol disappearance rate showed a 
half-life of 47 ± 14 h (Fig. 1). 
During the 4 h infusion maximum plasma D-DNM concentrations were reduced to 
23 ± 5 ng/ml. A nearly steady state concentration was reached during the first 
hour after the start of the infusion. The disappearance rate showed half-lives 
identical to those observed after bolus injection. Increase and decrease of 
plasma D-DNMol concentrations were as after bolus injection (Fig. 2). 
During 24 h infusion maximum plasma D-DNM concentrations were circa 6 ng/ml, 
observed from 6 h on. D-DNMol concentrations exceeded the plasma D-DNM 
concentrations 6 to 24 h after the start of the infusion. Terminal half-lives 
were similar to those noted after bolus injection (Fig. 3). 
80 
4 — I — t -
IC* 
10« 
ІШ 
0 24 4 72 0 24 4β 72 66 120 M4 1«θ 192 
—·- time (hours) 
FIGURE 1. (left) Concentrât ion-time curve of 4-demethoxydaunomycin 
(D-DNH) (closed symbols) and the metabolite 4-demethoxydaunomycinol 
(D-DNMol) (open symbols) m plasma (9,0) and m nucleated blood cells 
2 (Ш,и) 10 mg/m D-DNM was administered as rapid infusion on 3 
consecutive days (arrows) (patient 1). 
FIGURE 2. (right) Concentration-time curve of D-DNM and D-DNMol. 10 
y 
mg/m D-DNM was administered as 4-h infusion on day 1,2 and 3 
(arrows) (patient 4) Legends as under Fig. 1 
The shape of the plasma D-DNM concentration curve after oral ingestion was close 
to that observed during 4 h infusion (Fig 4) One hour after ingestion plasma 
D-DNM and D-DNMol concentrations were noted D-DNM concentration increased to 
maximum values of 10 to 20 ng/ml at 3 to 4 h later. Plasma D-DNMol 
concentrations were always higher than D-DNM concentrations, with a maximum of 
20 to 40 ng/ml at 4 to б h after ingestion. D-DNMol slightly accumulated during 
consecutive days. 
In all modes of administration the area under the curve (AUC) of the metabolite 
D-DNMol (AUCm) was larger than the AUC of the parent drug (AUCp), the ratio 
AUCm/AUCp being 2.0 to 2.5 in case of intravenous administration and 5.7 in case 
of oral ingestion (Table 1). 
Cellular pharmacokinetics. Short-lasting peak cellular D-DNM concentrations were 
α 
observed at 5 min after bolus injection (10890 ± 2100 ng/10 cells). No 
accumulation at subsequent days was noted (Fig. 1). A rapid first half-life 
time of 30 ± 9 min was followed by a second half-life time of 16 5 ± 5.7 h. 24 
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FIGURE 3 (left) Concentration-time curve of D-DNM and D-DNMol 10 
2 
mgjm D-DNM was administered as continuous 24-h Infusion during Э 
consecutive days (arrow) (patient 5) Legends as under Fig. 1. 
FIGURE 4 (right) Concentration-time curve of D-DNM and D-DNMol. 30 
2 
mg/αι D-DNM was administered orally at days 1,2 and 3 (arrows) 
(patient 7). Legends as under Fig. 1. 
h after injection cellular D-DNMol concentrations were slightly higher than 
cellular D-DNM concentrations, D-DNMol accumulated during three consecutive 
days Terminal half-life of cellular D-DNMol was 72 ± 11 h. 
During the 4 h infusion a few hours lasting maximum cellular D-DNM 
9 
concentrations were observed at 4490 ± 490 ng/10 cells (Fig. 2). Cellular 
D-DNMol concentrations finally surmounted the cellular D-DNM concentrations 
Marked inter-individual differences were seen (Table 2). 
During the 24 h D-DNM infusion cellular D-DNM and D-DNMol concentrations 
9 
steadily increased to maximum D-DNM concentrations of 1930 ± 540 ng/10 cells 
and D-DNMol concentrations of 1790 ± 650 (Fig. 3). After termination of the 
infusion cellular D-DNM concentrations slightly dropped, while cellular D-DNMol 
concentrations hardly decreased 
After oral ingestion of D-DNM the cellular D-DNM concentration-time curve very 
much resembled the 4 h infusion curve (Fig. 4). Cellular uptake of D-DNM 
9 
concentrations amounted to 4160 ± 1050 ng/10 cells. Cellular uptake of D-DNM 
and D-DNMol was rapid and almost parallel to the appearance of the drug and the 
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TABLE 1. Plasma pharmacokinetic parameters of the different ways of 
administration of 4-demethoxydaunomycin (D-DNM), during 3 consecutive 
days. Patient 1 and 2: bolus injection. Patient 3 and 4: 4-h 
infusion. Patient 5 and 6: 24-h infusion. Patient 7 and 8: oral 
administration. 
Pat 
1.1 
.2 
.3 
2.1 
.2 
.3 
3.1 
.2 
.3 
A.l 
.2 
.3 
5. 
6. 
7.1 
.2 
.3 
8.1 
.2 
.3 
A 
ng/ml 
43 
54 
77 
54 
43 
53 
29 
26 
30 
17 
17 
16 
4 
6 
10 
11 
5 
15 
10 
13 
В 
ng/ml 
7.2 
11.9 
10.4 
6.7 
Θ.0 
6.9 
9.5 
14.7 
5.6 
6.6 
6.4 
6.3 
9.4 
5.0 
6.4 
5.7 
3.9 
2.8 
5.8 
5.5 
Τ 
*1/2α 
h 
0.4 
0.3 
0.3 
0.3 
0.3 
0.4 
0.7 
0.1 
0.9 
0.4 
0.1 
0.1 
0.6 
0.2 
0.4 
0.6 
0.2 
1.4 
0.5 
0.8 
T1/2B 
h 
16.8 
11.0 
14.9 
13.8 
14.5 
21.1 
11.7 
10.7 
21.3 
18.4 
15.6 
18.8 
19.0 
6.2 
10.9 
14.9 
16.9 
9.4 
6.5 
12.7 
т
і/2еш A U C P 
h yg.h/L 
32 
60 
30 
39 
72 
56 
56 
34 
553 
473 
769 
504 
436 
393 
314 
397 
AUCm 
4487 
1116 
1955 
983 
962 
811 
1795 
2299 
CL 
ml/min 
1542 
1440 
1182 
1920 
1620 
1260 
1446 
1128 
1110 
1728 
1566 
1674 
2274 
2412 
3108 
2364 
3156 
3666 
3117 
2724 
AUC-ratio 
D-DNMol 
D-DNM 
8.10 
2.36 
2.54 
1.95 
2.20 
2.06 
5.71 
5.79 
1.1: patient 1, first day; 1.2: patient 1, second day, etc. 
A: measured peak (bolus injection) or maximal (infusion/oral) drug 
concentration. В: calculated concentration constant. 
Τ,,, and Τ, .„- : first and terminal half-life of day 1, 2 and 3. 
l/Zd 1/ZP 
T, ... : terminal T, ,„ of D-DNMol after the third day. 
1/ζ ßm 1 / Ζ 
AUCp and AUCm: AUC of D-DNM (p) and the metabolite (m) 
4-demethoxydaunomycinol (D-DNMol) up to 120 h. 
AUC-ratio: ratio of AUC's of D-DNMol over D-DNM. 
metabolite in plasma. Initially cellular D-DNMol uptake was less rapid than 
D-DNM uptake, but within a few hours after ingestion of D-DNM, D-DNMol 
concentrations exceeded cellular D-DNM concentrations, accumulating during the 3 
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consecutive days of D-DNM administration to 6760 ± 1600 ng/10 cells at day 3. 
These concentrations are 2 to 4 times higher than the ones observed after i.v. 
infusion (Table 2) On one occasion the patient vomited soon after ingestion. 
Both plasma and cellular D-DNM and D-DNMol concentrations were reduced compared 
with the previous days (Fig 4, third day, Table 1 and 2, patient 7). 
TABLE 2. Cellular pharmacokinetic parameters of the different ways of 
administration of 4-demethoxydaunomycin (D-DNM) administered during 3 
consecutive days. 
Pati 
1.1 
.2 
.3 
2.1 
.2 
.3 
3.1 
.2 
.3 
4.1 
.2 
.3 
5. 
6. 
7.1 
.2 
.3 
8.1 
.2 
.3 
ent A 
ng/ml 
8710 
10800 
11220 
12000 
8080 
14540 
4760 
4550 
5160 
3650 
4130 
4720 
2200 
2700 
4180 
3480 
2550 
6010 
4420 
4290 
В 
ng/ml 
2066 
2877 
2456 
1815 
2297 
1861 
2830 
2964 
2689 
2554 
2243 
2416 
753 
240 
1490 
2335 
1970 
5872 
4815 
3639 
Tl/2a 
h 
0.5 
0.4 
0.3 
0.5 
0.7 
0.8 
1.5 
0.3 
1.0 
0.7 
0.4 
0.7 
3.7 
1.6 
2.6 
0.1 
0.2 
0.1 
0.1 
2.1 
Τ1/2β 
h 
18.4 
7.8 
16 1 
11.4 
22.0 
23.6 
14.2 
12.3 
11.8 
11.1 
28 6 
34.4 
57.4 
97.0 
19.3 
15.7 
22.1 
8.4 
7.7 
10.9 
Tl/2ßm 
h 
66 
60 
72 
90 
46 
60 
60 
28 
AUCp 
Ug.h/L 
133742 
155120 
156914 
169170 
157350 
114060 
171603 
168300 
AUC-
AUCm D· 
yg.h/L 
98842 
120618 
159904 
93118 
171925 
87645 
364413 
533346 
-ratio 
-DNMol 
D-DNM 
0.74 
0.78 
1.02 
0.55 
1.09 
0.77 
2.12 
3.17 
Legend: see Table 1. 
The ratio of cellular AUCm/AUCp was 0.8 ± 0.2 after i.v. administration and 
2.6 ± 0.5 after oral ingestion. The ratios of the AUC of the cellular versus 
the plasma concentrations for D-DNM (and D-DNMol) were 292 ± 55 (115 ± 34) after 
intravenous and 485 ± 60 (218 ± 15) after oral administration. In order to find 
out, whether plasma concentrations of D-DNM plus the cytotoxic metabolite 
D-DNMol could predict for the cellular concentrations of D-DNM plus D-DNMol, the 
sum of the plasma AUCp + AUCm was correlated to the sum of the cellular 
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AUCp + AUCm. No correlation was observed between the total plasma concentration 
and the total cellular drug concentrations (r = 0.04, η = 8) 
Cellular D-DNMol concentrations were highest after oral administration (Fig 4) 
In that case cellular D-DNM concentrations were only half the short-lasting peak 
cellular concentrations observed after bolus administration, and were similar to 
those seen after prolonged 4 or 24 h infusion (Table 2). 
9 
Over a concentration range of 100 - 6200 ng per 10 bone marrow cells, cellular 
D-DNM concentrations in bone marrow cells were in the same order of magnitude as 
those observed m circulating nucleated blood cells (r = 0 71, ρ < 0.01, 
y = χ + 0.6, η = 15), cellular D-DNMol concentrations over a range of 80 - 5400 
9 
ng per 10 bone marrow cells, correlated even better with the nucleated blood 
cell concentration (r : 0.94, ρ < 0 001, y = χ - 0 02, n=15). 
In one patient 1 ml of cerebrospinal fluid could be investigated at the end of 
the 72 h infusion. No D-DNM or D-DNMol was detected. 
Clinical outcome. Complete remissions were obtained in 4 out of 6 évaluable 
patients. From these patients, one was treated in an unmaintained relapse of 
acute nonlymphocytic leukemia (ANLL) (type M2), the second had an extramedullary 
relapse of an acute lymphocytic leukemia. The third patient with ANLL (type M2) 
had not responded to previous non-anthracycline containing therapy and the 
fourth patient had an untreated ANLL (type M5) Remission duration was 8+ to 22 
weeks. In 2 patients no remission was obtained. One patient appeared to be 
resistant to two different subsequent regimens as well, the other thereafter 
reached a remission of only 13 weeks on high dose cytosine arabinoside and 
amsacrine. The non-evaluable patient died due to cerebral hemorrhage at day 10. 
In this limited number of patients no correlation was observed between succesful 
remission induction and maximal cellular D-DNM and/or D-DNMol concentrations. 
9 
Granulocyte nadir (< 0.5 χ 10 cell/L) was reached at 5.1 ± 2.6 days after the 
start, with recovery at 29.6 ± 5.9 days. These values are comparable with those 
observed in DNM containing regimens (6 ± 4 and 27 ± 5 days respectively, η = 20 
patients, chapter 5). Slight nausea and vomiting was observed only in case of 
oral administration and could easily be suppressed with conventional anti-emetic 
drugs. Alopecia was (sub)total in all patients. Diarrhoea was observed in one 
patient, but was not clearly drug related. No other signs of toxicity were 
noted. 
DISCUSSION. 
4-demethoxydaunomycin (D-DNM) was given intravenously at circa 25% of the dose 
of daunomycin (DNM) Peak plasma D-DNM concentrations (49 ± 15 ng/ml) were 21 
to 30% of the peak DNM concentrations we observed and described in chapter 5, 
i.e. in case of bolus injection (DNM: 227 ± 116 ng/ml), 4 h infusion (23 ± 5 
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versus 120 ± 30 ng/ml), or 24 h infusion (circa 6 versus 16 ± 6 ng/ml). 
Cellular D-DNM concentrations were 25 to 50% of the cellular DNM concentrations 
(chapter 5). As cardiotoxicity seemed to be related to peak plasma 
concentrations (2), the observed low plasma concentrations might have 
contributed to the reported reduced incidence of D-DNM cardiomyopathy (10). 
Whether, with regard to cytotoxicity any benefit can be expected from extension 
of the infusion-period, remains to be investigated. 
Terminal plasma half-life time of D-DNM was similar to that of DNM (18 ± 5 hr) 
(11). Although within one and the same patient the concentration-time curves on 
three consecutive days were rather similar, large variations in especially AUCp 
and AUCro were observed between different patients (Tables 1 and 2). In the case 
of oral D-DNM administration, plasma and cellular D-DNMol concentrations 
surmounted that of D-DNM due to the first-pass effect, during which extensive 
metabolization occurred. In general our data on plasma D-DNM and D-DNMol 
concentrations were in the range of those described by others (12, 13, 14). 
In patients 5 and 6 cellular D-DNM and D-DNMol concentrations were 500-1000 
times higher than the plasma concentrations, which suggest a facilitated 
cellular drug uptake against a concentration gradient, even at the very low 
plasma concentrations observed during continuous infusion. 
After oral D-DNM administration, rapid drug absorption was observed with maximum 
plasma concentrations at 2 to 4 h after ingestion. D-DNMol concentrations 
surmounted the D-DNM concentrations in plasma and in blood and bone marrow 
cells. Considerable cytoreduction was attained in the regimen with oral D-DNM, 
suggesting that cellular D-DNMol concentrations are important for the 
anti-leukemic activity in vivo as well. In fact, cytotoxic activity of D-DNMol 
has been proven in vitro (15). Differences in plasma and cellular ratios of 
AUCra/AUCp illustrated differences in influx and efflux patterns of D-DNM and 
D-DNMol. D-DNM was taken up more rapidly and in a greater amount (3), but also 
eliminated more rapidly from the cells than cellular D-DNMol, as is seen in case 
of more lipophilic drugs (5). 
The similarity between bone marrow and peripheral blood cell D-DNM and D-DNMol 
concentrations over the observed concentration range, suggested a similar 
concentration-time curve of cellular D-DNM and D-DNMol concentrations in bone 
marrow cells and in nucleated blood cells. 
Our observations in man differed markedly (in cells as well as in plasma) from 
those in mice (16), pointing once more to large interspecies differences 
existing in pharmacokinetic studies of cytostatics. This supports the need of 
pharmacokinetic studies in man. 
Since cellular D-DNM and D-DNMol concentrations lasted for several days, and 
accumulated at consecutive days, attention should be paid to drug scheduling. 
In mice the repeated-treatment schedule (treatment for 3 consecutive days) 
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appeared to be less effective than intermittent treatment with D-DNM 
administrations on days 1,3 and 6 or on days 1,5 and 9 (3) It may be 
worthwhile to investigate in clinical and cellular pharmacokinetic studies 
whether such intermittent administration schedules can improve the remission 
induction therapy 
The complete remissions obtained in 4 outof 6 patients of whom 2 had an 
unmaintained relapse after former anthracycline containing regimens, suggests 
that D-DNM is a potent anti-leukemic drug The possibility of oral 
administration discriminates this analogue from other anthracyclines, and has 
advantages in the outpatient treatment of leukemias. 
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CHAPTER 7 
CELLULAR AND PLASMA PHARMACOKINETICS OF WEEKLY 20 MG 4'-EPI-ADRIAMYCIN 
BOLUS INJECTION IN PATIENTS WITH ADVANCED BREAST CARCINOMA 
P.A.J. Speth, P.CM. Linssen, L.V.A.M. Beex, J.B.M. Boezeman and 
С. Haanen 
Cancer Chemotherapy and Pharmacology: in press 
SUMMARY. 
Weekly low dose injections of 20 mg 4'-epi-adriamycin (E-ADM) were given to 12 
postmenopausal patients with advanced breast cancer for at least 8 weeks. All 
patients had previously been treated with hormonal therapy and polyChemotherару 
not containing anthracyclines. E-ADM concentrations in plasma, urine and in 
blood and bone marrow cells were determined during 8 consecutive weeks. Plasma 
concentrations in the range of a few ng/ml were measured up to 72 to 96 h. 
Cellular concentrations appeared more than hundred-fold higher than plasma 
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concentrations and were 190 ± 66 ng/10 cells on day 8, before the next 
injection was given. Nevertheless, no serious bone marrow toxicity was 
observed. In 2 patients with an increased plasma bilirubin concentrations, 
cellular E-ADM concentrations were 20 to 40% higher than those observed in the 
other patients. Plasma concentrations of E-ADM and 4'-epi-adriamycinol showed 2 
to 3 times longer final half-life times and could be followed for a week. In 3 
patients a biopsy of skin metastasis was done. In 2 patients E-ADM could be 
demonstrated in the tumor tissue up to 7 days after the last injection. 
Although the number of patients investigated is too small to relate the drug 
kinetics with clinical response, it is of interest that the 2 patients with the 
highest cellular E-ADM concentrations responded better than the others. 
INTRODUCTION. 
In breast carcinoma, adriamycin (ADM) is one of the most effective cytostatic 
agents in single drug therapy (5, 6). Unfortunately cardiotoxicity of this drug 
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given as bolus injection limits its use beyond a cumulative dose of 550 mg/m 
body surface (5, 16, 16a). Therefore other schedules have been developed, like 
weekly low dose (20 mg) ADM bolus injections (10, 13, 16a) or continuous ADM 
infusions over longer periods (4). It has been claimed that these regimens are 
less cardiotoxic, while the therapeutic efficacy is maintained (4, 8). Recently 
the new analogue 4'-epi-adriamycin (E-ADM) has been reported to be equally 
potent and probably less cardiotoxic (7). Low toxicity and a very high response 
rate of 51% in a phase II study with weekly low dose E-ADM in pretreated 
postmenopausal patients with advanced breast carcinoma was reported (11). These 
results justified a multicentre controlled phase II study in which 
postmenopausal patients with advanced breast cancer were treated with 20 mg 
E-ADM weekly. This paper describes cellular and plasma pharmacokinetics in 12 
patients treated according to this protocol. Data on cellular E-ADM 
concentrations might elucidate part of the mechanism involved in the reported 
efficacy of this treatment schedule. 
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PATIENTS AND METHODS. 
Patients. Patients with advanced breast cancer and measurable disease (UICC 
criteria) were eligible for this study. All patients were previously treated 
with chemotherapy not containing anthracyclines. The mean age was 60 years, 
ranging from 42 to 71 years of age. Ten patients had normal bilirubin values, 
two patients had impaired liver functions with increased bilirubin values of 23 
ymol/L (patient 11) and 112 vmol/L (patient 12) (normal value < 10 vmol/L). 
Kidney function was normal in all patients. All patients were informed about 
this study and consented to it. The overall clinical results of this 
multicentre study will be reported separately. 
Chemicals. E-ADM for clinical use and the pure analytic standards of E-ADM and 
4'-epi-adriamycinol (E-ADMol) were kindly supplied by Farmitalia Carlo Erba 
(Milan, Italy). Other chemicals for extraction and chromatographic analysis 
were of analytical grade and were obtained from Merck (Darmstadt, F.R.G.). 
Study design. E-ADM was administered in a running infusion over 1-2 min once a 
week for at least 8 weeks. The dose was 20 mg, irrespective of the body 
surface. Blood samples were collected before the next injection; during the 
first, fourth and eighth week also at 5 and 30 min and at 1, 2, 4, 24, 48, 96 
and 168 h after the injection. In 4 patients bone marrow aspirates were taken 
before E-ADM administration at day 1, 22 and 50. Inhibition of clonogenic bone 
marrow cells was examined using the Colony Forming Unit assay for granulocytes 
and macrophages (CFU-GM). 24 h urine was collected for determination of E-ADM 
and its metabolites at day 7, 28 and 56 and 5 ml samples were stored at -20 С 
unt i1 analysis. 
Collection of the samples. Venous blood was collected in heparinized 
polypropylene tubes on ice. Plasma was removed after 10 min centrifugation at 
0 C, 900 g. Erythrocytes in the pellet were lysed with cold ammonium chloride 
(14). After centrifugation at 0 C the leucocytes were resuspended in cold 
phosphate buffered saline. The recovery of the leucocytes after the lysis step 
was 85-90%. Plasma samples and cell suspensions were stored at -20 С until 
analysis with high pressure liquid chromatography. Bone marrow samples were 
collected in buffered Acid Citrate Dextrose (ACD, formula A, pH 7.4). After 
centrifugation and diluting in phosphate buffered saline one part was used for 
the CFU-GM assay. Red cells and normoblasts in the other part were lysed with 
ammonium chloride. The remaining white cells were resuspended in PBS and stored 
at -20 С until analysis for E-ADM concentration. 
Extraction procedure and high pressure liquid chromatographic analysis. The 
method used has been described in chapter 2 (14). In short: after addition of 
adriamycinol as internal standard, 500 μΐ plasma or 250 μΐ sonicated cell 
suspension was extracted twice with chloroform/methanol 9:1 (v/v). After 
91 
evaporation of the organic phase, the dry residue was dissolved in 750 μΐ 
chloroform/methanol/Tris buffer 500 yl aliquots were injected on a Lichrosorb 
7SI60 column (100 mm χ 3.0 mm I.D.) With this extraction and chromotographic 
procedure no glucuronide metabolites can be detected. These metabolites which 
are unique for E-ADM (1, 7, 15) have no cytotoxic activity (F Ganzina, 
Farmitalia Carlo Erba, personal communication) We therefore considered them of 
no importance for this study, and used the same method, as in our previous 
studies (14). Measurement of peak-height ratio of drug and internal standard 
was used for quantification of the drug concentration Plasma and cell 
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concentrations were expressed in ng/ml, assuming 10 cells represent a volume of 
1 ml. The recovery of the extraction was 80-90% The detection limit was 1 ng. 
The day-to-day variation for extraction from cells and plasma for the whole 
procedure was 9 0% and 8% respectively (n = 18). 
Pharmacokinetic analysis Cellular and plasma E-ADM concentration-time data 
were fitted according to a two-compartment open model, and the pharmocokinetic 
data were calculated according to conventional procedures (18). 
RESULTS. 
Cellular and plasma E-ADM concentration data m 10 patients with normal plasma 
bilirubin values are given in Fig 1 
Plasma pharmacokinetics The peak plasma concentrations at 5 rain after the 
first bolus injection were 592 ± 112 ng/ml (n = 10) The plasma disappearance 
curve was biphasic with half-life times of 9 6 + 1 8 m m and 18.2 ± 5 1 h 
respectively. The main and cytostatic active metabolite (E-ADMol) was observed 
during the first three days after injection. No significant E-ADM accumulation 
was seen during 8 consecutive weeks (fig 2) Plasma pharmacokinetic parameters 
(half-lives, AUC, clearance and distribution volume) of weeks 1, 4 and 8 are 
summarized in Table 1 No significant differences were noted in the subsequent 
weeks. 
Cellular pharmacokinetics. Peak cellular (white blood cells) concentrations at 
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5 min after the first bolus injection amounted 4680 ± 1800 ng/10 cells 
(n = 10). Cellular pharmacokinetics revealed a biphasic disappearance curve 
with tl/2 values of 17.8 ± 8.3 m m and 49.7 ± 10 8 h respectively. The ratio 
cellular/plasma concentration increased from 7 9 at 5 m m after injection to 674 
at 48 h and 3800 at 72 h. On day 7 the cellular concentrations were still 
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190 ± 66 ng/10 cells (n = 104). Cellular pharmacokinetic parameters are 
summarized in Table 1 No significant cellular E-ADM accumulation was observed. 
In Fig. 2 an example of cellular and plasma concentration courses are given as 
measured over a period of 8 weeks in an individual patient. 
Impaired liver function. In 2 patients with an increased plasma bilirubin 
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FIGURE 1. (left) Cellular and plasma concentration data of 4'-epi-
adnamycin and 4'-epi-adnamycinol after 20 mg bolus injection during 
the first week in patients with normal bilirubin concentrations Hean 
±SD (n = 10 patients) О = cellular 4' -epi-adnamycin, # = plasma 
4'-epi-adriamycm, • = 4'-epi-adriamycmol. Arrow indicates moment of 
administration. 
FIGURE 2. (right) Cellular and plasma concentrations of 4'-epi-
adriamycm and 4'-epi-adriamycmol after weekly 20 mg bolus injection 
m a patient with normal bilirubin concentration during 8 consecutive 
weeks. Legends under Fig. 1 
concentrations, the disappearance rate of plasma and cellular E-ADM had markedly 
decreased (Fig. 3) compared to the values observed in the 10 patients with 
normal plasma bilirubin values. The peak plasma (535 ± 160 ng/ml) and peak 
α 
cellular (4160 ± 1920 ng/10 cells) concentrations at 5 min after bolus 
injection were in the same order of magnitude compared to values observed in 
patients with normal plasma bilirubin However, the plasma disappearance rates 
were lower, 11 4 ± 4 θ min and 55.2 ± 11.2 h for the first and the second 
half-life respectively. Plasma concentrations of E-ADM and E-ADMol at the next 
injection (day 7) were 1.6 to 4 7 ng/ml E-ADM and 0 to 4.0 ng/ml E-ADMol 
Cellular concentrations were 20-40% higher compared to those observed in 
patients with a normal liver function. In both patients the pretreatment 
jaundice improved during therapy In 5 patients with liver metastases and 
increased alkaline phosphatase levels but normal plasma bilirubin 
concentrations, plasma and cellular disappearance rates were in the normal 
range. 
93 
IO* 
ici 
** 
FIGURE 3. Cellular and plasma concentrations per ml of 4'-epi-
adriamycin and 4' -epi-adriamycmol after weekly 20 mg bolus injection 
m 2 patients with increased bilirubin concentrations. Mean ± SD. 
Legends under Fig. 1 
Urine E-ADM excretion. In the 24 h urine samples collected on day 7 of the 
first, fourth and eighth week only a small amount E-ADM, E-ADMol and some other 
metabolites were seen These samples were not analysed further. However, the 
presence of urinary E-ADM at the day of the next injection reflected a 
continuous plasma E-ADM presence, although the plasma concentrations were below 
the detection limit of 1 ng/ml. 
TUMOR CELL E-ADM CONCENTRATIONS. 
In the seventh week a skin metastasis was removed from one patient one hour 
after E-ADM injection, from a second patient in the ninth week just before the 
next injection and from a third patient two weeks after the last injection. 
Histological examination in all cases confirmed the cutaneous localisation of 
breast carcinoma. In samples of 13 and 30 mg tumour tissue cellular E-ADM 
concentration were determined. The tumour contained 1.68 yg E-ADM/gram tissue 
in the first sample (blood leucocyte concentration at that time was 2.5 Ug/gram 
cells) and in the second sample 11 ng/gram tumor tissue (blood leucocyte 
concentration at that time was 270 ng/gram cells). In the third sample in tumor 
and nucleated blood cells no E-ADM was found two weeks after the last injection. 
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TABLE 1. Plasma and cellular pharmacokinetic parameters of 20 mg 
4'-epi-adriamycin weekly bolus injection in 10 patients with normal 
plasma bilirubin values and 2 patients with increased plasma bilirubin 
concentrations. 
PLASMA PHARMACOKINETICS 
l/2a 
h 
normal bilirubin 
T, ,„„ A 
ng/ml 
1/20 
h 
(η = 10 patients) 
В AUC Cl Vf 
ng/ml lig.h/L l/min L 
Week 1 
week 4 
week 8 
Total 
0. 
0. 
0. 
0. 
.210, 
.110. 
.210. 
.210 
.03 
.02 
.02 
.02 
2015 
1513 
2114 
1815 
5921112 
5571211 
6581127 
5981160 
1114 
1012 
1313 
1113 
5421155 
5151195 
6271 59 
5611114 
44120 
57113 
371 7 
43114 
5661227 
618+215 
7101 95 
6011222 
total 
increased bilirubin (η = 2 patients, 8 weeks) 
0.2+0.08 55111 5351160 2013 902150 16+3 1150+505 
1/2α 
h 
CELLULAR PHARMACOKINETICS 
normal bilirubin (n = 10 patients) 
T, ,„„ А В AUC 1/20 
h 9 9 
ng/10 cells ng/10 cells Ug.h/L 
week 1 
week 4 
week 8 
total 
0, 
0, 
0. 
0 
.310. 
.310. 
.410. 
.3+0. 
.1 
,1 
.1 
.1 
47111 
561 9 
461 9 
50111 
468011800 
573011500 
495011400 
501011700 
13701170 
1660+290 
18601 75 
16711361 
152000145000 
170000131000 
166000+46000 
156000+33000 
total 
increased bilirubin (n = 2 patients, 8 weeks) 
0.210.02 64+1 416011920 20551360 206000+29000 
T. . and T....: first and second half life times. 
A and B: extrapolated concentrations constants. 
AUC: area under the curve. CI: plasma clearance. Vf: volume of 
distribution. 
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CLONOGENICITY OF HEMATOPOIETIC PROGENITOR CELLS. 
In 4 patients the effect on clonogenicity of bone marrow CFU-GM was determined 
before treatment and at 4 and 8 weeks of treatment. Compared to a control 
culture (bone marrow sample of normal patient) in all patients the number of 
colonies was depressed before the start of the treatment: mean 39% (range 
24-100%). No significant decrease in clonogenicity was observed during the 
subsequent cultures at week 4: mean 60% (range 36-96) and at week 8: 47% 
(range 6-50%) (Table 2). Cellular E-ADM concentrations in bone marrow cells at 
day 7 were 132 ± 123 ng/109 cells (range 0-310 ng/109 cells). 
TABLE 2. Number of CFU-GH* before treatment and in the fourth and 
eighth week of therapy, before the bolus injection. 
X growth (CFU-GM)** 
mean range η 
before 39 24-100 4 
4 weeks 60 36-96 3 
8 weeks 47 6-50 4 
* CFU-GM: Colony Forming Unit for Granulocytes and Macrophages 
** compared to a normal control, which was set at 100% 
PHARMACOKINETIC DATA AND CLINICAL RESULTS. 
2 
When the fixed dose of 20 mg bolus injection was expressed in mg/m body 
2 
surface, the mean administered dose was 12.5 mg/m , ranging from 11.1 to 13.9 
2 
rag/m . No relation was observed betwen the clinical result and the administered 
2 
dose expressed as mg E-ADM/m . 
Of the 12 patients described in this study 9 could be evaluated for response. 
Two patients with increased bilirubin concentrations had a partial remission of 
4 and 6 months respectively with improvement of liver function. Two others with 
normal bilirubin values had stable diseases at 9+ and 12+ months. The area 
under the plasma concentration curve (AUCp) and the area under the cellular 
concentration curve (AUCc) of the two patients with the increased bilirubin 
(AUCp 902 ± 50 vg.h/1 and AUCc 206000 ± 29000 pg.h/l) were higher than the AUC's 
observed in the other ten patients (AUCp 561 ± 114 vg.h/1 and 156000 ± 33000 
Vg.h/l). The AUCp and the AUCc of the two patients with stable disease did not 
differ significantly from the values obtained of those who failed to response 
(two-sided student-t test). 
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DISCUSSION. 
E-ADM is advocated as superior to ADM in the treatment of breast cancer (7), 
since it has been reported to be less myelotoxic (11) and less cardiotoxic at an 
equimolar dose (7). Besides bone marrow depression, alopecia and 
gastrointestinal disturbances (17), a major side effect of anthracycline 
treatment is cardiotoxicity, which has been related to the total cumulative dose 
(13, 17) and most probably to the peak plasma concentration as well. The last 
one is lowered by reduction of the administered dose or by reducing the infusion 
rate (8). 
In the weekly low dose regimen peak plasma concentrations are 2-4 fold lower 
than those observed after the high dose regimen (75 mg bolus injection) (15). 
The absence of nausea and vomiting may also be related to low concentrations as 
has been observed with continuous infusions. Despite continuous cellular 
presence of E-ADM in blood and bone marrow cells, no overt bone marrow toxicity 
(11) and hardly any alopecia was noted (3, 11). In several patients with low 
blood cell counts before therapy, the thrombocyte and leucocyte values even 
improved. 
2 
The tissue concentrations reported at 2 h after 10-20 mg/m injection (9) were 
in the range of Ε-ADN concentrations of nucleated blood cells, as were the 
cellular concentrations detected in the skin tumor. The prolonged presence of 
E-ADM in the tumor tissue (up to day 7) could point to one of the mechanisms 
involved in the observed response rate. 
Although the number of investigated patients is too low to draw conclusions on 
the efficacy of this schedule, the preliminary clinical results so far are not 
impressive. This is in agreement with the experience of Castiglione et al. (3) 
who even used higher weekly dosages. 
Increased bilirubin concentrations are known to be related to a reduced hepatic 
elimination (2). We observed a prolonged terminal plasma half-life and higher 
cellular E-ADM concentrations in these patients. The only two patients with a 
partial response had increased bilirubin concentrations, a higher area under the 
cellular and the plasma curve, plasma E-ADM and E-ADMol concentration 
continuously above 1 ng/ml. This observation may justify an extension of the 
study, with a higher weekly dose or shorter intervals, provided that side 
effects remain low, since this is the main advantage of this weekly low dose 
regimen. Since our data show a weak correlation between cellular 
pharmacokinetics of hematopoietic cells and therapeutic results, it may be of 
interest to measure tissue concentrations in relation to therapeutic results. 
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CHAPTER 8 
IN VITRO AND IN VIVO STRUCTURE-RELATED PHARMACOKINETIC DIFFERENCES OF 
FOUR ANTHRACYCLINES IN DISTINCT HEMATOPOIETIC CELL SUBTYPES 
Paul A.J. Speth, Peter CM. Linssen, Emiel F.S. Termond, 
Jan B.M. Boezeman, Hans M.C. Wessels and Clemens Haanen 
Submitted to Laboratory Investigation 
SUMMARY. 
Minor differences in chemical structure of adriamycin (ADM), A'-epi-adriamycin 
(E-ADM), daunomycin (DNM) and 4-demethoxydaunomycin (D-DNM) cause differences in 
the polarity of these drugs, D-DNM being less polar than DNM<E-ADM<ADM. 
Cellular pharmacokinetics of these drugs were studied during and after in vivo 
and in vitro exposure of normal human hematopoietic cells. 10 cells were 
exposed in vitro to 100 and 1000 ng/ml during 360 min and 5 min respectively, to 
simulate in vivo constant-rate infusion and bolus injection. Cellular 
anthracycline concentrations in subpopulations were measured by means of flow 
cytometry. 
In vitro, during 360 min exposure initial anthracycline uptake was fast. Steady 
state concentrations were not attained, except for lymphocytes exposed to D-DNM. 
Highest cellular anthracycline concentrations and highest area under the 
cellular curve (AUCc) was noted after incubation with D-DNM, followed in 
decreasing order by DNM, E-ADM and ADM. Final cellular drug concentrations were 
300-2500 times the medium concentration. Efflux, measured during 180 min 
reincubation, showed an almost instantaneous 30% loss of cellular ADM and E-ADM 
in each subpopulation, with hardly any further loss thereafter. Release of 
D-DNM and DNM was more gradual and longer lasting, to the greatest extent in the 
case of D-DNM (50-60% after 180 min). 
During 5 min exposure at higher anthracycline concentrations cellular ADM and 
E-ADM concentrations reached their optimum at once, whereas for DNM and D-DNM it 
took more time to enter the cells. Efflux patterns were similar to those 
described above, but efflux was observed to a greater extent with circa 60% 
(E-ADM and ADM) and 70% (DNM and D-DNM) loss of the peak concentration. 
In vivo, large differences between cellular and plasma pharmacokinetic 
parameters were observed. Anthracyclines accumulated in cells to several 
hundred-fold the plasma concentration. Half-life times, and the ratio parent 
drug/metabolite differed as well. The slopes of the ¿n vivo cellular 
concentration-time curves after the end of the bolus injection, were similar to 
the efflux curves observed after the 5 min exposure in vitro. The AUCc in vivo 
was largest for ADM and smallest for D-DNM, which is in contrast with the 
observations in vitro. 
Minor differences in anthracycline structure resulted in considerable variations 
in cellular drug handling, with large differences between in vitro and in vivo 
cellular pharmacokinetics. This may be of importance for the antitumor as well 
as for the toxic side effects of the anthracyclines investigated here. 
INTRODUCTION. 
Since the discovery of the cytotoxic antibiotic daunomycin (DNM), investigators 
100 
have continuously searched for dérivâtes with higher cytotoxic activity and less 
toxic side effects (13). This has resulted in a number of analogues of which 
adriamcyin (ADM), A'-epi-adriamycin (E-ADM) and 4-demethoxydaunomycin (D-DNM) 
are now in clinical use (3, 13). These drugs have only minor differences in 
chemical structure, but large differences in plasma pharmacokinetics (2, 17), 
suggesting different metabolic conversion and different cellular drug uptake. 
DNM has been applied primarily in the treatment of leukemias, whereas ADM has 
been used in a much wider range of malignancies (5). E-ADM and D-DNM have not 
been in clinical use long enough to define their pattern of activity. 
In this study cellular pharmacokinetics of these four anthracyclines were 
compared in vitro and in vivo in human hematopoietic cells. The use of flow 
cytometry (FCM) enabled quantitative measurement of drug concentrations in the 
hematopoietic subpopulations. High pressure liquid chromatography (HPLC) was 
used for determination of medium and plasma drug concentrations, as well as for 
the detection of metabolites. 
MATERIALS AND METHODS. 
Chemicals. DNM was obtained from Specia (Paris, France), ADM from Roger Bellon 
(Neuilly sur Seine, France), E-ADM and D-DNM were generously supplied by 
Farmitalia Carlo Erba (Milan, Italy). Chemicals for chromatographic purposes 
were of analytical grade and were obtained from Merck (Darmstadt, F.R.G.). 
Preparation of the cell suspension. Normal human bone marrow cells were obtained 
from cardiac surgery patients (Dept. of Cardiac Surgery, head prof. L.K. 
Lacquet). Bone marrow was collected in Acid Citrate Dextrose solution (ACD-A, 
formula A). Cells were used for experiments only if the suspension contained 
less than 20% peripheral blood admixture (8). After filtration through a 70 μπ> 
filter, the cells were washed twice and resuspended at a concentration of 10 
cells/ml in glucose phosphate buffer containing 1% fetal calf serum in 
polypropylene tubes. In prior experiments it was determined that at this cell 
concentration the extracellular drug concentration hardly diminished (19). The 
cell suspension was preincubated in a shaking waterbath at 37 С for 60 min, 
after which the drugs were added. 
For another set of experiments lymphocyte and monocyte suspensions with a purity 
of 96 and 84% respectively were prepared using counterflow centrifugation (11). 
In vitro anthracycline exposure. In order to simulate a bolus injection, cells 
were exposed to 1000 ng/ml of ADM, E-ADM or DNM for 5 min in 3 subsequent 
experiments. To simulate a long-term infusion, cells were exposed to 100 ng/ml 
for 360 min. D-DNM concentrations were 250 ng/ml and 25 ng/ml respectively, 
which in vivo is equimyelotoxic compared to the DNM concentration used (4). In 
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prior experiments cellular drug uptake for all four drugs was linear up to at 
least 5000 ng/ml medium concentration for 120 rain incubation. Samples in 
duplicate were taken at 1, 2.5 and 5 rain in case of 5 rain incubation and at 1, 
5, 10, 15, 30, 60, 120, 180, 240, 300 and 360 min in case of 360 min incubation. 
At the end of the 5 min or 360 min incubation the cell suspensions were 
centrifugated (900 g, 37 C, 5 rain), the supernatant was discarded, and the cell 
pellet was resuspended in drug-free medium at 37 С and reincubated for 180 min. 
One sample was taken immediately at the start of the reincubation (+1 min). 
Subsequent samples were taken at 5, 15, 30, 60, 120, and 180 min. Samples were 
immediately placed on ice and centrifugated (900 g, 0C, 5 min), the supernatant 
collected for high pressure liquid chromatographic determination of the drug 
concentration and erythrocytes and normoblasts in the cell pellet lysed with 
ammonium chloride buffer as described in chapter 2 (19). After centrifugation 
the cell pellet was resuspended in saline and kept on ice in the dark. Cellular 
drug concentrations were measured with flow cytometry, usually within a few 
hours. 
Flow cytometric determination of cellular and nuclear anthracycline 
concentrations• Three parameter flow cytometry (FCM) enabled quantitative 
determination of the anthracycline concentrations in subpopulations of 
hematopoietic cells as described in chapter 3 (19): myeloid cells, blast cells 
and/or monocytes and lymphocytes. Cells were analysed with a Cytofluorograf 50H 
(Ortho Diagnostics, Westwood, MA, U.S.A.) equipped with a 5W Argon laser 
(164-05, Spectra Physics, Mountainview, MA, U.S.A.) running at 0.5 W, using the 
488 mn line. Cellular drug concentrations were expressed in arbitrary 
fluorescence units per cell (FU/cell); values given have been corrected for the 
autofluorescence of the blank. In previous studies (19) for all four 
anthrасусlines a satisfying correlation was found between the cellular drug 
concentration as measured with high pressure liquid chromatography and with FCM: 
100 FU/cell correlated with approximately 4-5 fg anthracycline/cell. As with 
FCM the contribution of the parent drug and the 13-hydroxy metabolite to the 
total fluorescence cannot be separated, at the end of the incubation one sample 
was also assayed with HPLC for cellular presence of this metabolite. The 
metabolite never contributed to more than 8% of the total drug content. 
Therefore the contribution of the metabolite was not taken into further 
consideration. 
For FCM measurement of nuclear anthracycline concentrations a 0.5% Nonidet P-40 
(NP40) detergent solution was used (16). Twenty μΐ of this NP40 solution was 
added to 500 yl cell suspension and almost instantaneously a nuclear suspension 
was obtained, as was controlled by means of phase-contrast microscopy as well as 
by measurements of the scatter parameters. 
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High pressure liquid chromatography (HPLC). The method used has been described 
in chapter 2 (20). 500 yl supernatant or 250 yl sonicated cell suspension was 
extracted twice with chloroform/methanol 9:1, under addition of Tris buffer 
containing the internal standard. After evaporation of the organic phase, the 
residue was dissolved in 500 vl chloroform/methanol and injected into the 
straight-phase system, consisting of a Lichrosorb Si60 column (100 mm χ 3 mm, 
particle size 7 lim). Drug polarity (or lipophilicity) had previously been 
estimated by the determination of the partition coefficient, which very well 
correlated with the chromatographic mobility (Rf) of the drug on a RP8 column. 
Partition coefficients were 0.179 (ADM), 1 (E-ADM), 4.92 (DNM) and 19.5 (D-DNM) 
(Oosterbaan, personal communication). 
Patient study. Cellular and plasma pharmacokinetics of the four drugs were 
studied in vivo. The drugs were administered to the same patient on subsequent 
occasions to avoid interindividual differences. The patient was treated once a 
month for acute nonlymphocytic leukemia in remission. 75 mg anthracycline 
(D-DNM 18 mg) was administered as rapid bolus injection at day 1. The 
2 
chemotherapeutic regimen further consisted of cytosine arabinoside 200mg/m 
twice daily subcutaneously day 1 to 5, and vincristine 2 mg intravenously at day 
1. Venous blood samples were drawn at times indicated, up to 120 h, and 
processed for FCM and HPLC determination of cellular and plasma drug 
concentrations as described in chapter 2 and 3 (20). 
Curve fitting and calculations. Non-linear least-square fittings by means of 
NONLIN (10) were carried out on the plasma and cellular concentration-time 
profiles according to the open two-compartment model. The integrated equations 
were used to describe the model. The estimated model parameters are the 
concentration constants A and B, and the corresponding exponents α and β. The 
values of the half-life times t, ,_ and t, ,_., volume of distribution (Vf), and 
l/2a 1/Zp 
the total body clearance (CI) were calculated using conventional procedures 
(22). 
RESULTS. 
In vitro uptake studies. During 360 min incubation with 100 ng/ml (D-DNM 25 
ng/ml), the extracellular drug concentrations remained rather constant. 16% 
reduction of the medium D-DNM -concentration and at maximum 3-9% of the other 
drug concentrations was observed. In case of 5 min incubation these values were 
4% and 0.3-0.7% respectively. 
Between the different subpopulations only small differences in drug uptake were 
noted (Fig. 1, Table 1). Uptake in lymphocytes was always less than in the 
other subpopulations (significant for D-DNM), while the uptake in blast cells 
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FIGURE 1. In vitro cellular anthracycllne uptake and efflux. 10 
eel Is I ml were Incubated for 360 Bin with 100 ng ADM (Ο), E-ADtl (Ό) and 
DNH (•*•), and 25 ng D-DNH (a), and reincubated for 180 min. a: 
lymphocytes, b: monocytes/blast cells, c: myeloid cells. Data of 1 
experiment. 
and the myeloid cells did not differ markedly (Table 1). 
Initial uptake was rapid and amounted to 5-15% in the first 5 min (for details: 
see Fig. 1). Except for D-DNM, steady state concentrations were not reached 
during 360 min incubation. The overall anthracycline concentration/cell (mean 
of 3 experiments) attained at the end of the incubation was 1320 ± 315 FU/cell 
(D-DNM) at medium concentrations of 25 ng/ml, followed by 1353 ± 435 FU/cell 
(DNM), 529 ± 57 FU/cell (E-ADM) and 246 ± 70 FU/cell (ADM) at medium 
concentrations of 100 ng/ml. The value of the overall Area Under the cellular 
Curve (AUCc) of D-DNM was set at 100%. The AUCc values for the other 3 drugs 
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FIGURE 2. In vitro cellular anthracycline uptake and efflux. 10~' 
cells I ml were incubated for 5 min with 1 Mg ADM (O), E-ADM (o) and DNM 
(X), and 250 ng D-DNM (t¡) and reincubated for 180 min. Data of 1 
experiment. Legend: see Fig. 1. 
investigated were 106 ± 18% (DNM), 5 2 + 6 (E-ADM) and 21 ± 2% (ADM) respectively 
(Table 1, Fig. 3). 
In the 5 min exposure experiments the drug uptake patterns were different 
(Fig. 2, table 2). At 1 rain ADM and E-ADM mean cellular concentrations were 
105 ± 30% and 101 ± 10% of the 5 min concentration, whereas DNM and D-DNM 
concentrations at 1 rain arrived only at 46 ± 9% and 44 ± 10% of the 5 rain value 
(Fig. 2). Maximum overall cellular anthracycline concentrations at 5 rain were 
in decreasing order of magnitude 1760 ± 247 FU/cell (D-DNM), 790 ± 44 FU/cell 
(DNM), 625 ± 44 FU/cell (E-ADM) and 206 ± 46 FU/cell (ADM). The calculated 
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TABLE 1. Area Under the cellular Curve (AUCc) of the mean anthra-
cycline concentration in subpopulations of hematopoietic cells. 
Cells were incubated during 360 min. 
mean fluoresc. lymphoid cell blast cell myeloid cell 
D-DNM 
DNM 
E-ADM 
ADM 
323 
100 
350 
106 
171 
52 
68 
21 
+ 
-
± 
± 
-
+ 
± 
-
± 
± 
-
28 
88 
18 
36 
6 
7 
2 
197 
100 
43 
311 
158 
76 
255 
65 
78 
85 
22 
77 
+ 
+ 
± 
± 
+ 
± 
± 
± 
± 
± 
± 
39 
2 
78 
42 
9 
56 
30 
28 
15 
8 
29 
355 
100 
78 
416 
118 
105 
138 
39 
89 
57 
16 
100 
± 
± 
± 
± 
+ 
± 
± 
± 
± 
± 
+ 
28 
6 
21 
15 
9 
3 
3 
8 
11 
2 
14 
457 
100 
100 
402 
89 
100 
157 
35 
100 
57 
12 
100 
± 3 
± 57 
± 12 
± 16 
± 4 
± 31 
± 1 
On the first row: mean ± SD of Area under the Cellular 
Concentration χ time-curve (AUCc) of 3 experiments, expressed in 
FU/cell.min.1000. 
On the second row: Mean ± SD in percentage of the AUCc's related to 
the AUCc of D-DNM, which was set at 100%. 
On the third row: mean ± SD in percentage of the AUCc's related to 
the AUCc of the myeloid cells, which was set at 100%. 
AUCc's were 100% (set for D-DNM), 61 ± 8%, 57 ± 10% and 24 ± 2% respectively. 
The cells accumulated the different anthracyclines against a gradient. The 
9 
ratios of cellular concentration (ng/10 cells) versus medium concentration 
(ng/ml) were 2550 (D-DNM), 990 (DNM), 291 (E-ADM) and 443 (ADM) at the end of 
360 min incubation and 855, 69, 13 and 31 respectively at the end of 5 min 
incubation (data of 1 experiment). 
Efflux studies. After termination of the incubation and resuspension in 
drug-free medium, the cells were reincubated for 180 min (Fig. 1 and 2). The 
first sample was taken 1 min after resuspension in the drug free medium; an 
immediate loss of 23 ± 20% and 27 ± 6% had occurred in case of ADM and E-ADM, 
which only marginally increased after 15 min to a level of 36 ± 13% and 32 ± 8%. 
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The efflux of cellular D-DNM started rapidly (21 ± 10% in the first min) and 
continued to 64 ± 14% at the end of 180 min reincubation. DNM, on the other 
hand, was released very slowly initially (4 ± 4% during the first min), to 
37 ± 15% without stabilization at ISO min. 
In case of 5 min incubation at 1000 ng/ml (D-DNM 250 ng/ml), the pattern was 
very similar. The efflux in the first min was 58 ± 8% (ADM), 47 ± 6% (E-ADM), 
15 ± 3% (DNM). and 4 ± 7% (D-DNM). For ADM and E-ADM the efflux rate had 
decreased at 180 min, whereas for DNM and D-DNM the efflux continued to values 
TABLE 2. Area Under the cellular Curve (AUCc) of mean anthracycline 
concentration in subpopulations of hematopoietic cells. 
Cells were incubated during 5 min. 
D-DNM 
DNM 
E-ADM 
ADM 
mean fluoresc. 
5 
100 
3 
61 
3 
57 
1 
24 
+ 
-
± 
± 
-
+ 
± 
-
± 
± 
-
0.3 
0.1 
8 
0.3 
10 
0.1 
2 
lymphoid cell 
5 
100 
70 
2 
56 
103 
2 
48 
87 
1 
19 
± 
± 
± 
+ 
± 
± 
± 
± 
± 
± 
85 i 
0.6 
8 
0.3 
15 
18 
0.1 
4 
12 
0.2 
1 
: 10 
blast cell 
8 
100 
125 
3 
34 
110 
2 
32 
78 
1 
13 
+ 
± 
± 
± 
± 
± 
± 
+ 
± 
± 
76 ± 
2 
6 
0.2 
7 
6 
0.5 
3 
11 
0.1 
3 
13 
myelo 
7 
100 
100 
2 
39 
100 
3 
47 
100 
2 
14 
100 
+ 
± 
± 
± 
+ 
± 
± 
id cell 
1 
0.1 
8 
0.2 
8 
0.1 
2 
Legends as under Table 1. 
of respectively 37 + 15% and 74 ± 10%. The efflux was rather similar for all 3 
cell subsets, for both the long-lasting and the short-lasting incubation. 
From the FCM-efflux data an absolute loss of 2-18 ng per ml medium was 
calculated for the different anthracyclines. The supernatant anthracycline 
concentrations at 1 and 180 min of reincubation showed an increase in the 
expected range: from 0 to 4-12 ng/ml. 
Nuclear versus whole cell drug concentration. Almost pure lymphocyte and 
monocyte suspensions were incubated for 120 min, washed and reincubated. Uptake 
and efflux showed the same pattern as described above. The larger monocytes 
accumulated more anthracyclines per cell than the lymphocytes did, according to 
the pattern described above for the 360 min incubation. Addition of 20 μΐ 0.5% 
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TABLE 3. Nuclear versus whole cell anthracycline concentration in 
lymphocytes and monocytes, expressed in FU/cell. 
Incubation 
time 
120 min = end 
+ 90 min 
Incubation 
time 
120 min = end 
+ 90 min 
D-DNM 
135/293 
45% 
116/287 
40% 
D-DNM 
92/357 
26% 
92/248 
15% 
LYMPHOCYTES 
DNM 
426/571 
75% 
324/518 
63% 
MONOCYTES 
DNM 
661/1088 
42% 
188/676 
28% 
E-ADM 
150/145 
103% 
93/131 
91% 
E-ADM 
222/451 
49% 
166/417 
40% 
ADM 
88/78 
113% 
47/45 
101% 
ADM 
170/201 
85% 
101/170 
59% 
Upper row: nuclear anthracycline concentration/cellular concentration in 
FU/cell. Lower row: percentage of nuclear anthracycline concentration related 
to the whole cell concentration. 
120 min = end of incubation. +90 rain = at 90 min reincubation. 
NP40 to 500 vi cell suspension allowed rapid efflux of the cytoplasmatic 
anthracycline. The nuclear anthracycline concentration could be measured (table 
3). 
The ratio of nucleus versus whole cell anthracycline concentrations approached 
100% in an inverse order according to polarity of the four anthracyclines. 
Circa 40% of the cellular D-DNM in lymphocytes was nuclear bound and circa 100% 
of the cellular ADM. In monocytes with larger cytoplasm these percentages are 
20% lower. The monocyte nuclear D-DNM and DNM concentrations were lower than 
the lymphocyte nuclear drug concentrations, whereas for E-ADM and ADM this was 
reverse. 
In vivo cellular anthracycline concentrations. Fig. 3 gives concentration-time 
curves for cellular and plasma anthracycline concentrations measured in the same 
patient. The anthracyclines had been administered as bolus injections at 
subsequent occasions. Blood hemoglobin, leucocyte and thrombocyte counts in all 
occasions were the same. Large differences between cellular and plasma 
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FIGURE 3. Plasma and peripheral blood cellular concentration-time 
curve after a bolus injection of 75 mg ADH, E-ADH, DNH or IS mg D-DNM. 
Cellular parent drug (u), cellular metabolite (ο), plasma parent drug 
(*), plasma metabolite (O). 
pharmacokinetic parameters were observed (table 4). As contrasted to large 
differences in peak plasma concentrations (in decreasing order 
ADM>E-ADM>DNM>D-DNM), calculated peak cellular anthracycllne concentrations only 
marginally differed pei drug. AUCc was highest for ADM and lowest for D-DNM. 
In vivo, the anthracycllne concentrations in the different subpopulations of 
cells differed only marginally (Fig. 4). 
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FIGURE U. In vivo cellular concentration-time curves of subpopulations 
of peripheral blood cells after a bolus injection of 75 mg ADM (A), 
E-ADM (B), DNH (C) or 18 mg D-DHH (D). (o): lymphocytes, (Ώ): 
monocytes, (*): granylocytes. 
In Fig. 5 the area under the plasma curve (AUCp) was plotted versus the 
partition coefficient. The highest AUCp was found for the most hydrophilic 
compound (ADM), whereas the most lipophilic drug (D-DNM) had the lowest AUCp. 
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FIGURE 5. Relation between the partition coefficient and the in vivo 
Area Under the cellular Curve (AUCcell,О ; , the AUCplasma (a), and the 
in vitro AUCc 5 min (U) and AUCc 360 min С) incubation. 
Partition coefficients: ADM (0.179), E-ADH (1), DNH (4.92) and ΰ-DM 
(19.5). 
In contrast to what was expected from this AUCp rank and from the inverse of the 
in vitro AUCc's, the in vivo AUCc's were related to the partition coefficient in 
the same rank as the plasma AUC's. 
A good similarity was noted between the shape of the cell concentration-time 
curves in vivo and in vitro at reincubation. 
DISCUSSION. 
The main conclusions from this study are: 1) minor differences in chemical 
structure have large consequences on plasma and cellular pharmacokinetic 
parameters in vitro and in vivo (Table 1, 2 and 4); 2) all anthracyclines 
studied were accumulated to a great extent intracellularly by all subpopulations 
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TABLE 4. Plasma and cellular pharmacokinetic parameters. 
DRUG 
ADM 
E-ADM 
DNM 
D-DNM 
ADM 
E-ADM 
DNM 
D-DNM 
dose 
mg 
75 
75 
75 
IB 
75 
75 
75 
18 
туг» 
h 
0.15 
0.15 
0.5 
0.4 
0.06 
0.03 
5.8 
0.6 
т^гр 
h 
48 
38 
18 
49 
110 
45 
20 
15 
A 
ng/ml 
В 
ng/œl 
PLASMA 
3330 
2780 
540 
78 
36 
22 
13 
3 
CELLS 
11900 
9050 
12050 
6630 
4630 
6540 
3460 
1030 
AUC 
Vg.h.L 
2000 
1390 
710 
200 
1320000 
420000 
190000 
29000 
Vf 
L 
1300 
1860 
2640 
6400 
Cl 
L/h 
48 
54 
85 
78 
T, .„ and T, .„„: first and second half life times. 
1/2а 1/2р 
A and В: extrapolated concentrations constants. 
AUC: area under the curve. Vf: volume of distribution. CI¡plasma 
clearance 
against a concentration gradient; 3) no steady state concentrations were 
observed during 360 min incubation. The accumulation pattern in vitro was 
biphasic; 4) different subpopulations of human hematopoietic cells have 
different patterns of drug handling in vitro (Table 1 and 2), to a minor extent 
also in vivo; 5) differences in cellular anthracycline concentrations between 
lymphocytes and monocytes are due to mainly differences in cytoplasmatic 
localized but also in nuclear bound quantities of drugs (Table 3); 6) short 
exposure to high external drug concentrations in vitro and in vivo causes high 
initial drug uptake, but subsequently also a relatively larger loss, compared to 
long-term exposure to lower drug concentrations and 7) data from in vitro 
experiments cannot simply be translated to in vivo conclusions or observations 
(Fig. 2, 3 and 4). 
Studies on structure-activity relationships indicated that structural features 
determine the polarity (or lipid solubility) of the drugs. This properties are 
expressed in the partition coefficient. As these factors are inversely related 
to cellular drug uptake (2, 3, 13) and to the binding to DNA (1), they also 
affect the biological activity of anthracyclines (1, 13, 14). 
Earlier described structure related differences in plasma pharmacokinetic 
studies in dogs (15) are in accordance with our data. Differences in speed and 
extent of cellular drug uptake, determine differences in distribution volume and 
thus in peak plasma concentration. 
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In cellular pharmacokinetic studies in vitro the maximal uptake of ADM and DNM 
in 1Л210 cells appeared to be related to the partition coefficient (2) during 
long-term exposure. We also observed lower accumulation of ADM compared to DNM, 
with an intermediate value of E-ADM, and extremely high values for D-DNM. The 
efflux pattern simulated the pattern observed in vivo well, except for DNM, 
where the observation period was probably too short. Also in vivo a more 
pronounced DNM efflux from the cells started only after a few hours after drug 
administration (18). As ADM was observed to bind to DNA to a higher degree than 
DNM (14), this may also explain the different pattern of efflux: rapid release 
of the loosely bound drug is followed by much slower efflux of the more tightly 
and mainly DNA bound drug from the nucleus (18). The higher the lipophilicity, 
the less has been tightly bound in the nucleus, and retained intracellularly. 
Multiple transport routes and a complicated system of cellular drug uptake must 
be concluded from our observations. Diffusion (18, 19) and an uphill carrier 
must be present (6) as a considerable concentration gradient is generated. Even 
at high (5-10 yg/ml) external drug concentrations no saturation phenomena have 
been observed in vitro (18, 19). 
Although membrane transport has been documented to be the rate limiting step to 
drug uptake (18), also an intracellular gradient must exist between cytoplasm 
and nucleus (14) as can be concluded from the nuclear anthracycline 
concentration data (Table 3). This may explain part of the extreme 
intracellular accumulation. Initial nuclear drug uptake of ADM has been found 
many times larger than that of DNM (17). 
Changes in polarity and in DNA-binding ability have been considered the main 
factors for differences in activity in vivo (12, 21). A partition coefficient 
dependent sequence of RNA and DNA inhibition, which paralleled the antitumor 
activity in vitro to a certain extent, has been reported, although the 
differences in vitro were more marked than in vivo in the animal model (2). 
In conclusion, plasma pharmacokinetic parameters did not predict for cellular 
pharmacokinetic parameters and in vitro cellular pharmacokinetic patterns may 
largely differ from in vivo findings as well. In vitro it is difficult to 
simulate factors like extensive tissue distribution, subsequent reduced peak 
plasma concentrations, metabolism and continuous excretion of the drug. 
Therefore, a great need exists for the direct determination of cellular 
pharmacokinetic parameters in vivo. 
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CHAPTER 9 
INFUSION-RATE DEPENDENT CELLULAR ADRIAMYCIN CONCENTRATIONS AND CYTOTOXICITY 
TO HUMAN BONE MARROW CLONOGENIC CELLS (CFU-GM) 
R. Raijmakers, P. Speth, T. de Witte, P. Linssen, J. Wessels and С Haanen 
Submitted to British Journal of Cancer 
SUMMARY. 
To study the inhibitory effect of infusion-rate dependent cellular ADM 
concentrations on the clonogenicity of human hematopoietic cells, cytotoxicity 
was related to cellular ADM concentrations. These concentrations were measured 
after j'n vivo short- and long-lasting infusions. The infusions were simulated 
by in vitro exposure during 5 min to high (up to 12.5 vg/ml), and 2 and 24 h 
exposure to low (up to 0.5 yg/ml) ADM concentrations. ADM rapidly accumulated 
intracellularly to levels 100-fold the plasma and medium concentrations. After 
a bolus injection or 5 min exposure in iM'tro, high, only short-lasting cellular 
ADM concentrations were observed. Both in vivo and in vitro rapid uptake was 
followed (at reincubation) by a rapid and up to 90% loss of apparently loosely 
bound cellular ADM. In the case of long-lasting infusions (4 to 24 h) in vivo, 
or long-term incubations in vitro, the cells accumulated ADM more gradually, and 
the subsequent loss was markedly reduced. The net result was a comparable 
cellular ADM concentration after short-lasting and long-lasting infusion of the 
same amount of drug. However, in vitro the exposure dose had to be increased 
with the duration of the exposure to obtain comparable cellular ADM 
concentrations. The achieved cytotoxic effect correlated well with the cellular 
ADM concentrations, which were observed after efflux of the loosely bound 
cellular ADM. Short-lasting high cellular ADM concentrations observed after 
bolus injection appeared not essential for the cytotoxic effect on clonogenic 
cells. 
INTRODUCTION. 
Adriamycin (ADM), usually given as a bolus injection, can also be administered 
as an infusion for several hours or days. Prolonged administration has the 
advantage of avoiding high peak plasma concentrations (1, 2), thus reducing 
side-effects such as nausea, vomiting and cardiotoxicity (2). Given as bolus 
2 
injections the cumulative ADM dose is limited to 550 rag/m , but this dose can be 
safely exceeded if ADM is applied as continuous infusion (2, 3). Therapeutic 
efficacy of continuous infusion appeared comparable with that of bolus 
injection, as was observed for leukemia (4) and breast cancer (5). 
No data are available about the implications of the different modes of 
administration on cytotoxicity to clonogenic cells. Cellular ADM 
concentrations, measured in human hematopoietic cells after different exposure 
times, have not been related to inhibition of clonogenicity. In this study the 
in vivo pattern of infusion-rate dependent cellular ADM concentrations was 
simulated in vitro by varying the exposure times and concentrations. 
Cytotoxicity of the different ways of ADM administration on normal hematopoietic 
clonogenic cells was determined, to answer the question whether peak ADM 
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concentrations observed after bolus injection, are essential for the cytotoxic 
effect. 
MATERIALS AND METHODS. 
Drugs. ADM was obtained from Laboratoire Roger BelIon S.A. (Neuilly sur Seine, 
France). The ADM concentrations in the stock solutions were checked by high 
pressure liquid chromatography. 
ADM measurements in vivo. Patients with leukemia in remission were treated with 
2 2 
ADM (30mg/m , day 1), Vincristine (1 mg/m , day 2) and cytosine arabinoside (200 
2 
mg/m , day 1 to 7). ADM was administered as bolus injection or as continuous 
infusion of 4 or 24 h. Sequentially blood samples were drawn in heparinized 
polypropylene tubes on ice for determination of plasma and cellular ADM 
concentrations. After centrifugation plasma was collected and stored at -20 С 
until analysis (6). The red cells in the pellet were lysed with NH.Cl (6). 
After centrifugation the cell pellet was resuspended in phosphate buffered 
saline. Part of the suspension was kept on ice for flow cytometric 
determination of ADM concentrations in blast cells and part of the cell 
suspension was stored at -20 С for analysis by high pressure liquid 
chromatography (HPLC). 
In vitro ADM exposure. Normal bone marrow was used for in vitro ADM exposure. 
Aspirates, obtained from cardiac surgery patients (Dept. Cardiac Surgery, head: 
Prof. L.K. Lacquet) were collected in Acid Citrate Dextrose (ACD-A, pH 7.4). 
After addition of isotonic glucose phosphate buffer (buffer) the cells were 
centrifuged to remove plasma and fat (7). The pellet was resuspended in 35 ml 
buffer supplemented with 5% fetal calf serum (FCS), layered on 15 ml of Percoli 
(density 1.085 g/ml, pH 7.4, 300 mosm/kg) and centrifuged to remove the bulk of 
red cells and mature granulocytes (7). Cells at the interphase were washed 
twice with buffer and resuspended in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% FCS. 
In each experiment, 30 ml cell suspensions at a concentration of 10 cells/ml 
were aliquoted in 50 ml polypropylene tubes (Greiner, Nürtingen, F.R.G.) and 
pre-incubated at 37 С for 1 h. ADM was added and the suspensions were incubated 
for 5 min (0.2 - 12.5 vg/ml), 2 h (0.05 - 5 pg/ml) and 24 h (0.005 - 0.5 vg/ml) 
respectively. At the end of the incubation cellular anthracycline 
concentrations were determined with flow cytometry. The cell suspensions were 
then diluted twice with cold buffer (0 C) to stop further drug uptake and 
centrifuged (900 g, 0C, 5 min). After a second wash step the pellet was 
resuspended in culture medium. A sample was taken for FCM-analysis of cellular 
anthracycline concentrations to determine the amount of loosely bound ADM which 
was removed from the cells during the wash steps. Part of the cell suspension 
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was plated in semi-solid medium to assay for clonogenic potential. Part of the 
cell suspension was diluted in liquid medium, in order to determine efflux in 
time of cellular ADM during reincubation. 
Granulocyte-macrophage colony forming cells (CFU-GM) assay. All cultures were 
performed in duplicate in 35 mm Petri dishes (Costar, Cambridge, Mass, U.S.A.) 
as described previously (7). In brief: each dish contained 2 ml of a cell 
suspension (10 cells/ml) in DMEM supplemented with 20% FCS, 5% (v/v) colony 
stimulating activity from human placental conditioned medium as described by 
Verma et al. (8) and 0.3% (w/v) bacto agar (Difco, Detroit, Mich, U.S.A.). The 
cultures were incubated at 37 С in a fully humidified atmosphere of 5% CO. in 
air. After 12 days cell aggregates consisting of 40 cells or more were scored 
as colonies. 
Light scatter and cellular fluorescence measurement by FCM. FCM measurements 
were performed on a System 50H Cytofluorograf (Ortho Diagnostic Systems, 
Westwood, MA, U.S.A.) equipped with a 5-W argon laser (164-05, Spectra Physics, 
Mountainview, CA, U.S.A.) excitating at 486 nm with an intensity of 0.5 W (6). 
Fluorescence was measured with a barrier filter OG550 (Melles Griot Optical 
Industries, Costa Mesa, CA, U.S.A.). The combination of forward light scatter 
(FLS) and perpendicular light scatter (PLS) was used to discriminate the blast 
cell subpopulation from other white cell subpopulations and cell debris. From 
3 
each sample at least 12x10 cells were analysed at a flow rate of 1000 cells/s. 
FLS, PLS and fluorescence per cell (FU/cell) were measured in area mode, stored 
in list mode and analysed on a PDP 11/34 computer (Digital Electronic Company, 
Maynard, MA, U.S.A.). Blast cell ADM concentrations were expressed in arbitrary 
FU/cell representing the mean fluorescence of this cell subpopulation. All 
fluorescence data presented are corrected for autofluorescence by subtracting 
the blank value. As described in chapter 3 (6), the arbitrary fluorescence 
units correlated well with cellular ADM concentrations determined by HPLC. 
Measurement of plasma and cellular ADM by HPLC. The straight-phase HPLC method 
used was described in chapter 2 (9). In brief: to 250 μΐ sonicated cell 
suspension or 500 μΐ plasma 3 ml chloroform/methanol 9:1 (v/v) was added, 
followed by 100 μΐ Tris buffer (1 M, pH β.8) containing daunomycin as internal 
standard. After two extractions with chloroform/methanol 9:1 (v/v), the 
chloroform phase was evaporated. The residue was dissolved in 750 μΐ 
chloroform/methanol, with addition of 50 μΐ Tris buffer. A 500 μΐ sample was 
injected into the column (Lichrosorb 7SÌ60 column 100 χ 3.0 mm I.D.). Detection 
was carried out with a fluorometer (λ-excitation at 488 nm, X-emission above 550 
nm)(FS 970 L.S. Fluorometer, Schoeffel Instr, Ramsey, NJ, U.S.A.). The 
detection limit of ADM and metabolites was 1 ng. The within-day precision of 
the method (n = 17) was 7.0%. In a previous study peripheral blood cellular ADM 
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concentrations correlated well with the simultaneously investigated bone marrow 
ADM concentrations (n = 47, r = 0.82) (chapter 4A). 
Curve fitting. The ADM concentration-response curves were fitted according to a 
model described by the formula: 
f(x) = -
1 + bxC 
This function contains three dimensions: (a) represents the maximal plating 
efficiency (=100%), (b) represents the concentration at which inhibition 
amounted to 70%, (c) represents the slope of the downward leg of the curve. The 
model was fitted according to the Gauss-Newton regression procedure with the use 
of least square criteria (10). 
RESULTS 
In vivo plasma and cellular ADM concentrations. The courses of cellular and 
plasma ADM and plasma adriamycinol concentrations after bolus injection, or 4 
and 24 h infusion are illustrated in Fig. 1. After a bolus injection of ADM (30 
2 
mg/m ) peak plasma ADM concentrations of over 1000 ng/ml were noted. The plasma 
disappearance curve of ADM showed a biphasic pattern with a rapid first 
half-life of 4 min, followed by a terminal half-life time of circa 40 h. 
Cellular accumulation of ADM followed the plasma levels almost simultaneously 
and reached peak concentrations of circa 4 times the peak plasma values as 
indicated in Fig. 1. The cellular ADM disappearance curves were also biphasic. 
A short-lasting rapid phase (t. .. of 10 min) was followed by a phase with a slow 
disappearance rate with a t . . . of circa 100 h. The discongruency between plasma 
and cellular ADM half-life times resulted in cellular ADM concentrations, that 
were 3 logs higher than the plasma concentrations at 24 to 48 h after 
administration. 
When the same dose of ADM was administered as a 4-h constant-rate infusion, 
maximal plasma concentrations were circa 60-80 ng/ml. The rapid ADM efflux from 
the cells now occured to a much smaller extent after the end of the infusion, 
and therafter the cellular ADM and plasma disappearance curve had similar 
half-life times as observed in case of bolus injection. 
Constant-rate infusion of 24 h resulted in even lower maximal plasma levels (20 
ng/ml) and a slow, but continuous increase of cellular ADM concentration during 
the infusion period. Immediately following the termination of the ADM infusion, 
hardly any loss of ADM was observed. In all three modes of drug administration 
1 h after the plasma ADM had reached negligible contents, almost identical 
cellular drug concentrations were attained. 
In vitro cellular ADM concentrations. Human hematopoietic cells were exposed to 
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FIGURE 1. (left) Plasma (9) and cellular (x) ADM and plasma (O) adria-
2 
mycinol concentrât ions after ADIf 30 mg/m administered respectively as 
bolus injection (a), 4-ft (b) and 24-h (c) continuous infusion. Arrows 
indicate the duration of administration. 
FIGURE 2. (right) Example of cellular ADM concentrations attained 
after in vitro exposure of bone marrow cells during 5 min to 5 ug 
ADH/ml (a), 2 h to 400 ng ADH/ml (b) and 24 h to 40 ng ADM/ml (c). 
Arrows indicate the incubation times and concentrât ions (height). 
a range of ADM concentrations for 5 rain, 2 and 24 h. Cellular ADM uptake and 
release were measured during incubation and subsequent reincubation in drug-free 
medium (n = 5). At incubation no saturation was observed. As an example, in 
Fig. 2 the course of cellular ADM concentrations for the different incubation 
times is given, at ADM concentrations with resulted in circa 80% 
growth-inhibition. Essentially similar cellular ADM concentration courses were 
observed as seen after in vivo bolus injection and short- or long-term infusion 
(Fig. 1). A rapidly attained and high cellular ADM concentration after the 
short-lasting exposure, was followed by a considerable loss (87-91%) during the 
two wash steps (second and third measure point in Fig. 2). During the 2 h and 
24 h exposure a gradual increase of cellular ADM concentrations was followed by 
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a less pronounced loss after the wash steps (27-51% and 12-23% respectively, 
mean of 5 experiments). 
adnamycin medium concentration ( jug/ml ) 
FIGURE 3. Inhibition of clonogenic cells at increasing ADM 
concentrations for different incubation times. (+)= 5-min 
incubation, ( ж )= Z-h incubation, (0)=24-h incubation, (Ώ)= 
continuous exposure. The relative number of colonies is expressed as 
mean percentage of two duplicate control cultures for each Incubation 
time (n=5). SD varied from 5-15%. 
Cellular ADM concentrat ions and clonogenicity (CFU-GM). The 
concentration-response curves for all 3 exposure times are plotted in Fig. 3 
(n = 5). They were well reproducible. The concentration at which 50% 
inhibition of clonogenic cells occurred (IC50) was calculated from the fitted 
curves. After 5 min exposure the IC50 was 2.2 yg/ml ADM. Prolonged exposure 
showed cytotoxicity at lower ADM medium concentrations, the 1C50 was 0.35 and 
0.05 Vg/ml after 2 and 24 h respectively. An even lower IC50 of 0.0056 Vg/ml 
was achieved after continuous exposure during culturing when ADM was added to 
the semi-solid culture medium. The exposure to ADM at the IC50 can also be 
expressed as the product of the medium concentration χ incubation time (CxT). 
In contrast to the in vivo observations, with a fairly constant area under the 
curve (equal to CxT), the in vitro CxT increased with the exposure time to 
attain the IC50, with values of 0.18, 0.7, 1.2 and 1.6 ug.h/ml for the 5 min, 2 
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h, 24 h, and 12 days exposure respectively. 
Fig. 4 shows the tightly bound cellular ADM concentration after the ADM exposure 
and reincubation, plotted against the inhibition of clonogenicity. The 
different concentration-response curves all were in the same range. Apparently, 
the inhibition of clonogenic cells was directly related to the tightly bound 
cellular ADM concentrations, which remained after efflux of the loosely bound 
ADM fraction. The short-lasting high ADM peak-concentration, nor the time-span 
of exposure were of primary importance for the inhibitory effect. 
100 
cellular adnamydn concentration (FU /cell) 
FIGURE 4. Inhibition of clonogenicity plotted against cellular ADH 
concentrations (expressed as FU/cell) measured at reincubation after 
ADH exposure. (+)=5-min, (x)=2-h and (0)=24-h incubation. The 
relative number of colonies is expressed as percentage of two 
duplicate control cultures for each incubation time. (n=4). 
DISCUSSION. 
In vivo different cellular ADM concentration-time curves were observed after 
administration of the same dose of ADM as bolus injection, or as short or 
long-lasting infusion. Similar patterns were observed after in vitro exposure 
simulating the in vivo administration times. The shorter the infusion in vivo, 
the more of the accumulated cellular ADM was lost immediately after the end of 
the exposure. 
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Loss (18-27%) of cellular ADM after subsequent washing steps has been found 
before (11), although extremely high incubation concentrations were used. 
Apparently, part of the cellular ADM was loosely bound, and part was bound more 
tightly. The shorter the exposure to a certain dose, the higher the fraction of 
ADM that appeared loosely bound. The mechanism behind this observation is 
speculative. It may be explained by a very fast cytoplasmatic accumulation 
followed by a time-dependent slow intercalation into DNA (12). 
Based on in vitro experiments some authors (13, 14) stressed the importance of 
the cellular peak-concentrations of anthracyclines with respect to the cytotoxic 
effect. In their study the product of concentration χ time (= dose) was larger 
after longer lasting exposure times to obtain the same cytotoxic effect. This 
was confirmed in our study. However, in vivo, administration of the same dose 
at different infusion rates resulted in almost the same plasma and cellular ADM 
concentrations (chapter 5). Due to the totally different exposure conditions in 
the body and in the test tube, results from in vitro studies may not just be 
translated to in vivo conclusions. This also applies for another study (15), in 
which from in vitro experiments it was concluded that the high concentrations of 
drug present in the plasma for short periods of time following rapid intravenous 
infusion were only weakly cytotoxic. The use of lower ADM dosages during 
long-term infusion was suggested. We showed that short-lasting exposure to a 
high concentration can be just as cytotoxic as a long-lasting exposure to a 
lower ADM concentration, provided similar cellular ADM concentrations have been 
attained after the disappearance of plasma or medium ADM concentrations. 
Preliminary results from our laboratory show that the results of this study also 
are valid for leukemic clonogenic cells (chapter 10). 
Good similarity of the in vivo and the in vitro cellular ADM 
concentration-curves was observed. Cellular ADM concentrations correlated well 
with inhibition of clonogenicity. This provides arguments that not peak plasma 
or cell ADM concentrations are essential for the cytotoxic effect, but only the 
tightly bound cellular ADM concentrations measured after the loosely bound ADM 
has been removed, no matter how this final cellular ADM concentration has been 
attained. 
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CHAPTER 10 
IN VIVO CELLUUR ADRIAMYCIN CONCENTRATIONS RELATED TO INHIBITION OF NORMAL 
AND LEUKEMIC HUMAN CLONOGENIC BONE MARROW CELLS 
Paul A.J. Speth, Reinier A.P. Raymakers, Jan B.M. Boezeman, Peter CM. 
Linssen, Theo J.M. de Witte, Hans M.C. Wessels and Clemens Haanen 
Sumitted for publication: Cancer Research 
SUMMARY 
Inhibition of clonogenicity of normal and leukemic human hematopoietic 
progenitor cells was studied after in vivo and m vitro exposure of bone marrow 
cells to adriamycin Flow cytometric determination of cellular adriamycin 
concentrations in blast cells -expressed in fluorescence units/cell (FU/cell)-
correlated well with the extent of cytotoxicity 
After 2 h jn vitro exposure to 500 ng adriamycin/ml, the adriamycin 
concentrations of leukemic (n = 7) and normal (n = 4) bone marrow blast cells 
amounted to 254 ± 158 and 249 ± 53 FU/cell respectively, resulting m a moderate 
decrease of clonogenicity of 44 ± 30 and 54 ± 27% Exposure to 2000 ng/ml 
revealed adriamycin concentrations of 1184 ± 472 FU/cell for leukemic blasts and 
1024 ± 281 FU/cell for normal blast cells, resulting in inhibition of 
clonogenicity of 96 ± 7% and 99 ± 1% respectively No differential toxicity for 
leukemic and normal clonogenic cells was noted 
2 
After jn vivo adriamycin administration of 30 mg/m on three subsequent days, 
drug concentrations in leukemic blast cells amounted to no more than 216 ± 98 
FU/cell (n = 8 patients) This implies that inhibition of clonogenicity after 
administration of conventional dosages will be circa 50% for both leukemic and 
normal bone marrow progenitor cells, resulting in a considerable reduction of 
tumor load However, these concentrations are too low eradicate all leukemic 
clonogenic cells As a 2 log inhibition of clonogenicity m vivo can only be 
attained after administration of non-tolerated dose of adriamycin, m vitro 
adriamycin sensitivity testing on clonogenic cells has little value as a 
predictive test for the ultimate clinical response 
INTRODUCTION 
Anthracyclines are incorporated in most standard regimens for remission 
induction therapy in adult acute nonlymphocytic leukemia (1). Plasma 
pharmacokinetic studies have revealed a large drug distribution volume 
consistent with a considerable drug accumulation in extravascular compartments 
(2, 3) Studies on cellular anthracycline concentrations revealed cellular drug 
concentrations 500 to 800 fold higher than those observed in plasma (4, 5, 6). 
Parameters of cellular and plasma pharmacokinetics appeared completely different 
from each other No correlation between plasma pharmacokinetic parameters and 
the ultimate clinical result was observed (4, 7, 8). 
Cellular adriamycin concentrations occurring m vivo after drug administration 
showed cellular adriamycin retention during several days (5, 6) The same 
intracellular drug persistence was observed after m vitro incubation (9) 
In this study the extent of cytotoxicity of cellular adriamycin concentrations 
upon colony growth capacity of human normal and leukemic blast cells was 
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determined. Bone marrow cells were exposed in vitro to adriamycin 
concentrations, resulting in cellular drug concentrations of the same order as 
those occurring in vivo after adriamycin administration. Thus, inhibition of 
leukemic and normal clonogenic cells could be investigated and related to 
cellular adriamycin concentrations attained in vivo with conventional drug 
dosage schedules. 
PATIENTS, MATERIALS AND METHODS. 
Chemicals. Adriamycin was obtained from Roger Belion (Neuilly sur Seine, 
France). Pure adriamycin and adriamycinol for chromatographic purposes were 
kindly provided by prof. F. Arcaraone (Farmitalia Carlo Erba, Milan, Italy). 
All further chemicals used were obtained from Merck (Darmstadt, F.R.G.) and were 
of analytical grade. 
Bone marrow sampling and storage. Bone marrow was aspirated from 7 newly 
diagnosed patients with acute nonlymphocytic leukemia and from 4 patients with 
normal bone marrow and collected in Acid Citrate Dextrose (ACD-A buffer, pH 
7.4). After washing with Hanks Buffer Balanced Salt solution (HBBS) the cells 
were layered on a Percoli cushion (density 1.085 g/ml, pH 7.4, 300 mosmol/kg). 
Cells from the interphase were washed twice and resuspended in Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 20% Fetal Calf Serum. The cell 
suspension was diluted 1:1 with 20% (v/v) dimethylsulphoxide in DMEM, 
cryopreserved in a number of 2 ml vials (Nunc, Intermed, Copenhagen, Denmark) 
using a temperature-controlled freezing procedure (10), and stored in liquid 
nitrogen. Cryopreserved bone marrow was used to avoid day-to-day variations in 
culturing conditions. 
In vitro adriamycin exposure. Cryopreserved bone marrow samples of 7 patients 
with acute nonlymphocytic leukemia and of 4 healthy volunteers were rapidly 
thawed, incubated with DNAse during 10 min, washed, counted and resuspended in 
Tris buffered DMEM supplemented with 10% fetal calf serum at a final cell 
concentration of 10 cells/ml (10). After 30 min preincubation, adriamycin was 
added to final concentrations ranging from 50 to 2000 ng/ml. The samples were 
incubated for 2 h. At the end of the incubation a sample was taken for flow 
cytometric determination of the adriamycin concentration in blast cells as 
described below. Subsequently cells were washed twice with cold HBBS and 
resuspended in culture medium. To calculate the loss of cellular adriamycin 
during the washing procedure, cellular adriamycin concentrations were determined 
just prior to plating as well. 
Clonogenic assay for leukemic and normal colony forming units of hematopoietic 
cells. The assay for the committed myeloid progenitor cells for normal (CFU-GM) 
and leukemic (CFU-L) clonogenic bone marrow cells has been described earlier 
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(11). All assays were performed in duplicate in 35 mm Petri dishes containing 2 
ml of the cell suspension. The optimal cell concentrations in the cultures used 
were determined before in order to obtain an adequate number of colonies per 
dish. The cells were reuspended in DMEM, supplemented with 20% fetal calf serum 
(v/v), 5% (v/v) placenta conditioned medium as a source of colony stimulating 
factor and 0.3% (w/v) Bacto agar (Difco, Detroit, Michigan, U.S.A.). Cultures 
were incubated at 37 С in a fully humidified atmosphere of 5% CO. in air. After 
12 days cell-aggregates consisting of 40 cells or more were scored as colonies, 
and aggregates of 5 to 40 cells as clusters. 
Collection of patient samples after in vivo adriamycin administration. Cellular 
adriamycin concentrations were determined in blood and bone marrow cells of β 
patients with acute nonlymphocytic leukemia and 3 patients with Hodgkin's 
disease without bone marrow infiltration up to 216 h after the start of the 
therapy. All were treated according to the AML-6 protocol of the European 
Organisation on Research and Treatment of Cancer consisting of Adriamycin 30 
2 2 
mg/m bolus injection on day 1,2 and 3, vincristine 1 mg/m bolus injection on 
2 
day 2 and cytosine arabinoside 50 mg/m bolus injection twice daily with 100 
2 
mg/m as 24 h continuous infusion from days 1 to 7. The results of this 
pharmacokinetic study can be read in more detail in chapter 4A. A good 
correlation was observed between blood and bone marrow cellular adriamycin 
concentrations (r = 0.82, η = 47). The procedure of sample collection has been 
described in chapter 2 (13): bone marrow samples were collected in cold ACD-A 
and filtered through a 70 ym filter. Peripheral blood admixture in the 
suspension was determined (12) to exclude samples with more than 20% admixture 
of nucleated blood cells from the study. Erythrocytes and normoblasts were 
lysed with ammonium chloride. The remaining white cells were resuspended in 
cold NaCl-solution (0.9%). Part of the suspension was stored at -20 С for 
analysis with high pressure liquid chromatography (HPLC), part was kept on ice 
for flow cytometric determination of cellular adriamycin concentration, which 
was usually done within a few hours. Blood samples were drawn in heparinized 
polypropylene tubes, and kept at 0 С to stop further adriamycin metabolism. 
After centrifugation at 0 C, plasma was removed and stored at -20 С until 
analysis. Erythrocytes in the pellet were lysed and the white cells were 
processed as described above. 
Flow cytometric determination of blast cellular adriamycin concen­
tration. Cellular adriamycin concentrations in blast cells were determined with 
three parameter laser flow cytometry as has been described in chapter 3 (13). 
In short: cell samples were analysed using a 50H Cytofluorograf (Ortho 
Diagnostic Systems, Westwood, MA), equipped with a 5 W Argon laser exciting at 
48Θ nm with an output of 500 mW. Combination of forward and perpendicular light 
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scatter signals enabled identification of cell subsets like blast cells, 
lymphocytes, myeloid cells and cell debris (13). Due to its fluorescent 
properties, cellular adriamycin concentrations can be quantitated in cells of 
distinct subpopulations from its fluorescence intensity and expressed in 
arbitrary Fluorescence Units/cell (FU/cell) representing the mean fluorescence 
per cell from a selected subpopulation. Fluorescence data given were corrected 
for autofluorescence by subtraction of the blank value. Of each sample at least 
4 
10 cells were analysed at a flow-rate of 1000 cells/s. Data of cellular 
adriamycin concentrations obtained by flow cytometry correlated well with the 
results of the determination by HPLC (r = 0.99, η = 9)(13); 100 FU/cell appeared 
9 
to correspond with circa 4 to 5 fg/cell, assuming the volume of 10 cells to be 
1 ml. Cells from each subpopulation were sorted to verify their identity 
microscopically. 
HPLC analysis of cellular and plasma adriamycin content. The method was 
described in chapter 2 (13). In brief: To 250 μΐ cell suspension or to 500 yl 
plasma 3 ml chloroform/methanol 9:1 (v/v) and 100 yl Tris buffer (IM, pH 8.8) 
was added. After two extractions and evaporation of the chloroform phase, the 
residue was dissolved in 750 yl chloroform/methanol 9:1 (v/v). A 500 yl sample 
was injected onto the Lichrosorb 7SÌ60 column (100 χ 3 mm inner diameter). 
Detection was carried out using a fluorometer with excitation wavelength of 488 
nm and emission above 550 nm. Peak-heights were measured and drug 
concentrations were calculated from a calibration curve of peak-height versus 
concentration. The detection limit of adriamycin was 1 ng. 
Statistical analysis. Data obtained from the clonogenic assays and from 
measurements of cellular adriamycin concentrations were analysed for statistical 
significant differences, using the Wilcoxon 2-sample test. Only significant 
differences are indicated in the text. 
RESULTS. 
Flow cytometric discrimination of the blast cell population. Multiparameter flow 
cytometry of normal and leukemic bone marrow samples enabled discrimination of 
the blast cell subpopulation based on their forward and perpendicular light 
scatter signals. The higher the percentage of blast cells in the suspension, 
the higher the number of blast cells in the scatter defined rectangle indicated 
in Fig. 1. This was confirmed from microscopical examination after sorting. In 
a normal bone marrow sample containing 1-2% blast cells, in the cell scatter 
rectangle indicated in Fig. 1A over 60% of the sorted cells were blast cells, 
together with some erythroblasts, monocytes and non-blastic myeloid cells. In 
leukemic bone marrow with more than 20% blast cells, close to 100% of the sorted 
cells in the scatter window indicated were blast cells (Fig. 1С). Moreover, 
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viable cells can be studied separately from dead cells and cell debris. 
Especially when cryopreserved cells are used, the amount of dead cells and 
debris can be relatively high (Fig. IB and 1С). These dead cells and cell 
debris outside the scatter defined blast-window contained considerably more 
adrlamycin compared with the viable cells (Fig. 2C). 
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FIGURE 1. Two parameter (forward and perpendicular) light scatter plot 
of normal fresh bone marrow (A), cryopreserved normal bone marrow (B) 
and cryopreserved bone marrow of a patient with acute nonlymphocytic 
leukemia (C). The blast cell subpopulations are indicated by the 
rectangle numbered 3. Note the amount dead cells (population 1) and 
cell debris (population 5) in the cryopreserved bone marrow samples. 
Population Ζ consists of lymphocytes and population 4 of mature 
myeloid cells. 
Cellular adriamycln concentrations in vitro. Cellular adrlamycin concentrations 
in blast cells were determined both at the end of the in vitro adriamycln 
exposure and just prior to plating. For both leukemic and normal bone marrow 
cells a linear correlation was observed between the extracellular adrlamycin 
concentrations and the resulting blast cell adrlamycin concentrations in the 
range tested (n = 8, r-value always better than 0.95), which implies an 
essentially non-saturable cellular adriamycln uptake. After washing just prior 
to plating a proportional loss of 48 ± 11% of the initial cellular adrlamycin 
was observed over the adriamycln concentration range tested, indicating a free 
cellular adriamycln fraction of circa 48% which was removed during the washing 
procedure. 
Clonogenicity and cellular adrlamycin concentration in vitro. After 2 h exposure 
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of leukemic and normal bone marrow to 100 ng adriamycin/ml clonogenicity of 
leukemic cells was depressed 20 ± 17% (normal bone marrow 8 ± 9%) at cellular 
adriamycin concentrations of 76 ± 41 FU/cell (76 + 46 FU/cell). See Table 1. 
Moderate suppression of 44 ± 30% (normal bone marrow 55 + 25%) was observed 
after 2 h in vitro exposure to 500 ng adriamycin/ml (Fig. 4A), resulting in 
cellular drug concentrations of 254 + 158 FU/cell (normal bone marrow 249 ± 53 
FU/cell). At extracellular concentrations of 2000 ng/ml both normal CFU-GM and 
leukemic CFU-L (Fig. 4A) were almost completely inhibited (leukemic cells: 
96 ± 7% and normal cells 99 ± 1%). Adriamycin concentrations in the blast cells 
were 1184 ± 472 FU/cell (normal bone marrow 1024 ± 281 FU/cell). The 
concentration at which 50% inhibition of clonogenicity was observed (IC50) for 
leukemic cells was reached at 230 ± 102 FU/cell after 2 h exposure to 545 ± 252 
ng/ml. The IC90 for leukemic bone marrow was reached at cellular adriamycin 
concentrations of 936 ± 240 FU/cell after 2 h exposure to 1146 ± 166 ng/ml, and 
at 679 ± 155 FU/cell after exposure to 911+129 in case of normal bone marrow 
(Table 2). Cellular adriamycin concentrations in leukemic blast cells (n = 7) 
were in the same range as those obtained in normal bone marrow blast cells 
(n = 4), whether they were freshly obtained or thawed after cryopreservation (no 
significant differences). 
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FIGURE 2. Forward end perpendicular light scatter plot of a leukemic 
bone marrow (A). Fluorescence versus scatter plot of the blank (B). 
After in vitro exposure to 500 ng adriamycin/ml for Ζ Ь (С). Note the 
adriamycin accumulation in part of the dead cells. 
Cellular adriamycin concentrations in vivo. An example of a plasma and cellular 
(blast cells) adriamycin concentration-time curve is shown in Fig. 3. 
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Adriamycin (30 mg/m ) was administered as a 1 min bolus injection. In the blast 
cells a short-lasting peak-cellular adriamycin concentration of 96 FU/cell (4160 
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ng/10 cells) at 1.5 min after the start of the infusion is followed by a 
longer-lasting plateau-concentration from 10 min on of circa 60 FU/cell. At 24 
h the cellular adriamycin concentration still amounted to 46 FU/cell (not shown 
in the figure). 
TABLE 1. Blast cell adriamycin concentrât ions after in vitro exposure, 
related to inhibition of clonogenicity. 
Normal and leukemic human bone marrow cells were incubated with 
indicated concentrations of adriamycin for 2 h. Blast cell adriamycin 
concentrations (FU/cell) were determined just before plating by means 
of flow cytometry. 12 days after plating colonies were scored. 
medium adriamycin blast cell adriamycin inhibition of clonogenicity 
concentration concentration (control set at 100%) 
(ng/ml) (FU/cell, mean ± SD) (%, mean ± SD) 
50 
100 
500 
1000 
2000 
leukemic 
n=7 
48 ± 68 
76 ± 41 
231 ± 180 
850 ± 455 
1184 ± 472 
normal 
n=4 
35 ± 34 
76 ± 46 
249 ± 53 
641 ± 112 
1023 ± 281 
leukemic 
n=7 
12 ± 16 
20 ± 17 
44 + 30 
86 ± 13 
96 ± 7 
normal 
n=4 
11 ± 10 
8 ± 9 
55 ± 25 
94 + 6 
99 ± 1 
No significant differences were noted between attained cellular 
adriamycin concentrations or inhibition of clonogenicity of leukemic 
and normal cells at the different medium concentrations. 
The time-course of cellular adriamycin concentrations in leukemic and normal 
blast cells was determined in 8 patients with acute leukemia and 3 patients with 
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a malignant disease without bone marrow involvement. Adriamycin (30 mg/m ) was 
administered on 3 subsequent days. Maximum cellular adriamycin concentrations 
-measured within 5 min after the end of the bolus injection- were 96 ± 29 
FU/cell in circulating leukemic cells (n = 8 patients) and 140 ± 69 FU/cell in 
cells of patients with normal bone marrow on day 1, 173 ± 58 (165 ± 100) FU/cell 
on the second day and 216 ± 98 (279 ± 149) FU/cell on the third day 
respectively. In general, the peak cellular adriamycin concentration after 
bolus injection decreased rapidly with 30-50%. Shortly after the termination of 
the drug infusion, the apparently bound cellular adriamycin concentrations were 
62 ± 20, 97 ± 43 and 122 ± 50 FU/cell respectively. In contrast with the 
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moderate decrease of cellular adriamycin concentrations, plasma concentrations 
were reduced by two to three decades, from maximum concentrations at 5 min of 
over 8000 ng/ml to 10-30 ng/ml after 2 h. 
TABLE 2. In vitro adriamycin sensitivity of myeloid progenitor cells 
from 7 patients with acute nonlymphocytic leukemia and 4 normal 
controls. D90: medium adriamycin concentration (ng/ml) or blast cell 
adriamycin concentration (TU¡cell) at which 90% growth inhibition is 
expected. Derived from Table 1. 
Patient 
1 
2 
3 
4 
5 
6 
7 
blasts 
(% in sample) 
96 
71 
72 
89 
65 
25 
49 
(ng/ml) 
1360 
966 
1170 
1040 
1390 
1154 
940 
D90 
(FU/cell) 
1030 
999 
1090 
984 
1260 
477 
712 
Mean ± SD 1146 ± 166 936 ± 240 
Control 1 
Control 2 
Control 3 
Control 4 
2 
3 
1 
0 
751 
850 
1100 
943 
706 
487 
911 
610 
Mean ± SD 911 ± 129 679 ± 155 
Clonogenicity and cellular adriamycin concentration in vivo. The range of 
cellular adriamycin concentrations, attained in the treatment of acute leukemia 
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after three repeated administrations of adriamycin 30 mg/m has been indicated 
in Fig. 46. The highest inhibition of clonogenlclty which can be expected from 
the in vivo observed cellular adriamycin concentrations is circa 65%. 
In 2 patients (leukemia in remission) clonogenlclty was determined of normal 
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bone marrow cells obtained before and 1 h after adriamycin 30 mg/m bolus 
injection, given as part of the maintenance therapy. Clonogenlclty was 
depressed from 100% (before) to 79% and 44% respectively, with blast cell 
adriamcyin concentrations of 53 and 74 FU/cell. In 1 patient with Hodgkin's 
disease without bone marrow involvement, clonogenlclty was determined of bone 
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FIGURE 3. Cellular and plasma adriamycin concentration-time curve 
during the first 60 min after 55 mg adriamycin bolus injection (1 min) 
in a leukemic patient. (%) adriamycin concentrations in leukemic 
cells (FU/cell, left) (ng/ml, right) respectively, assuming 10 cells 
representing a volume of 1 ml. (O) plasma concentration of adriamycin 
in ng/ml. (Ώ) plasma concentration of the metabolite adriamycinol in 
ng/ml. 
marrow cells obtained before, at 5 min and 2 h after an adriamycin bolus 
2 injection of 50 mg/m . The number of colonies had been reduced to 13% and 19% 
respectively (blast cell adriamycin concentration: 144 and 71 FU/cell). 
In 1 patient with chronic nonlymphocytic leukemia, treated with adriamycin 6-h 
2 
infusions of 30 to 90 mg/га every two months, on six subsequent occasions 
inhibition of clonogenicity was assayed during, at the end and after the 
infusions. Maximum plasma and cellular adriamycin concentrations amounted to 
q 
171 ng/ml and 4460 ng/10 cells (69 FU/cell) respectively. Inhibition of 
clonogenicity was 36 ± 8% after 3 h and 54 ± 6% at the end of the infusion and 
37 ± 55% one day afterwards. One week later no inhibition was observed: 
clonogenicity was 104 ± 8%. after a week. 
DISCUSSION. 
One of the modes of action of adriamycin is considered to be binding to DNA by 
intercalation between base pairs. In a number of cytotoxicity studies using 
cell-lines, resistance to adriamycin appeared only marginally related to 
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FIGURE 4. A. Inhibition of clonogenicity (%) plotted versus 
adriamycin concentration in the medium (nglml). Incubation of 2 h. 
( + ) Normal bone marrow (fresh and thawed). (O ) leukemic bone 
marrow. (% ) patient with resistant leukemia. 
B. Inhibition of clonogenicity (%) plotted versus bound cellular 
adriamycin concentrations (FU¡cell). The batched area represents the 
bound cellular adriamycin concentrât ions observed in blast cells 1 to 
2 h after in vivo adriamycin administrât ion. 
differences in the rate of uptake (14), but almost completely to the cellular 
retention of the drug. 
In this study human hematopoietic clonogenic cells were exposed to adriamycin in 
vitro as well as in vivo. Colony growth inhibition was related to adriamycin 
concentrations retained in the blast cells. 
Flow cytometry enables quantitative measurement of mean cellular adriamycin 
concentrations in very small numbers of viable cells of distinct subpopulations 
(13, 15). This is in contrast with fluorometric or chromatographic techniques 
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(16), where neither adriamycin concentrations in subpopulations can be 
determined, nor the contribution of the relatively high drug concentration in 
dead cells and debris (Fig. 2C) to the mean cellular adriamycin concentrations 
of the different cell subpopulations can be specified (9, 15). 
In this study, no significant difference in cellular adriamycin uptake and 
retention was noted between leukemic blast cells of the different patients, nor 
between leukemic and normal blast cells. Only one patient in this study 
appeared completely resistant to various remission induction courses (patient 4, 
Table 1). Adriamycin uptake and retention by his blast cells did not differ 
essentially from those in the other patients or controls, neither in vitro, nor 
in vivo. Also the inhibition of clonogenicity was in a comparable range. 
A good correlation was observed between the cellular adriamycin concentration in 
leukemic and normal blast cells and inhibition of clonogenicity. Complete 
inhibition, deduced from extrapolation of the inhibition curves, will be 
attained at cellular adriamycin concentrations of circa 1200 FU/cell, equivalent 
to approximately АО fg/cell, or 80x10 molecules adriamycin/cell. The number of 
9 
adriamycin binding sites has been calculated to be 1.5x10 (15). Thus an 
average of 1:20 occupied binding sites results in a complete inhibition of 
clonogenicity. 
No differential toxicity was observed, which is in agreement with observations 
by Buick et al. (17), but in contrast with other studies (18, 19). Besides, it 
appeared that the highest cellular adriamycin concentrations observed in vivo 
were far below in vitro attained drug concentrations which result in complete 
inhibition of clonogenicity (9, 19). Although substantial reduction of leukemic 
clonogenic cells is obtained, which is even enhanced due to the usually 
polychemotherapeutic approach, our study provides arguments for the fact that in 
leukemia residual disease partly may persist due to limited cellular adriamycin 
concentrations attained with present-day therapeutic regimens. Therefore 
attention should be paid to other drug schedules as proposed e.g. by Casazza 
(20). 
Opposite to studies by Park et al. (18), our study gives little support to the 
assumption that the clonogenic assay can be used as a predictive test for the 
ultimate clinical response to adriamycin chemotherapy, due to the limited range 
of cellular adriamycin concentrations which can be attained in vivo (21) and due 
to the lack of differential toxicity. 
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CHAPTER 11 
CONCLUDING REMARKS AND OUTLINE FOR FUTURE INVESTIGATIONS 
CONCLUDING REMARKS. 
Anthracyclines belong to the most potent cytostatic agents. They are applied in 
empirically developed treatment schedules for leukemias and other malignancies. 
To improve the results of chemotherapy, more insight is needed in the mechanisms 
of action of these drugs. Therefore knowledge of among others drug 
concentrations at the cellular level is necessary. 
In this study an attempt has been made to measure cellular anthracycline 
concentrations in malignant and normal hematopoietic cells and to interprete the 
significance of the observed cellular drug concentrations in relation to cell 
kill. 
Major conclusions were: 
1. Laser flow cytometry (FCM) and high pressure liquid chromatography (HPLC) 
appeared complementary tools in the investigation of cellular anthracycline 
pharmacokinetics and pharmacodynamics. The main advantage of FCM is the 
possibility to quantify cellular anthracycline concentrations in single viable 
cells, and even to sort these cells out. HPLC appeared to be a necessary 
supplementary tool, as with this technique the amount of parent drug and 
metabolites can be determined. In this study a good relation between FCM- and 
HPLC-determined cellular anthracycline concentrations was observed. Different 
drug handling by subpopulations of hematopoietic cells has been demonstrated 
with FCM. 
2. This study of cellular pharmacokinetics of anthracyclines in man has shown 
that plasma anthracycline concentrations per se do not predict for cellular drug 
concentrations. Initially, cells accumulated the anthracyclines against a 
gradient during administration. Thereafter, the cell to plasma ratio increased 
to over 400, due to the divergent half-life times of anthracyclines in plasma 
and cells. 
Bolus injection and long-term infusion of the same anthracycline dose appeared 
to result in similar leukemic cell anthracycline concentrations. Peak cellular 
anthracycline concentrations attained after bolus injection were of no benefit, 
and -as follows from literature- even seemed to contribute to the dose limiting 
cardiotoxicity. As long-term infusion was better tolerated by the patient, this 
should be the preferred mode of anthracycline administration. 
3. Minor stereochemical modifications appeared to cause large changes in plasma 
pharmacokinetics and even more pronounced in cellular pharmacokinetics. Of all 
four drugs studied, cellular uptake of the more lipophilic drugs daunomycin and 
A-demethoxydaunomycin was highest both in vivo and in vitro, although in vivo 
peak plasma concentrations were lower. As the efflux was more pronounced as 
well, these drugs appeared to be less tightly bound in the cellular cytoplasme 
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or to the nucleus, when compared with the more hydrophilic drugs adriamycin and 
4'-epi-adriaraycin. In these comparative studies large differences between in 
vitro and in vivo cellular pharmacokinetics have been demonstrated. Therefore, 
translations from in vitro observed pharmacokinetic patterns to in vivo 
circumstances can be rather hazardous. 
4. With regard to the cytotoxic effect, our studies revealed that the dose of 
anthracyclines administered is not optimal. The leukemic cell anthracycline 
concentrations reached in vivo were high enough to realize some cell kill and 
reduction of tumor load, but were insufficiently high to eradicate all 
clonogenic tumor cells. Furthermore, nondividing cells probably escaped from 
the treatment, as anthracycline uptake appeared to be cell cycle dependent 
-uptake in nondividing cells was half of the uptake in dividing cells 
(unpublished observations). However, administration of far higher doses will 
not be possible in clinical practice, as no differential kill between leukemic 
and normal hematopoietic cells was observed. 
FUTURE PERSPECTIVES. 
Last years the best results obtained in the treatment of adult acute leukemia 
amounted to 70-85% complete remission. These remission induction percentages 
did not improve any further, despite attempts with new drugs or higher dosages 
of conventional drugs. The duration of the remission is limited, 1 to 1.5 year. 
Real cures are almost never attained. 
Treatment of malignant lymphoma and testicular carcinoma has illustrated that 
many patients with these malignancies can be cured with help of chemotherapy. 
This justifies further research to improve the therapeutic index of 
anti-leukemic and anti-cancer chemotherapy. Questions to answer are: 
1. Can higher efficacy be obtained by rationally designed dosage schedules, in 
which currently used drugs are administered in a more adequate dose, with 
improved spacing, with a better rate of administration, as well as in a rational 
combination with other drugs? 
2. Can the toxicity (nausea, vomiting, organ toxicity) of the currently used 
drugs be reduced by alternative ways of administration, without diminishing the 
efficacy? 
3. Can the therapeutic index be improved by targeting with help of liposomes or 
monoclonal antibodies? 
A. Have new drugs a considerably better efficacy or reduced toxicity? 
5. Can knowledge of cell kinetic aspects of tumors be exploited to improve the 
therapeutic results? 
Ad 1. 
Dose escalations will result in only marginally improved therapeutic results. 
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However, administration as continuous infusion might allow this escalation, 
without a more pronounced toxicity. From our studies it cannot be concluded 
whether the sequence and the interval can be improved. As monotherapy in 
animals has shown that the sequence as well as the interval may be of importance 
(1, 2, 3), this aspect certainly deserves further investigation. 
From a cell kinetic point of view, in patients with slowly proliferating tumors 
it could be even an advantage to administer higher dosages of anthracyclines as 
prolonged infusion over more than 72-96 h. 
Ad 2. At present anthracyclines in the treatment of leukemias and solid tumors 
are administered as bolus injections. Reduction of toxicity turned out to be 
possible by continuous infusion of the drug (at least up to 96 h) with 
maintenance of cytotoxic effects. Others have demonstrated better tolerance and 
persistance of efficacy applying continuous anthracycline infusion during 3 
weeks or longer (4, 5), but increasing damage to normal clonogenic stem cells 
has as yet not been excluded. Increase in frequency of mucositis may turn out 
to be a limiting factor. 
ad 3. 
Drug targeting may become a new and selective way of administering cytotoxic 
agents. Encouraging observations of reduced toxicity with preservation of 
activity with liposome entrapped adriamycin in animals have been reported (6). 
Also targeting with use of monoclonal antibodies may lead to an important 
break-through. 
ad 4. 
As anthracyclines are considered to be one of the cornerstones in the treatment 
of leukemias, investigators have searched for more potent analogues with less 
side effects. Whether different analogues will be more potent remains to be 
proven, but there is evidence that the analogue 4-demethoxydaunomycin, which is 
administered at lower dosages, is at least equally potent and less toxic (7). 
The possibility of oral administration of this drug offers a new approach to 
treatment in the out-patient department and may contribute to a better quality 
of life. 
ad 5. 
As during or after the end of the maintenance therapy, given to a patient in 
complete remission of acute leukemia, rather often a relapse is observed, 
apparently clonogenic tumor cells have escaped from the treatment. Not enough 
of the administered drugs apparently have reached the clonogenic cell, the cell 
might have been temporarily insensitive due to cell kinetic factors, or might 
have been resistant due to specific cell biological behaviour. 
Recent studies showed that these escape mechanisms, to be taken together as 
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resistance, should be considered as a complex in which many different factors 
play a role. At present FCM probably is the only technique which allows 
isolation of viable cells with low anthracycline concentrations. These cells 
might have been escaped from anthracycline treatment and be responsible for 
relapse of the disease. Such cells will be the subject of studies directed to 
the mechanism of resistance to anthracycline treatment. 
The Netherlands Cancer Foundation (KWF) will enable further investigations in 
this direction at the Department of Hematology. 
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SUMMARY 
SUMMARY 
Anthracyclines belong to the most potent cytostatic drugs in the treatment of 
cancer. Up to now anthracycline chemotherapy mainly has been developed 
empirically. For further improvement of chemotherapy with more rational 
arguments, anthracycline cellular pharmacokinetics and pharmacodynamics in 
humans have to be investigated. In chapter 1 a short overview is given of the 
anthracycline drug and of what is known concerning their cellular 
pharmacokinetics and pharmacodynamics in relation to cell kinetics and 
clonogenicity. 
High performance liquid chromatography (HPLC) has proved to be the most valuable 
method to determine anthracycline concentrations of the parent drug and the 
metabolites in body fluids. Chapter 2 described, that best extraction recovery 
of anthracyclines from human hematopoietic cells is attained when 250 ul 
sonicated cell suspension (containing less than 40x10 cells per ml) were 
extracted twice with 3 ml chloroform/methanol (9:1, ν/ν), under addition of 100 
lil 1 M Tris buffer, pH 8.8. The method has been applied in the studies of the 
in vivo cellular pharmacokinetics in human normal and malignant hematopoietic 
cells, described in the next chapters. 
In chapter 3 the use of laser flow cytometry (FCM) has been described to 
quantify cellular anthracycline concentrations in small amounts (a few 
thousands) of viable individual cells. Major cell subpopulations present in 
bone marrow and peripheral blood can be discriminated by forward and 
perpendicular light scatter signals. Fluorescent properties of anthracycline 
antibiotics as a third parameter allow measurement of the concentration of these 
cytotoxic drugs in single cells of interest by FCM. A satisfying correlation 
was found between the mean cellular fluorescence measured by FCM and the overall 
cellular concentration of adriamycin, daunomycin, and their main metabolites 
determined with high pressure liquid chromatography (HPLC). In incubation 
experiments with human hematopoietic cells, the final cell concentration of 
various anthracyclines was linear with the extracellular anthracycline 
concentration and had a more complex relationship with cell density, incubation 
time, temperature, and type of compound. FCM analysis is a rapid, sensitive and 
quantitative method for measurement of cellular anthracycline concentrations in 
subpopulations. It provides information complementary to data obtained from 
HPLC. 
Hardly any information is available from literature concerning anthracycline 
concentrations in the target-cell obtained during chemotherapy of patients. In 
chapter 4A cellular and plasma concentrations of ADM were measured in 18 
patients with nonlymphocytic leukemia after ADM administration, either as bolus 
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injection or as 4, 8 and 24 h infusion at 3 subsequent days of treatment. Peak 
plasma ADM concentrations after the third bolus injection amounted to 1640 ± 70 
ng/ml and were reduced 10 times during 4h infusion, 20 times during β h infusion 
and 35 times to 47 ± 5 ng/ml after 3x24 h infusion. The ratio cell:plasma ADM 
concentrations increased with time, up to 1000 times. Plasma half-life time was 
40-50 h, cellular ADM concentrations have a long half-life time of circa 85-110 
h. After continuous infusion and bolus injection of the same dose, similar 
leukemic blast cell ADM concentrations were attained at 7710 ± 1190 ng/109 
cells. A satisfying correlation was observed between nucleated blood and bone 
marrow cellular ADM concentration. As a comparable therapeutic efficacy was 
observed in all regimens, the antileukemic effect appeared not to be related to 
the peak plasma concentrations, while acute toxicity phenomena decreased with 
increasing duration of the infusion. Continuous ADM infusion thus deserves more 
attention in the treatment of patients with anthracyclines. 
Except from the reduction in side effects, a possible therapeutic gain can be 
attained by applying long-term infusion in the treatment of patients with slowly 
growing tumors like multiple myeloma. In chapter 4B ADM concentrations were 
measured in 7 patients with advanced multiple myeloma, to whom ADM was 
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administered as 96 h infusion of 9 mg/m /24 h every three weeks. Plasma ADM 
concentrations reached maximum concentrations of 15.8 ± 4.4 ng/ml. Cellular ADM 
concentrations in nucleated blood cells gradually increased throughout the 96 h 
9 
infusion up to 2927 ± 748 ng/10 cells. Bone marrow cells at that time 
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contained 2962 ± 847 ng/10 cells. FCM determination of ADM concentrations in 
plasma cells in the bone marrow revealed mean concentrations corresponding with 
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circa 4000 ng/10 cells. The area under the cellular concentration-time curve 
of 96 h infusion revealed similar values as observed after bolus injection of a 
comparable total dose. These pharmacokinetic studies showed that in continuous 
infusion plasma cells in the bone marrow continuously accumulate ADM, although 
plasma ADM concentrations remain very low. 
In chapter 5 cellular and plasma concentrations of daunomycin (DNM) were 
measured in 20 patients with nonlymphocytic leukemia, to evaluate the effect of 
the duration of DNM infusion on leukemic cell drug concentrations. DNM was 
administered as described in chapter 4A. Peak plasma DNM levels were 227 ± 116 
ng/ml in case of bolus injection and were reduced 15 times after 3x24 h DNM 
infusion, daunomycinol (DNMol) peak concentrations were 171 ± 53 and 98 ± 34. 
ng/ml respectively. Terminal plasma half-life time was 14 ± 4 h. Leukemic cell 
DNM concentrations at the end of 3 days administration were comparable: 
16810 ± 2580 ng/109 cells in case of bolus injection and 10310 ± 5510 ng/109 
cells after constant-rate infusions respectively. Leukemic cell DNMol 
concentrations were circa 5000 ng/109 cells. Cellular DNM and DNMol 
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concentrations decreased rapidly with a terminal half-life of 13 ± A h. The 
ratio of the cellular¡plasma concentrations increased in time up to 1000 at 24 h 
after the administration. The area under the cellular curve was in the same 
order of magnitude in case of bolus injection or 72 h infusion. DNM 
concentrations in nucleated blood and bone marrow cells correlated well. After 
continuous infusion a reduction of unwanted side effects was noted, whereas 
target cell DNM concentrations at the end of the infusion were similar. 
Comparable therapeutic efficacy was attained, as after bolus injection. 
In chapter 6 in the phrame of a phase II study cellular and plasma drug 
concentrations were measured of 4-demethoxydaunomycin (D-DNM), a new 
anthracycline analogue, which is administered at a 25% lower dose compared to 
2 
DNM and which can also be given orally. D-DNM was given orally (30 mg/m ), or 
2 
intravenously (10 mg/m ) to 7 patients with acute leukemia on 3 consecutive 
days, replacing daunomycin in a conventional polychemotherapy regimen. Peak 
plasma D-DNM concentrations at 5 min after bolus injection were circa 50 ng/ml, 
and less with long-term infusion schedules. Rapid and extensive formation of 
4-demethoxydaunomycinol (D-DNMol) was observed, with accumulation of plasma and 
cellular D-DNMol on subsequent days. The shape of the D-DNM concentration-time 
curve after oral ingestion resembled the one observed during a 4 h infusion. 
D-DNM concentrations in nucleated blood and bone marrow cells were in the same 
order and amounted to 292 to 465 times the plasma concentration, cellular 
D-DNMol concentrations were 115-218 times higher. After oral D-DNM ingestion, 
plasma and cellular D-DNMol concentrations surmounted D-DNM concentrations. 
D-DNM disappearance rates in plasma and cells were almost comparable, with a 
terminal half-life of circa 15 h. Complete remissions were obtained in 4 out of 
6 évaluable patients, of whom two had an unmaintained relapse after former 
anthracycline containing regimens. 
As a remarkable number of remissions had been described with a non-toxic 
schedule consisting of weekly low dose injections of 20 mg 4'-epi-adriamycin 
(E-ADM) given for at least β weeks to patients with advanced postmenopausal 
breast cancer, in chapter 7 E-ADM concentrations in plasma and in blood and bone 
marrow cells were determined during 8 consecutive weeks. Cellular 
concentrations appeared more than hundred-fold higher than plasma concentrations 
9 
and amounted to 190 ± 66 ng/10 cells on day 6, before the next injection was 
given. No serious bone marrow toxicity was observed. In two patients with an 
increased plasma bilirubin concentration, cellular E-ADM concentrations were 20 
to 40% higher than those observed in the other patients, while terminal plasma 
half-life times were 2 to 3 times longer. In two patients E-ADM could be 
demonstrated in the tumor tissue of skin metastasis up to 7 days after the last 
injection. Although the number of patients investigated is too small to relate 
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drug kinetics with clinical response, it is of interest that the two patients 
with the highest cellular E-ADM concentrations responded better than the others. 
To define differences in cellular pharmacokinetics between in vitro and in vivo 
exposure of human hematopoietic cells to anthracyclines with minor differences 
in chemical structure, studies were done (chapter S) during and after 5 rain and 
6 h exposure to adriamycin (ADM), 4'-epi-adriamycin (E-ADM), 
4-demethoxydaunomycin (D-DNM) and daunomycin (DNM). Initial anthracycline 
uptake always was fast. In general, lymphocyte anthracycline concentrations 
were lowest. Except D-DNM, no steady state concentration was attained for any 
drug or subpopulation. Maximum cellular anthracycline concentration and area 
under the cellular curve (AUCc) was highest for D-DNM, followed in decreasing 
order by DNM, E-ADM and ADM. At reincubation an almost instantaneous 30% loss 
of cellular ADM and E-ADM in each subpopulation was noted with hardly any 
further loss thereafter. Release of D-DNM and DNM was more gradually and longer 
lasting, to the greatest extent in the case of D-DNM (50-60% after 3 h). At 5 
min exposure to high drug concentrations efflux patterns were similar but to a 
greater extent with circa 60% loss (E-ADM and ADM) and 70% (DNM and D-DNM) of 
the peak concentration. The slopes of the in vivo cellular concentration-time 
curves after bolus injection, were similar to those observed after the 5 min 
exposure in vitro. However, in vivo the AUCc was largest for ADM and smallest 
for D-DNM. Large differences between cellular and plasma pharmacokinetic 
parameters were observed. In vitro cellular drug handling differed considerably 
from in vivo cellular pharmacokinetics. Minor differences in anthracycline 
structure resulted in considerable variations in cellular drug handling, which 
may be of importance for the antitumor as well as for the toxic effects. 
In chapter 9 the inhibitory effect of infusion-rate dependent cellular ADM 
concentrations on the clonogenicity of human hematopoietic cells was studied. 
Cytotoxicity (evaluated by means of the clonogenic assay CFU-GM) was related to 
cellular ADM concentrations. In vivo short- and long-lasting infusions were 
simulated by in vitro exposure during 5 min to high (up to 12.5 tig/ml) and 2-24 
h exposure to low (up to 0.5 yg/ml) ADM concentrations. The rapid and extensive 
loss after short exposure were in contrast to the more gradual and less 
extensive loss after long-term exposure. The net results were comparable 
cellular ADM levels. The in vitro achieved cytotoxic effect correlated well 
with the cellular ADM concentrations, measured after efflux of the loosely bound 
cellular ADM. Short-lasting high cellular ADM concentrations as seen after 
bolus injection appeared not to be essential for cytotoxic effect on clonogenic 
cells. These results show that prolonged ADM administration has to be preferred 
above bolus injection, as in vivo side effects are less pronounced after 
infusion, while the effect on clonogenic cells is similar. 
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In chapter 10 these studies were extended to leukemic human hematopoietic 
progenitor cells. Flow cytometric determination of cellular adriamycin 
concentrations in blast cells correlated well with the extent of inhibition. 
After 2 h in vitro exposure of 10 cells/ml to 500 ng adriamycin/ml, the 
adriamycin concentration of leukemic and normal bone marrow blast cells amounted 
to 254 ± 158 and 249 ± 53 FU/cell respectively, resulting in a moderate decrease 
of clonogenicity of 44 ± 30 and 54 ± 27%. Exposure to 2000 ng/ml revealed 
adriamycin concentrations of circa 1100 FU/cell, resulting in inhibition of 
clonogenicity of circa 98%. No differential toxicity for leukemic and normal 
clonogenic cells was noted. After in vivo adriamycin administration of 30 mg/m2 
on three consecutive days, drug concentrations in leukemic blast cells amounted 
to not more than 216 ± 98 FU/cell. This implies that inhibition of 
clonogenicity after administration of conventional dosages will be restricted to 
circa 50% for both leukemic and normal bone marrow progenitor cells; these 
concentrations are too low to ever result in a complete eradication of leukemic 
clonogenic cells. In vitro adriamycin sensitivity testing on clonogenic cells 
has little value as a predictive test for the ultimate clinical response, as far 
higher adriamycin dosages cannot be administered, due to toxic effects. 
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Samenvatting 
Anthracyclinen behoren tot de krachtigste cytostatica (middelen die gebruikt 
worden bij de behandeling van patiënten met kanker om kankercellen te doden). 
Anthracyclinen worden met name met succes toegepast bij patiënten met acute 
leukemie en diverse vormen van kanker. Met het gebruik van die middelen is tot 
nu toe vooral proefondervindelijk voortgang geboekt. De laatste jaren evenwel 
lijken er geen grote vorderingen meer gemaakt te worden op het gebied van de 
chemotherapie (behandeling van kanker met cytostatica). 
Om verder te komen met de behandeling is meer inzicht nodig in het hoe en waarom 
van de werking van deze cytostatica. Van belang daarbij is te weten hoeveel 
cytostaticum in de te doden kwaadaardige cel terecht komt. Hiermee houdt de 
cellulaire farmacokinetiek zich bezig. De vraag welke invloed de in de cel 
aanwezige hoeveelheid cytostaticum heeft op onder andere de stofwisseling van de 
cel die moet leiden tot de celdood, wordt bestudeerd in de farmacodynamiek. 
In dit proefschrift is een aanzet gegeven tot het bestuderen van de cellulaire 
farmacokinetiek en farmacodynamiek van vier soorten anthracyclinen die gebruikt 
worden bij de behandeling van patiënten met leukemie en borstkanker. 
In hoofdstuk 1 wordt een overzicht gegeven van de begrippen cellulaire 
farmacokinetiek, farmacodynamiek, celkinetiek en wat daarover bekend is in 
relatie tot anthracyclinen in het algemeen. Verder wordt het doel en de opzet 
van deze studie toegelicht. 
In hoofdstuk 2 wordt "de hoge druk vloeistof chromatografie (HPLC) methode" 
beschreven die in dit onderzoek gebruikt is. Hierbij dient eerst het 
anthracycline uit een groot aantal cellen, of uit plasma geëxtraheerd te worden. 
Vervolgens kunnen de concentraties bepaald worden. De condities waaronder een 
maximaal rendement van de extractie en de analyse verkregen worden, zijn 
beschreven. 
In hoofdstuk 3 wordt "de laser flow cytometrie (FCM) methode" beschreven, die 
gebruikt is om in individuele cellen de anthracycline-concentratie te bepalen. 
Een voordeel van deze methode is, dat hierbij slechts kleine celaantallen nodig 
zijn; bovendien kunnen de concentraties in levende cellen bepaald worden. Op 
grond van lichtverstrooiing kunnen met FCM verschillende cel-soorten in een 
celsuspensie onderscheiden worden. Aangezien anthracyclinen fluorescerende 
eigenschappen hebben, kan met FCM van iedere cel tegelijkertijd met de 
lichtverstrooiingseigenschappen ook de in de cel aanwezige hoeveelheid 
anthracycline bepaald worden. De met HPLC en met FCM bepaalde cellulaire 
anthracycline concentratie kwamen goed met elkaar overeen. De opname van 
verschillende anthracyclinen in de cel blijkt door een groot aantal factoren 
beïnvloed te worden. Hiermee moet tijdens experimenten rekening gehouden 
worden. 
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Aangezien er maar weinig bekend is van het beloop van de cellulaire 
anthracycline concentraties bij patiënten die met dit middel behandeld worden, 
is in de achtereenvolgende hoofdstukken de cellulaire farmacokinetiek bestudeerd 
van vier stoffen die behoren tot de groep van de anthracyclinen: adriamycine 
(ADM), daunomycine (DNM), 4-demethoxydaunomycine (D-DNM) en 4'-epi-adriamycine 
(E-ADM). Daarbij is geprobeerd antwoord te geven op de volgende vragen: 
hoeveel van het middel komt bij de gebruikelijke manier van behandelen 
(inspuiten in korte tijd: bolus injectie) terecht in de cel die opgeruimd moet 
worden? Hoeveel van het middel komt in die cel terecht wanneer dezelfde 
hoeveelheid van het middel uitgespreid over een langere toedieningstijd (continu 
infuus) wordt toegediend? Het voordeel van die laatste toedieningswijze ligt in 
een vermindering van ongewenste bijwerkingen zoals misselijkheid en braken, en 
op langere termijn mogelijk ook vermindering van hartspierbeschadiging. 
In hoofdstuk 4A wordt de cellulaire farmacokinetiek van ADM beschreven. ADM is 
daarbij toegediend als 3x1 bolus injectie en als 3x24 uurs infuus. Door deze 
laatstgenoemde methode blijven de maximale plasma concentraties 30-40 maal lager 
in vergelijking met de concentraties na een bolus injectie, terwijl de 
cellulaire concentraties uiteindelijk op eenzelfde niveau uitkomen. De cellen 
blijken ADM tegen een flinke concentratie gradient van wel 100-1000 maal op te 
nemen en vast te houden. Hoewel het aantal onderzochte patiënten klein is, 
lijkt het therapie effect niet minder te zijn bij de langdurige infusie. 
In oofdstuk 4B wordt hetzelfde onderzoek beschreven bij patiënten met de ziekte 
van Kahler. Dit is een kwaadaardige ziekte, waarbij de zieke cellen langzaam 
groeien. Er zijn aanwijzingen in de literatuur, dat juist bij deze "langzame 
groeiers" een langdurige blootstelling (96 uur) aan ADM even effectief, zo niet 
effectiever is dan de therapie met bolus injecties. Ook nu blijkt dat de wijze 
van toediening geen invloed heeft op de uiteindelijk bereikte cellulaire ADM 
concentratie, terwijl de bijwerkingen bij langdurig infuus verminderd worden. 
In hoofdstuk 5 wordt het effect van DNM bolus injectie en langdurige infusie bij 
de behandeling van patiënten met leukemie onderzocht. Het verloop van de 
cellulaire en plasma DNM concentraties is anders dan werd waargenomen bij 
infusie van ADM, maar het resultaat is in grote lijnen weer hetzelfde: 
cellulaire concentraties liggen in dezelfde orde van grootte, evenals het 
therapie effect. De bijwerkingen zijn bij een infuus minder. 
4-demethoxydaunomycine (D-DNM) is een nieuw anthracycline. Het wordt gegeven in 
25% van de gebruikelijke dosis, en kan bovendien ook als capsule toegediend 
worden, hetgeen bij de andere beschreven middelen niet mogelijk iâ. Ih 
hoofdstuk 6 wordt van D-DNM de cellulaire en plasma farmacokinetiek onderzocht. 
De maximale plasma concentraties zijn veel lager dan die waargenomen bij DNM. 
De toediening als capsule kan vergeleken worden met toediening als 4-uurs 
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infuus, met dit verschil dat bij de capsule een groot deel van het middel als 
werkzaam afbraakprodukt in het bloed en in de cellen terecht komt. Bij de 
beperkte patiëntengroep uit dit onderzoek blijkt D-DNM effectief te zijn. 
Bij de behandeling van patiënten met borstkanker wordt gezocht naar therapieën 
met zo gering mogelijke bijwerkingen. In dit kader werden patiënten behandeld 
met een wekelijks infuus van een lage dosis 4'-epi-adriamycine (E-ADM). Omdat 
hierbij inderdaad weinig onderdrukking van de bloedvormende cellen plaats vindt, 
worden in hoofdstuk 7 de cellulaire en plasma concentraties van E-ADM beschreven 
welke bij deze behandeling worden gevonden. Het blijkt, dat in de bloed- en 
beenmergcel voortdurend een -zij het geringe- hoeveelheid E-ADM aanwezig is. 
Een vergelijkbare hoeveelheid werd teruggevonden in uitzaaiingen in de huid. 
Bij twee patiënten met geelzucht bleken de cellulaire concentraties hoger te 
zijn. Bij hen werd ook een -tijdelijk- beter effect gezien. Of deze therapie 
van waarde is, is niet bewezen. 
In hoofdstuk 8 wordt in vitro onderzoek (laboratorium) vergeleken met in vivo 
onderzoek (waarnemingen bij patiënten). Daartoe zijn concentraties van vier 
anthracyclinen gemeten in de verschillende soorten bloed- en beenmergcellen met 
behulp van de FCM. Het geven van een bolus injectie bij een patient kan 
nagebootst worden met een 5 minuten durende incubatie. De cellen nemen de 
verschillende middelen razendsnel op. maar verliezen na een kortdurende 
blootstelling aan een hoge concentratie ook weer relatief veel van het middel. 
Na een langdurige blootstelling nemen zij het middel langzamer op, maar 
verliezen nadien ook minder. De opname in de cel van de verschillende middelen 
blijkt erg bepaald te worden door de electrische lading (polariteit) van de 
stof. De opname in de verschillende soorten cellen verschilt niet erg 
duidelijk. Tussen in vitro en ¿n vivo cellulaire farraacokinetiek bestaan grote 
verschillen, omdat in vitro nauwelijks of geen rekening kan worden gehouden met 
de verdeling in het lichaam van het te onderzoeken middel. Dit moet een 
vraagteken doen zetten bij de "vertaling" van veel in vitro onderzoek naar de 
praktijk bij de mens, als niet de concentratie in de cel zelf gemeten kan 
worden. 
In hoofdstuk 9 wordt een aspect van de farmacodynamiek bestudeerd in vitro, 
namelijk het remmend effect van ADM op beenmergcellen die nog de capaciteit 
hebben te groeien en kolonies te vormen (clonogeen zijn). Dit wordt onderzocht 
met behulp van de donogene assay (CFU-GM: Colony Forming Units van 
Granulocyten en Macrofagen). Beenmergcellen werden in vitro blootgesteld aan 
verschillende concentraties ADM gedurende 5 minuten, 2 uur en 24 uur. Met name 
de cellulaire ADM concentratie gemeten na wegwassen van het buiten de cel 
aanwezige ADM, blijkt sterk te correleren met de groeiremming in de CFU-GM. 
Daarbij is het niet van belang of deze concentraties bereikt worden door middel 
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van een langdurige blootstelling aan een lage ADM concentratie, dan wel een 
kortdurende blootstelling aan een hoge ADM concentratie. In vitro zijn hiervoor 
verschillende doses (concentratie χ tijd) nodig. Om eenzelfde groeiremmend 
effect te verkrijgen dient de ADM concentratie in het incubatiemedium relatief 
veel hoger te zijn, naarmate de incubatietijd langer wordt. Dit in 
tegenstelling to In vivo, waar met dezelfde dosis eenzelfde cellulaire 
concentratie bereikt wordt, onafhankelijk van de duur van de infusie. 
In hoofdstuk 10 wordt het in hoofdstuk 9 beschreven verband ook onderzocht voor 
donogene leukemie cellen. De groeiremmende capaciteit van ADM blijkt gelijk te 
zijn voor normale en voor leukemische donogene cellen. Bovendien werd 
geconstateerd, dat de bij de patient met leukemie bereikte cellulaire ADM 
concentraties, niet in het concentratiebereik liggen waarbij de leukemie cellen 
volledig worden gedood. Dit impliceert tevens, dat testen waarbij gekeken wordt 
naar de gevoeligheid van een kwaadaardig gezwel voor een cytostaticum, van zeer 
beperkte waarde zijn bij het voorspellen van het uiteindelijke resultaat van de 
behandeling. 
Concluderend kan gesteld worden, dat voor anthracyclinen het bestuderen van de 
plasma-farmacokinetlek van geringe waarde is voor de voorspelling van de 
anthracycline concentratie in de cel die uiteindelijk door het middel opgeruimd 
zal moeten worden. 
Bij de behandeling van patiënten met anthracyclinen lijkt toediening als 
langdurig infuus te verkiezen boven die als bolus injectie, omdat de 
bijwerkingen aanzienlijk gereduceerd worden, terwijl het therapeutisch resultaat 
er niet minder om is. Kleine verschillen in de chemische structuur van de 
verschillende onderzochte middelen blijken grote gevolgen hebben voor de 
verdeling in het lichaam en de opname in de cel. Veel in vitro onderzoek heeft 
alleen waarde als met name de concentratie van het onderzochte middel in de cel 
bepaald kan worden, en het effect van die concentratie op de remming van de 
groei van die cel. 
Bij de huidige wijze van behandeling worden in kwaadaardige cellen in de patient 
voldoende hoge anthracycline concentraties bereikt om het gezwel aanzienlijk in 
omvang doen afnemen en het celaantal te verminderen, maar de concentraties zijn 
onvoldoende hoog om ook alle (met name donogene) kwaadaardige cellen op te 
ruimen. 
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DANKWOORD 
Dit onderzoek was als een opera, gespeeld met ondersteuning door het groot 
Hematologie koor en orkest. Het Koningin Wilhelmina Fonds (KWF) zorgde de 
afgelopen jaren bij Peter Linssen en mij voor brood op de plank, zodat we ons 
onbekommerd aan de muziek konden wijden. Ze maakte het ook mogelijk dat de 
resultaten bij enkele gelegenheden opgevoerd konden worden. Het Ank van 
Vlissingen Fonds en de Maurits en Anna de Koek Stichting droegen bij aan het 
vernieuwen en onderhouden van de bij deze opera gebruikte geavanceerde 
instrumenten en requisieten. De Direkties van het St.Radboudziekenhuis en van 
de Faculteit der Geneeskunde steunden dit onderzoek door gastvrij de repetities 
binnen haar muren te laten plaats vinden. Farmitalia Carlo Erba deed een 
Italiaanse duit in het zakje. 
Ingenieur Jan Boezeman en professor Peter Linssen (zoals hij bij correspondentie 
uit Oostblok-landen veiligheidshalve wordt aangeschreven) speelden ieder een 
hoofdrol in deze opera. Ze leerden me heel wat ins en outs van hun 
gebruikers-vriendelijk gemaakte instrumenten. En meer nog dan dat. Voor en na 
de repetities speelden zich vele vruchtbare discussies tussen ons af, waardoor 
we elkaar steeds weer een partijtje te blazen gaven, of er ook wel van 
afhielden. 
Een niet weg te denken rol speelde eveneens "Lucie" in de Dr.Veeger Kliniek en 
later haar nicht in het laboratorium Bloedziekten. Heel wat nachtelijke uren 
brachten we samen door! Meestal piepte je alleen maar instemmend of 
protesterend, soms ging je dwars liggen, maar dan was Jan er weer. De 
verpleging zorgde vaak voor koffie, met of zonder babbel. 
In het laboratorium-deel pur sang speelden met name Gemma Blankenborg, Helene 
van der Heijden, Ammoniumchloride-Mariet Hillegers-Ewals, Gaby Martens-Ticoalu, 
Arie Pennings, Aart Plas, Everdien Scheltinga-Koekman, John Smeulders, en 
Jacqueline Vet hun partij mee, gesteund door Henk-Jan Aanstoot en Petra Muus. 
De dames (en heren) van "de routine" en van Unit 6 kwamen sterk uit in de 
vrolijke intermezzi. Jan Lintsen (Instrumentele Dienst) maakte het als geen 
ander mogelijk, dat op zijn instrumenten de muziek zeer zuiver klonk. 
In ruil voor noten werden andere noten steeds met gulle hand aangeleverd door de 
heren Hartvaat-chirurgen (Hoofd: prof.dr. L. Lacquet), met steun van de dames 
en heren van de afdeling Cardioanaesthesie (Hoofd: prof.dr. G. Linssen). 
Fons van de Loo speelde een voortreffelijke solo-partij. Tijdens de proloog en 
de epiloog was de samenwerking met Marijn Oosterbaan, Rita Dirks en Ernie1 
Termond van de afdeling Klinische Farmacie (hoofd: prof.dr. E. van der 
Kleijn) uiterst plezierig. 
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Theo Vervuurt stemde bij wat er Engels vals was. De doctores René van Hoesel en 
Reinier Raijmakers vlooiden de partituur nog eens grondig door. Dr. Andries 
Hoitsma toeste of het ene wijsje statistisch significant verschilde van het 
andere melodietje. 
De heer J. Wiese maakte met hulp van C. Nicolaesen (Medische Tekenkamer) 
prachtige plaatjes bij de partituur. De afdeling Medische Fotografie 
vereeuwigde ze voor deze bundel en voor de opvoeringen in en buiten den lande. 
Op drs. E. de Graaff en later drs. S. Bakker deed ik nooit tevergeefs een 
beroep om eens in het gecomputeriseerde partituur-bestand te kijken, of anderen 
zo'n muziekstukje ook al eens gecomponeerd of zelfs al uitgevoerd hadden. 
In het klinische deel speelden de patiënten de hoofdpartij. Zij zorgden er mede 
voor dat deze jonge onderzoeker op het (r)echte spoor bleef. De 
verpleegkundigen van A51, A52, de polikliniek en een enkele keer de 
hematologische buitenposten leverde van harte hun bijdrage, al was het soms even 
wennen met "pompen Paultje". 
De staven van de afdelingen Bloedziekten en Medische Oncologie hebben een deel 
van deze opera mede mogelijk gemaakt door hun oplettendheid. Als ware 
road-manager heeft de leiding van het laboratorium Heraato-oncologie tijdens dit 
muzikale staaltje veel meer meer gedaan dan af en toe een schouder te geven om 
uit te huilen, als bij een repetitie weer eens wat mis ging. 
Agnes steunde me op het andere front, en blijft als leste de beste. 
159 
CURRICULUM VITAE 
Geboren op 7 september 1950 te Roermond als zoon van Erna Weterings en Louis 
Speth. Na het eindexamen gymnasium β aan het Stedelijk Lyceum te Maastricht, 
volgde de studie Geneeskunde aan de Katholieke Universiteit te Nijmegen, alwaar 
het artsexamen op 30 september 1977 werd afgelegd. In 1972 verbleef hij 4 
maanden in het Artificial Lung Test and Evaluation Facility Laboratorium, 
Providence, RI, U.S.A. (hoofd: prof.dr. P.M. Gaietti) en in 1977 werkte hij 
4 maanden in Sumve District Hospital, Tanzania (hoofd: drs. Η. Sleegers). Na 
de opleiding tot internist aan de afdeling Inwendige Geneeskunde van het 
St.Radboudziekenhuis (hoofd: prof.dr. C.L.H. Majoor t, en per januari 1980 
prof.dr. A. van 't Laar) werd hij op 1 december 1982 ingeschreven in het 
Specialistenregister. Vanaf 1 maart 1982 was hij middels een subsidie van het 
Koningin Wilhemina Fonds (SNUKC 82-7) verbonden aan de afdeling Bloedziekten 
(hoofd: prof.dr. C.A.M. Haanen) voor onderzoek naar cellulaire anthracycline 
concentraties en de implicaties hiervan op celkinetiek en clonogeniciteit. 
Per 1 juli 1986 zal hij toetreden tot de staf van de afdeling Medische Oncologie 
(Hoofd: prof.dr.D.J.Th. Wagener) van het St.Radboudziekenhuis, Nijmegen. 
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STELLINGEN 
BEHORENDE BIJ HET PROEFSCHRIFT VAN 
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1. De intracellulaire anthracycline concentratie welke wordt 
bereikt na toediening van dit cytostaticum is afhankelijk 
van de dosis en m e t van de snelheid van toediening. 
Aangezien bij toediening als langlopend infuus de 
bijwerkingen aanzienlijk geringer zijn dan bij toediening 
als bolus injectie, verdient de eerste vorm de voorkeur. 
Dit proef s e h n ft. 
2. Laser flow cytometne is de enige techniek waarmee 
anthracycline concentraties in individuele levende cellen 
kunnen worden gemeten. 
Dit proefschrift. 
3. Het failliet van de plasma farmacokinetiek ten aanzien 
van het individualiseren van chemotherapie met anthra-
cyclinen lijkt nu ook te gaan gelden voor de cellulaire 
farmacokinetiek. 
Dit proe fschn ft. 
4. De maximale intracellulaire anthracycline concentraties 
die in vivo kunnen worden bereikt, zijn te laag om alle 
leukemische donogene cellen te doden. Deze waarneming 
plaatst het denken over de rol van an thracyclinen in een 
heel ander daglicht. 
Dit proefschrift. 
5. Het is onjuist gegevens van in vi tro en van dier­
experimenteel farmacokinetisch onderzoek te "vertalen" naar 
de humane in vivo situatie, indien niet eerst is onderzocht 
welke gevolgen verschillen in metabolisme hebben voor de 
cellulaire farmacokinetiek en farmacodynamiek. 
Dit proefschrift. 
6. Een fundamentele hinderpaal op de weg naar meer succes in 
de toepassing van farmacokinetiek van cytostatica bij de 
behandeling van kanker, is onze beperkte kennis van 
farmacodynamiek. 
J.M. Collins. Pharmacologic principles of cancer 
treatment. Saunders, Londen, 1982, ρ 79. 
Dit proefschrift. 
7. Herhaalde impedantie-plethysmografie is een niet-
invasieve methode met hoge specificiteit en sensitiviteit 
voor de diagnostiek van de proximale diepe veneuze trombose. 
Voor de diagnostiek van de kuitvene trombose voldoet flebo-
grafie veel beter. In hoeverre bij een flebografisch aange­
toonde kuitvene trombose met negatieve plethysmografie van 
het bovenbeen antistolling geïndiceerd is, is nog contro-
versieel . 
M.W.Huisman, H.R. Bulier, J.W. ten Cate, 3. Vree-
ken. Serial impedance plethysmography for suspec-
ted deep venous thrombosis in outpatients. N. 
Engl.J.Med. 314: 823-828, 1986. 
8. Goed naar de patient luisteren, is vaak al meer dan het 
halve werk. 
P.A.J. Speth, B.J. Brenmnkmeyer, Th. Thien. Ex-
plosieve diarree tijdens gebruik van bètablok-
keerders. Ned. Tijdschr. Geneeskd. 126: 1374-
1378, 1982. 
F.M.N. Nagengast, P.A.J. Speth, J.H.M, van Ton-
geren. Familiair coloncarcinoom. Ned. Tijdschr. 
Geneeskd. 128: 796-800, 1984. 
9. Diagnostiek van lymfoproliferatieve ziekten is zonder 
merker-onderzoek niet volledig. Een biopt verdient daarbij 
de voorkeur. 
10. Onderwijs geven en onderwijs genieten hebben het hoogste 
rendement als zowel de docent als de student zich daarop 
grondig voorbereiden. 
Arnold Meterings. Met collegiale hoogachting. 
Bosch en Keuning, Baarn, 1985, pp 56-58. 
11. Onder het begrip complete remissie dat in de hematologie 
en de oncologie wordt gehanteerd, wordt in tegenstelling tot 
hetgeen het suggereert, slechts het niet meer aantoonbaar 
zijn van resterende tumorcellen verstaan. Bij een 
verfijnende diagnostiek zal het percentage complete 
remissies dat wordt bereikt, dan ook evenredig dalen. 
12. Alleen indien een voortdurende resuscitatie-scholing van 
een groot deel van de bevolking plaats zal vinden, zal het 
aantal fataal verlopende gevallen van hartstilstand kunnen 
worden gereduceerd. 
P.M. van Kalmthout, P.A.J. Speth, J.R. Rutten. J. 
Th.Ch. Vonk. Evaluation of lay skills in cardio-
pulmonary resuscitation. Br. Heart. J. 53: 562-
566, 1985. 
13. Langdurige ernstige eiwit-energie ondervoeding op zeer 
jeugdige leeftijd, zoals die in veel ontwikkelingslanden 
wordt gezien, is een belangrijke factor in het veroorzaken 
van -niet meer in te halen- biologische en geestelijke 
achterstand bij deze bevolkingsgroep. 
G.A.Clugston. The effect of malnutrition on brain 
growth and intellectual development. Tropical 
Doctor 11: 32-38, 1981. 
14. "Hoewel een ziekenhuis en een begraafplaats met het 
klasse-stelsel één opmerkelijke overeenkomst hebben, is er 
ook een duidelijk verschil: op een begraafplaats spreken ze 
je, als de kist al zakt, toe alsof je nog leeft; in een 
ziekenhuis behandelen ze je alsof je al dood bent." 
Maarten 't Hart. De aansprekers. De arbeiders-
pers, Amsterdam, 1979, ρ 57. 
15. Het spreekwoord uitzonderingen bevestigen de regel, 
ontkracht -gezien de weinige doden tijdens de vele 
marathons- de andere zegswijze: hardlopers zijn doodlopers. 
Nijmegen, 19 juni 1986 Paul A.J.Speth 



